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Abstract 
 
DNA methylation has an emerging role in pathogenesis and diagnosis of acute myeloid 
leukaemia (AML). In order to obtain a global view of the DNA methylation changes in 
AML genome, we applied methylated DNA immunoprecipitation followed by next-
generation sequencing (MeDIP-seq) to AML patients from 4 different cytogenetic 
subtypes [t(8;21), t(15;17), trisomy 8 and normal karyotype] and normal bone marrows 
(NBMs). The MeDIP-seq signals were quantified, generating DNA methylation profiles 
with a 100bp resolution. Whole-genome DNA methylation average was 3% less in AML 
than NBM. This limited global hypomethylation was observed mainly in SINE repeat 
sequences. DNA methylation of specific genomic regions e.g. promoters, gene bodies, 
CpG islands (CGIs) and CGI shores clearly discriminated AML from NBM and 
differentiated each AML subtype. The preferential methylation was found in CGIs 
located outside the promoters. Additionally, significant hypomethylated interspersed 
repeat sequences differentiated each AML subtype. The MeDIP-seq data was validated 
by bisulphite pyrosequencing and Illumina Infinium Array. Two genes (SPHKAP and 
DPP6) with significantly methylated promoters were also of interest and further analysis 
of their expression showed them to be repressed in AML. Transfection of cancer cell 
lines with vector expressing SPHKAP revealed 2 times increase in the intracellular level 
of sphingosine-1-phosphate as measured by mass spectrometry. Moreover, HHEX, 
which was one of the genes that showed differential intragenic methylation in trisomy 8 
AML, was also differentially repressed in trisomy 8 AML. In conclusion, novel MeDIP-
seq data was presented with CGIs methylation, intragenic DNA methylation and 
hypomethylated repeats were characteristic for each AML subtype. 
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Chapter 1. Introduction 
 
 
1.1  Acute myeloid leukaemia 
  
Acute myeloid leukaemia (AML) is a heterogeneous form of cancer in which many 
molecular and cytogenetic somatically acquired events have been described (Mrozek et 
al. 2000). The incidence rate of AML increases with age (Erba 2007) ranging from 0.7 
to 3.9 per 100,000 population below 60 years and from 6.7 to 19.2 per 100,000 
population above 60 years, with a median age above 70 years (Ries et al. 2000). Five 
year disease-free survival is 30% for patients less than 60 years. However, for patients 
more than 60 years, the survival rate decreases to 5-10% (Fanning et al. 2009). The 
cause of AML is unknown but there are risk factors that could contribute to leukaemia 
e.g. antecedent haematological disorders which include myelodysplastic syndrome 
(MDS) (List et al. 2008) and myeloproliferative disorders (Abdulkarim et al. 2009). In 
addition, Down syndrome (Rosner and Lee 1972) and Fanconi‟s anaemia patients 
(Dufour and Svahn 2008) are at risk of developing AML. Exposure to chemotherapy 
also increases the incidence of developing therapy-related acute myeloid leukaemia (t-
AML) (Pedersen-Bjergaard 2005). The most common balanced chromosomal 
rearrangements: t(8;21)(q22;q22), inversion (16)(p13q22)/ t(16;16)(p13;q22) and 
t(15;17)(q22;q21) are considered risk factors associated with favorable outcomes. This 
is in contrast to the outcomes of AML with normal karyotype or complex chromosomal 
aberrations (Grimwade et al. 1998). 
Chapter 1 
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1.1.1  AML Pathogenesis 
 
There are two main theories of leukaemogenesis (Cheng and Sakamot 2005). The first 
suggests that oncogenic transformation of haematopoietic stem cells occurs at different 
stages of stem cell differentiation resulting in differentiation arrest and clonal expansion 
of immature progenitor cells. The second theory argues that mutations responsible for 
leukaemic transformation occur only in primitive multipotent stem cells, which 
differentiate and acquire specific phenotypic lineage markers (Kennedy and Barabe 
2008) (Figure 1.1). Either blockage of differentiation or inappropriate cell proliferation 
are both linked to molecular dysfunctions in AML (Licht and Sternberg 2005). These 
molecular dysfunctions involve alteration in the functions of transcription factors e.g. 
the core binding factor complex, MLL protein, retinoic acid receptor (RAR) and CEBPα 
either by their fusion as a result of chromosomal translocation or by point mutation. For 
example, point mutation of CEBPα is strongly linked to a block of myeloid 
differentiation (Kato et al. 2011).  
The core binding factor complex, which is involved in activating genes responsible for 
normal myeloid development, consists of a heterodimer of RUNX1 protein and CBFB 
protein. Therefore, in t(8;21) AML and inversion 16 AML, the resulting fusion proteins; 
AML1-ETO (also known as RUNX1-RUNX1T1) and CBFB-MYH11 respectively 
deregulate normal myeloid development and initiate leukaemogenesis. In addition, the 
fusion proteins can repress target genes through recruitment of co-repressor complexes 
(Licht and Sternberg 2005). A notable example of blockage of differentiation is in AML 
with the t(15;17) translocation, since the resultant fusion protein PML-RARα leads to a 
Chapter 1 
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block of myeloid differentiation at the promyelocytic step (Martens et al. 2010). Also, 
the MLL gene is a frequent partner for recurrent translocations in AML and the resultant 
fusion proteins provoke a persistent activation of HOX gene family hence increasing the 
self-renewal process of leukaemic stem cells (LSCs) (Ferrando et al. 2003; Milne et al. 
2005). The existence of LSCs and their role in initiating AML was first demonstrated 
through isolating human AML cells which were CD34
++
 CD 38ˉ and transplanting them 
into immunocompromised mice. LSCs were responsible for the production of different 
AML blast cells in the transplanted animals, the blast cells were phenotypically matched 
with the original human AML subtypes (Bonnet and Dick 1997). This is due to the 
powerful proliferation and the self-renewal capability of LSCs i.e. one LSC can produce 
a million of AML blast cells (Uribesalgo and Di Croce 2011). The phenotypic 
similarities between haematopoietic stem cells (HSCs) and LSCs suggested that HSCs 
could transform into LSCs through oncogenic mutations (Pardal et al. 2003). Therefore, 
AML is developed through a multistep process since HSCs undergo mutation to induce 
pre-leukaemia stem cells (PSCs) which induce LSCs through genetic or epigenetic 
changes. The AML blast cells carry the mutations implicated in the pathogenesis while 
LSCs maintain and propagate the AML phenotype (Figure 1.1). Moreover, BMI-1 gene 
is one of the controllers of the self-renewal of both HSCs and LSCs (Lessard and 
Sauvageau 2003). BMI-1 protein is a member of polycomb groups that are responsible 
for the chromatin remodelling since BMI-1 forms heterodimers with other polycomb 
group proteins that bind to the chromatin and subsequently induce gene repression 
(Pardal et al. 2003). This suggested that LSCs could be eliminated using BMI-1 
inhibitors (ten Cate et al. 2010). The second controller of the self-renewal of LSCs is 
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Wnt/B-catenin signalling pathway as the Wnt signaling pathway is elevated in LSCs 
(Misaghian et al. 2009). This may be due to mutations and internal tandem duplications 
of FLT3 gene. Additionally, the oncofusion proteins resulting from translocation (8;21) 
i.e. (AML1-ETO) and translocation (15;17) i.e. (PML-RARα) lead to an increase in the 
expression of Wnt signalling pathway which stimulates the growth of LSCs and the 
expansion of HSCs (Misaghian et al. 2009). Furthermore, 3 transcriptional or 
chromation remodelling factors are highly expressed in HSCs/ LSCs to maintain the 
self-renewal process (Somervaille et al. 2009): MYB gene (transcriptional activator 
important for leukaemic transformation of HSC), CBX5 gene (CBX5 recognizes 
methylated H3K9 resulting in heterochromatin formation) and HMGB3 gene (a high 
motility group protein which has an important role in DNA replication). 
In addition to the phenotypic markers e.g. CD34 and CD38, LSCs could be 
distinguished from bulk AML samples by the expression of some genes that are 
differentially expressed during the early myelopoiesis e.g. HOPX and GUCY1A3 
(Gentles et al. 2010). HOPX encodes a homeodomain protein which can recruit histone 
deacetylase (HDAC) activity without directly binding DNA.
 
Moreover, GUCY1A3 
encodes a guanylate cyclase enzyme that catalyzes the conversion of guanosine 
triphosphate into cyclic guanosine monophosphate; cyclic guanosine monophosphate is 
known to stimulate HSC proliferation (Gentles et al. 2010). Another stem cell factor that 
is involved in the self-renewal of LSCs and HSCs is SALL4 gene (Jeong et al. 2011). 
The expression of SALL4 was higher in drug resistant AML patients than drug-
responsive patients. SALL4 exerts its effect through interaction with BMI-1 and Wnt/B-
catenin signalling pathway (Ma et al. 2006). 
Chapter 1 
21 
 
Other molecular dysfunctions in AML include mutation in receptor tyrosine kinases e.g. 
FLT3, c-Kit or Jak2 results in abnormal progression of cell proliferation and the escape 
from programmed cell death through the release of an anti-apoptotic factor „BCL2‟ by 
an activated protein tyrosine kinase (Andreeff et al. 1999). Similarly, P53 mutation or 
mutation of its controller NPM (Kurki et al. 2004) disrupts the apoptotic process in 
AML (Shen and White 2001). Moreover, inhibition of the functional activity of P53 can 
be achieved through MLL-fusion proteins (Wiederschain et al. 2005). AML fusion 
proteins also act as repressors of DNA repair genes leading to genome instability 
(Alcalay et al. 2003). Furthermore, Ras-mitogen activated protein kinase (Ras-MAPK) 
pathway as well as P53 mutation and NPM1 mutation lead to loss of cell cycle control in 
AML (Licht and Sternberg 2005). 
Recently, the genetic mutations in AML have been classified into 3 classes (Dombret 
2011); class I is associated with genes involved in signal transduction e.g. FLT3 
mutation. The second class affects genes involved in cellular differentiation e.g. RUNX1 
mutation. The third class of mutations affects genes that control what is known as „the 
epigenetic status‟ of the cell e.g. DNMT3A mutation. The last class of mutations will be 
discussed in more detail further in this chapter. 
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Figure ‎1.1 AML pathogenesis 
The normal haematopoietic stem cell (HSC) undergoes differentiation into common 
myeloid progenitor cell (CMP) which differentiates into granulocytic-macrophage 
progenitor cell (GMP) and megakaryocyte-erythroid progenitor cell (MEP). For 
transformation into AML, the HSC or CMP undergoes mutation to give rise to pre-
leukaemia stem cell (PSC). The PSC proliferates into leukaemic stem cell (LSC). The 
LSC is responsible for production of AML blast cells (Jordan and Guzman 2004; Kuo et 
al. 2006;Castilla 2008). 
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1.1.2 AML Classification 
 
1. The first classification of AML was performed by a group of seven French, American 
and British haematologists (FAB group) (Bennett et al. 1976). The FAB group used both 
the morphology of cells and the cytochemical stains [e.g. myeloperoxidase (MPO), 
nonspecific esterase (NSE), and Sudan Black B (SBB)] to describe the six main types of 
AML (M1, M2, M3, M4, M5 and M6). However, cytogenetics were not included in this 
classification. M0 and M7 were incorporated into FAB classification in 1991, 1985 
respectively (Bennett et al. 1991; Bennett et al. 1985) (Table 1.1). 
Table ‎1.1 FAB classification of AML (Bennett et al. 1976) 
Type Name Incidence 
(Boyer 1997) 
M0 Minimally differentiated acute myeloblastic leukaemia 2-3% 
M1 Acute myeloblastic leukaemia without maturation 20% 
M2 Acute myeloblastic leukaemia with granulocytic maturation 30% 
M3 Acute promyelocytic leukaemia 10% 
M4 Acute myelomonocytic leukaemia, M4eo myelomonocytic 
leukaemia with bone marrow eosinophilia. 
25-30% 
M5 Acute monocytic leukaemia 10% 
M6 Acute erythroid leukaemia 4% 
M7 Acute megakaryoblastic leukaemia 1-3% 
 
2. The World Health Organization (WHO) published another classification for AML 
(Jaffe et al. 2001) which involved genetic, clinical features, cell morphology and 
cytochemistry to determine the different disease subtypes. Such factors assisted in better 
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defining the disease and subsequently therapy (Sekeres et al. 2007). A revision was 
performed for the WHO classification in 2008 to take into account the new genetic and 
clinical data that improved the disease diagnosis (Swerdlow et al. 2008) (Table 1.2). The 
WHO classification includes AML with balanced chromosomal aberrations which 
involves AML with t(8;21), t(15;17), inversion 16 and AML with 11q23 abnormalities. 
AML with t(8;21)(q22; q22) (FAB classification M2) accounts for 12% of AML 
patients since t(8;21) AML involves the AML1 gene on 21q2 [AML1 encodes a core 
binding factor alpha (CBFA), which is a transcriptional activator] and the ETO gene on 
8q22. The AML1-ETO oncofusion protein contributes to the initiation of 
leukaemogenesis (Caligiuri et al. 1997). Acute promyelocytic leukaemia (APL) AML 
with t(15; 17)(q22; q12) (FAB classification M3) represents 8% of AML patients. APL 
is commonly associated with disseminated intravascular coagulation (DIC) (Kwaan et 
al. 2002). The molecular abnormality involves RARα (retinoic acid receptor alpha) gene 
which is a transcriptional regulator on 17q12. RARα gene fuses with promyelocytic 
leukaemia (PML gene) on 15q22 resulting in a PML-RARα oncofusion protein. AML 
with inversion (16)(p13; q22) or t(16; 16)(p13; q22) (FAB classification M4) represents 
12% of all cases of AML. inv(16)(p13; q22)/ t(16; 16)(p13; q22) results in the fusion of 
CBFB (core binding factor beta) gene at 16q22 and MYH11 gene at 16p13 resulting in 
the oncofusion protein CBFB-MYH11 (Marlton et al. 1995). Both t(8;21) AML and 
inv16 AML are known as core binding factor leukaemia. For AML subtypes, that are 
associated with reciprocal translocations e.g. t(8;21) AML, t(15;17) AML and inversion 
16 AML, the oncofusion proteins recruit histone deacetylase (HDAC) enzyme together 
with the co-repressors; NCOR, SIN3 and SMRT to target genes. This results in gene 
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inactivation which triggers the DNA methyltransferases (DNMTs) to be directed 
towards the inactive genes. Together, that stimulates the polycomb repressor complex 2 
and EZH2 enzyme which is responsible for the trimethylation of histone H3 at lysine 27 
(H3K27) ending into formation of a heterochromatin protein and gene repression (Plass 
et al. 2008). 
In addition, AML with 11q23 abnormalities comprises 5% of cases of AML and is 
associated usually with monocytic features. The MLL (mixed lineage leukaemia) gene at 
11q23 is a partner with 40-60 genes in AML. MLL gene is a transcriptional activator 
because of the SET domain at the C terminal that acts as a methyltransferase for H3K4. 
On fusion of MLL with other genes e.g. AF9, the SET domain is lost. However, this loss 
of SET domain function is compensated by other enzymes e.g. histone acetyltransferases 
(HATs) (Uribesalgo and Di Croce 2011). Moreover, AML with activating mutations of 
FLT3 (fms-like tyrosine kinase 3) or with point mutation of CEBPα (CCAAT-enhancer 
binding protein alpha) or NPM1 (nucleophosmin) are all represent 40-45% of AML. The 
most common mutation of FLT3 is the internal tandem duplication (ITD) which results 
in constitutive activation of tyrosine kinase (Griffith et al. 2004). Additionally, CEBPα 
is a transcriptional factor gene that is important in normal haematopoiesis. CEBPα 
mutation affects the DNA binding and initiate leukaemogenesis (Snaddon et al. 2003). 
Besides, NPM1 is a transcription factor that is involved in nuclear-cytoplasmic shuttling 
of proteins. One effect of the NPM1 mutations is the delocalization of ARF which is a 
growth inhibitor (Korgaonkar et al. 2005). The common clinical picture for those 
patients (with mutations in FLT3/ CEBPα/ NPM1) is normal cytogenetic (Schlenk et al. 
2008). Furthermore, AML with myelodysplasia related changes is characterized by 
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dysplasia in two or more myeloid cell lines where the dysplasia is identified in 50% or 
more of the cells of at least two lineages. AML with multilineage dysplasia could occur 
with or without prior MDS or myeloproliferative disorder (Gahn et al. 1996). 
Additionally, therapy related myeloid neoplasms include MDS or AML that occur 
following chemotherapy e.g. 2 years following treatment with Topoisomerase II 
inhibitors or 6 years following treatment with Alkalyting agents. The chromosomal 
abnormalities in the last subtype are usually complex (3 or more distinct abnormalities) 
(Smith et al. 2003).  
Another way to classify the AML subtypes was based on the gene expression profiling. 
In a microarray-based study of the expression of approximately 13,000 genes, 285 adult 
AML patients were clustered into 16 distinct groups depending on the strong similarities 
of the gene expression profiling between AML patients (Valk et al. 2004). The clusters 
included t(8;21) AML, t(15;17) AML, inv 16, mutations in FLT3, mutations in CEBPα, 
monosomy 7 and over expression of EVI1. Also, novel clusters of AML were identified 
including mainly normal karyotypic AML patients associated with poor survival. 
Moreover, several types of AML have been identified using whole genome sequencing 
(WGS) and exome sequencing. For example, whole genome sequencing of a therapy-
related AML female patient following treatment of ovarian and breast cancer revealed a 
novel heterozygous 3-kilobase deletion removing exons 7-9 of TP53 gene in the germ-
line DNA of patient normal skin (Link et al. 2011). Besides, whole genome sequencing 
of acute promyelocytic leukaemia female patient showed abnormal insertion of PML 
gene into chromosome 17 that produced a classic pathogenic PML-RARα fusion gene 
(Welch et al. 2011). This cytogenetic abnormality could not be detected by the routine 
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cytogenetic analysis. In addition, exome sequencing of AML patients showed mutation 
of DNMT3A in M5-AML (Yan et al. 2011) and NK AML (Ley et al. 2010), which was 
associated with poor prognosis. Also whole exome sequencing of a NK AML patient 
revealed a mutation in BCOR gene located on chromosome Xp11.4 (Grossmann et al. 
2011). On a wider scale, this gene was found mutated in NK patients (3.8% of NK 
patients) and associated with poor prognosis. 
Table ‎1.2 WHO classification of AML (Swerdlow et al. 2008) 
Acute myeloid leukaemia with recurrent genetic abnormalities 
   AML with t(8;21)(q22;q22); RUNX1-RUNX1T1 (older name: AML1-ETO) 
   AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 
   AML with  t(15;17)(q22;q12); PML-RARα 
   AML with t(9;11)(p22;q23); MLLT3-MLL 
   AML with t(6;9)(p23;q34); DEK-NUP214  
   AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1 
   AML (megakaryoblastic) with t(1;22)(p13;q13). 
   Provisional entity: AML with mutated NPM1.  
   Provisional entity: AML with mutated CEBPα. 
Acute myeloid leukaemia with myelodysplasia-related changes. 
Therapy-related myeloid neoplasms.  
Acute myeloid leukaemia, not otherwise specified 
      AML with minimal differentiation  
      AML without maturation  
      AML with maturation  
      Acute myelomonocytic leukaemia  
      Acute monoblastic/monocytic leukaemia  
      Acute erythroid leukaemia 
         Pure erythroid leukaemia 
         Erythroleukaemia, erythroid/myeloid 
     Acute megakaryoblastic leukaemia  
     Acute basophilic leukaemia  
     Acute panmyelosis with myelofibrosis 
Myeloid sarcoma  
Myeloid proliferations related to Down syndrome 
   Transient abnormal myelopoiesis 
   Myeloid leukaemia associated with Down syndrome 
Blastic plasmacytoid dendritic cell neoplasm. 
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1.1.3 AML Diagnosis 
 
1.1.3.1 Immunophenotypic characteristics of AML 
 
At least 20% blast cells present in peripheral blood or in aspirated bone marrow film are 
required for diagnosis of AML. The percentage of blast cells was decreased from 30% in 
the FAB classification to 20% in the WHO classification. However, this percentage is 
not essential in AML with recurrent chromosomal abnormalities since a confirmation of 
such cytogenetic rearrangements is satisfactory for AML diagnosis (Vardiman et al. 
2009). The second step is to confirm the myeloid lineage of blasts cells. Because of the 
heterogeneity of AML, blast cells exhibit different cell surface antigens (CDs) 
(Andoljsek et al. 2002) (Table 1.3). Common myeloid markers (CD13, CD33) can 
distinguish between M0 and acute lymphoblastic leukaemia (ALL) (Bain et al. 2001). 
Interestingly, it was thought that CDs could be related to the prognosis of AML patients. 
For example, CD56+ is a poor prognostic marker in both t(8;21) AML and t(15;17) 
AML. By contrast, multiple phenotypic markers (CD13+, CD33+, HLA-DR-, and 
CD34-) showed association with a good prognosis in acute promyelocytic leukaemia 
(Mason et al. 2006). Also, MPO is another common myeloid marker, which should be 
present in the cytoplasm of at least 3% of the blasts (Matsuo et al. 2003). Multi-
parameter flow cytometry is used for detection of CDs and for the enzyme cytochemical 
analysis (Nguyen et al. 1998; Kaleem et al. 2003) (Table 1.3).  
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Table ‎1.3 Commonest CDs in each phenotype of AML  
AML  Immunophenotypic characteristics 
M0 CD13++/CD33++/CD34++/CD117++/HLA-DR++/TdT+ 
M1 CD13++/CD33++/CD34++/CD65+/CD117++/ MPO+/HLA-DR++/TdT+ 
M2 CD13++/CD15++/CD33++/CD34+/CD65++/CD117++/MPO++/HLA-DR ++/TdT+ 
M3 CD13++/CD33++/CD65+/CD117+/MPO++/HLA-DR- 
M4 CD11c++/CD13++/CD14++/CD36+/CD65++/CD117+/ MPO++/HLA-DR++/TdT+ 
M5 CD11c++/CD13++/CD14+/CD36+/CD65++/ MPO++/HLA-DR++/TdT++ 
M6 CD13+/CD33+/CD34+/CD36++/CD117+/MPO+/HLA-DR+/TdT+/GpA+/H antigen++ 
M7 CD13++/CD33++/CD34+/CD36+/CD42+/CD41++/CD61++/ CD117+/HLA-DR++ 
-; <10% of the leukaemia is positive, +; 25%-75% of the leukaemia is positive, ++; >75% of leukaemia 
is positive (van Dongen et al. 2002).  
 
1.1.3.2 Cytogenetic analysis 
 
AML has been described with various cytogenetic abnormalities that can affect its 
phenotype (Tomonaga et al. 1985), clinical presentation (Mrozek and Bloomfield 2008) 
and outcome (Slovak et al. 2000). The cytogenetic abnormalities in AML are divided 
into 3 major groups (Mrozek and Bloomfield 2008; Pedersen-Bjergaard et al. 2008). The 
first cytogenetic group includes balanced chromosomal aberrations that consist of 20% 
of AML (Slovak et al. 2000) and involve the recurrent reciprocal translocations e.g. 
t(8;21)(q22;q22), t(15;17)(q22;q12) and inv(16)(p13.1q22). AML patients in this group 
usually are young and have a favorable outcome. The second major group includes 
unbalanced chromosomal aberrations, which can be a deletion of a part or a whole 
chromosome e.g. del (5q)/ monosomy 5, del (7q)/ monosomy 7 or a gain of a whole 
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chromosome e.g. plus 8, which is the most common numerical aberration in AML 
(Wolman et al. 2002). Patients in the second cytogenetic group usually are older with an 
unfavorable outcome. The third major cytogenetic group is AML with a normal 
karyotype (NK) and an intermediate outcome. AML patients with a normal karyotype 
represent approximately 40% of AML (Manola 2009). The most common cytogenetic 
abnormalities of AML are summarized in Table 1.4 with their outcomes (Slovak et al. 
2000; Mrozek and Bloomfield 2008). 
Therefore, the cytogenetic analysis assists in disease classification, predicting the 
response to chemotherapy and subsequently survival of AML patients (Grimwade et al. 
1998). A Giemsa banded karyotype is usually used for karyotype analysis. However, the 
limitations of this technique include the inability to detect submicroscopic chromosomal 
translocations, which are smaller than a chromosomal band and the need for experienced 
cytogeneticists (McGrattan et al. 2008). Moreover, a single case of AML may have 
complex chromosomal rearrangements that require another method to complete the 
karyotype analysis. Fluorescent in situ hybridization (FISH) is used to complement G-
banding. FISH has the advantage that it examines each chromosome separately (Amiel 
et al. 1996) and can detect the submicroscopic chromosomal alterations. However, the 
technique is limited to the sites defined by FISH probes (McGrattan et al. 2008). 
Additionally, comparative genomic hybridization (CGH) and at a higher resolution 
level, the array comparative genomic hybridization (aCGH) techniques have been 
developed with a better probe specificity (Shaffer et al. 2008). CGH and aCGH 
techniques detect the chromosomal copy number changes but not the translocations, 
inversions or insertions.  
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Table ‎1.4 Cytogenetic abnormalities in AML with their outcomes (Slovak et al. 2000) 
I-Favorable 
Inversion (16)/ t(8;21)/ t(15;17) 
II- Intermediate 
Normal karyotype (NK) 
Trisomy 6, Trisomy 8/ -Y, Del (12p) 
Other noncomplex karyotype 
III-Unfavorable 
Monosomy 5, 5q-, Monosomy 7, 7q- 
Abnormal 3q, Abnormal 9q 
11q23(MLL), t(9;22)/ 20q-, 21q-/ 17p, t(6;9) 
Complex karyotype (Involving 3 or more unrelated abnormalities). 
IV- Unknown  
All other abnormalities 
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1.2 Epigenetics 
 
An epigenetic trait is a heritable phenotype, which results from changes in a 
chromosome without affecting the underlying DNA sequence (Berger et al. 2009). The 
role of epigenetics is to adapt the DNA structure to make it more efficient in performing 
its function. This adaptation can be either by adding a methyl group to the DNA bases 
(DNA methylation) or by modifying the alkaline proteins, which are responsible for 
wrapping the DNA inside the nucleus (histone modifications) (Figure 1.2). Both DNA 
methylation and histone modifications control the gene expression and DNA 
architecture through different mechanisms (Esteller 2007).  
Histone modifications include acetylation, methylation, phosphorylation and 
ubiquitination of the amino acids components of histones (Wang et al. 2004). For 
instance, histone acetylation induces transcriptional activation since acetylation of lysine 
residues at the N terminal end of the histone proteins removes the positive charges and 
decreases the affinity between histones and DNA, thus making it easier for RNA 
polymerase and transcription factors to bind to DNA (Nightingale et al. 1998; Sterner 
and Berger 2000). The histone acetylation process is activated by histone 
acetyltransferases (HATs) and is inhibited by histone deacetylases (HDACs) (Richon et 
al. 2000). By contrast, methylation of histones results in variable effects on gene 
expression. For example, methylation of H3K9, H3K27 and H4K20 results in a compact 
chromatin which interferes with the accessibility to the transcription factor binding sites 
(Klose and Zhang 2007; Cedar and Bergman 2009). However, methylation of H3K4, 
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H3K36 and H3K79 are usually associated with transcription activation (Yan and Boyd 
2006; Wang et al. 2007; Klose and Zhang 2007).  
 
1.3 DNA methylation 
 
DNA methylation is the most stable epigenetic modification; it was discovered in 1948 
through separating the DNA bases using paper chromatography (Hotchkiss 1948). DNA 
methylation involves addition of a methyl group to the 5' position of the pyrimidine ring 
of cytosine, which is followed by guanine (CpG dinucleotide). In mammals, DNA 
methylation occurs mainly at the CpG sites (Robertson and Jones 2000). However, non-
CpG DNA methylation e.g. CpA and CpT were found in other cell types e.g. embryonic 
stem cells (Ramsahoye et al. 2000). The DNA methylation process is controlled by a 
group of enzymes; DNA methyltransferases (DNMTs) (Okano et al. 1999).  
 
1.3.1 DNA methyltransferases (DNMTs) 
 
There are three active forms of DNMTs: DNMT1, DNMT3A and DNMT3B. In 
addition, DNMT3L is an inactive form of DNMT, which acts as a stimulator of the 
catalytic activity of DNMT3A and DNMT3B (Oki and Issa 2010). DNMT enzymes play 
essential roles in the DNA methylation pathways: de-novo and maintenance 
methylations (Smith and Baker 1997). De-novo methylation involves formation of a 
newly methylated cytosine in the DNA while maintenance methylation involves 
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addition of a methyl group to the DNA when one strand is already methylated. After 
implantation of the embryo, the DNA methylation pattern is widely erased to remove 
germ cell methylation pattern, and to set somatic cell pattern through de-novo 
methylation (Zhu et al. 2006). The de-novo methylation depends mainly on DNMT3A, 
DNMT3B with a collaboration of DNMT3L (Jia et al. 2007). Newly methylated DNA 
strands are replicated and copied to the next generations of cells by DNMT1 since 
DNMT1 has a greater affinity to hemimethylated DNA. Therefore, DNMT1 is the key 
for maintenance methylation i.e. maintenance methyltransferase (Brueckner and Lyko 
2004). Homozygous mutation of DNMT1 gene in the embryonic stem cells results in 
embryonic lethality (Li et al. 1992). Similarly, homozygous mutation of DNMT3B 
results in death of the embryo, while homozygous mutation of DNMT3A results in death 
of the mice at 4 weeks of age (Okano et al. 1999). 
 
1.3.2 DNMT inhibitors 
 
The DNA methylation process is reversed using DNMT inhibitors e.g. 5'-azacytidine 
(azacitidine) and its deoxy analogue 5-aza-2′-deoxycytidine (decitabine). Both 
azacitidine and decitabine have been approved by the Food and Drug Administration 
(FDA) and are used in treatment of MDS. Azacitidine and decitabine work as false 
substrates that are incorporated into DNA during replication and into RNA during 
transcription (Berg et al. 2007; Oki and Issa 2010; Fathi and Abdel-Wahab 2012). In 
low-doses, azacitidine or decitabine covalently binds to DNMT1 and eventually results 
in DNMT1 degradation without DNA synthesis arrest. However, the demethylating 
Chapter 1 
35 
 
agents have side effects of low specificity and side effects related to haematological 
perturbations e.g. thrombocytopenia (Ehrlich 2002; Rius and Lyko 2011). The combined 
chemotherapy of multiple demethylating drugs might reduce their side effects through 
decreasing the dose of each drug (Amatori et al. 2010). In addition, some trials have 
been carried out to improve the drug design (Brueckner and Lyko 2004). For instance, a 
third nucleoside DNMT1 inhibitor „zebularine‟ is similar in function to azacitidine and 
decitabine. However, zebularine has a longer half-life and selectively incorporated into 
malignant rather than normal cells (Fathi and Abdel-Wahab 2012). Other demethylating 
agents such as non-nucleoside antisense DNA methyltransferase and small interference 
RNA are under development (Das and Singal 2004). 
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Figure ‎1.2 Epigenetic mechanisms 
DNA strands are wrapped around histone proteins, forming nucleosomes which are 
organized into chromatin. DNA methylation occurs at 5-position of cytosine in a 
reaction catalyzed by DNMTs. Histone modifications include acetylation, methylation 
and phosphorylation of the histone proteins. Both DNA methylation and histone 
modifications customize a unique epigenetic feature that controls the chromatin 
organization and gene expression (Luong 2009). 
 
1.3.3 Biological functions of DNA methylation 
 
DNA methylation has important developmental and physiological functions e.g. 
genomic imprinting. Genomic imprinting is a biological process occurs in the 
developing oocyte and sperm and is controlled by DNMT3A and DNMT3L (He et al. 
2011). During this process, erasure of gene imprinting followed by de-novo DNA 
methylation is needed to specify the alleles according to the parental origin (Reik and 
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Walter 2001). Subsequently, the gene will be expressed from the non-imprinted allele 
which is inherited either from the mother e.g. H19 or from the father e.g. IGF2. 
Interestingly, after implantation of the embryo, the imprinted genes escape the step of 
de-novo methylation and are kept throughout the embryogenesis (Zhu et al. 2006). 
 In addition and in order to equalize the gene product between female XX and male XY, 
random DNA methylation of one of X chromosomes during the early embryonic 
development in females is essential (Panning 2008; Nora and Heard 2009).  
Moreover, the presence of 5-methylcytosines in the promoter of some genes leads to 
their silencing either by altering binding of transcription factors or by enhancing the 
binding of HDACs and methyl-CpG binding domains (MBD1-4) around the 
transcription start site (TSS) (Youssef et al. 2004; Klose and Bird 2006; Recillas-Targa 
et al. 2006; Fernandez-Fernandez 2007). DNA methylation also suppresses the repetitive 
sequences, resulting in their silencing hence maintaining the genome integrity 
(Robertson 2001).  
The role of DNA methylation in DNA mismatch repair (MMR) pathway was shown 
through targeting DNMT1 enzyme to the newly replicated DNA via the proliferating 
cell nuclear antigen (PCNA) (Robertson and Jones 2000).  
Furthermore, DNA methylation is one factor in ageing which is a gene and tissue 
specific process (Ono et al. 1993). For instance, the positive correlation between age and 
DNA methylation in human brain is related to genes responsible for DNA binding and 
regulation of transcription (Hernandez et al. 2011). By contrast, DNA methylation of 
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repetitive regions is inversely correlated with age in the heart, thymus and liver tissues 
(Richardson 2003).  
 
1.3.4 The link between DNA methylation and histone modifications 
  
One of the important functions of DNA methylation is modulation of chromatin 
structure. It has been suggested that histone-modifying enzymes such as HDACs are 
inter-reliant on DNMT1 since DNMT1 recruits methyl-CpG binding protein (MBP), 
which brings HDAC to target genes. At the same time, HDAC is needed to remodel the 
chromatin before DNA methylation occurs (Fuks et al. 2000) (Figure 1.3). In addition, 
histone methyltransferase (EZH2), which is a polycomb complex protein, recruits 
DNMT1 to CpG sites of EZH2 target promoters through a direct contact (Vire et al. 
2006). Another repressive effect of EZH2 is through facilitating the trimethylation of 
H3K27. H3K27me3 binds to chromodomain protein leading to gene silencing 
(McGarvey et al. 2007; Cedar and Bergman 2009). Furthermore, DNA methylation 
enhances H3K9 dimethylation resulting in a compact chromatin, subsequently gene 
repression (Hashimshony et al. 2003). By contrast, DNA methylation has inhibitory 
effects on both di and trimethylation of H3K4 (H3K4me2 and H3K4me3 respectively) 
with variable effects on transcription (Okitsu and Hsieh 2007).  
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1.3.5 Factors affecting the epigenetic status of genes 
 
Some factors affect the epigenetic status of genes: 1) Hormonal: changes in the levels of 
sex hormones alter the nuclear architecture and the gene methylation pattern (Petronis 
2001). 2) Diet: deficiency of folate, choline, and methionine in diet reduces the level of 
S-adenosylmethionine thus leading to global DNA hypomethylation and initiation of 
cancer in rodents (Davis and Uthus 2004). 3) Ageing: an inverse correlation was found 
between the age of a group of elderly people and the methylation level of Alu repeats 
(Bollati et al. 2009). 4) Chemicals e.g. arsenic exposure have led to hypomethylation of 
Ras gene in mice (Okoji et al. 2002).  
 
1.3.6 CpG methylation 
 
The total number of CpG sites in the human genome is around 28 million (Beck and 
Rakyan 2008). There are 2 categories of CpG sites in the genome with different 
methylation profiles. The first category includes 98% of CpG sites where CpGs are 
infrequent; average 1 per 100bp, and heavily methylated (Illingworth et al. 2008). This 
heavily methylated pattern in normal cells is essential to inhibit the transcription of non-
coding DNA thus maintaining the genome stability (Herman and Baylin 2003). The 
second category corresponds to 2% of CpG sites where CpGs are more frequent 
(1/10bp) but methylation free. The second category is known as CpG islands (CGIs), 
which are located in 40-60% of the promoters in mammalian genes (Fatemi et al. 2005).  
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CGIs can be described by 2 definitions; the first definition is the formal one where the 
guanine (G) + cytosine (C) content is > 0.5, and the CpG observed/ expected ratio is > 
0.6 in a sequence length ≥ 200bp (Gardiner-Garden and Frommer 1987). The second 
CGI definition is a revised one, that is to exclude the GC-rich genomic sequences e.g. 
Alu repeats, where the G + C content is > 0.55, and the CpG observed/ expected ratio is 
> 0.65 in a sequence length ≥ 500bp (Takai and Jones 2002).  
Most of the promoters are associated with dense CGIs (CpG density > 10%) and usually 
are unmethylated in various normal tissues (Eckhardt et al. 2006). Few subsets of 
promoters are associated with CGIs of CpG density < 10% or with non- CGIs and 
usually are methylated (Eckhardt et al. 2006). An exception for this rule was reported 
since genes with densely methylated CGIs promoters were detected in normal somatic 
tissues (Shen et al. 2007). 
There are some possible explanations for the protection of CGIs from DNA methylation 
such as active demethylation of cis-acting sequences, which are present in CGIs (Frank 
et al. 1991; Turker 1999). In addition, H3K4 methylation protects the islands from being 
methylated during de-novo methylation in early embryo. H3K4me is catalyzed by H3K4 
methyltransferase; the latter interacts with RNA polymerase II, which is attached mainly 
to CGIs within the promoters (Ooi et al. 2007; Weber et al. 2007). However, in chronic 
wound inflammation, the interaction between H3K27me and H3K9me makes CGIs 
within the promoters of some tumor suppressor genes more liable to be methylated. The 
resulting suppression of those genes stops the progenitor cells at an abnormal step of 
clonal expansion, subsequently initiation of oncogenesis (Ohm et al. 2007). Moreover, 
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each tumor type is identified with its particular group of methylated genes (Melki et al. 
1999; Feltus et al. 2003).  
Recently, some studies reported detection of tissue-specific differentially methylated 
regions (T-DMRs) and cancer-specific differentially methylated regions (C-DMRs) 
present frequently in areas outside CGIs termed as CGI shores with a significant 
correlation with gene expression (Doi et al. 2009; Irizarry et al. 2009). CGI shores are 
located within 2 Kb of CGIs with relatively low CpG density.  
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Figure ‎1.3 Epigenetic control of gene expression 
Transcriptionally active DNA is characterized by an opened chromatin with widely 
spaced nucleosomes (light blue circles), unmethylated cytosines (white circles) and 
acetylated histones H3 lysine (green triangles). This opened chromatin structure is 
accessible to enzymes e.g. HATs and transcriptional factors. Chromatin is transformed 
to transcriptionally inactive through a reaction regulated by DNMTs resulting in 
synthesis of methylated cytosines (red circles). DNMT recruits proteins like MBPs 
(methyl-CpG binding protein) which bring HDACs. All these factors lead to compact 
nucleosomes (dark blue circles) with deacetylated histones (dark pink arrows) and 
methylated specific histones H3 lysine (red ovals) (Lindsey et al. 2005). 
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1.4 DNA methylation and Cancer 
 
For initiation of cancer, it is generally thought that the functions of the two alleles of a 
tumor suppressor gene (TSG) are lost. This is known as the „Knudson‟s two-hit 
hypothesis‟ (Knudson 1971) (Figure 1.4). In somatic tumors, promoter 
hypermethylation of the second copy of a TSG following a mutation of the first copy or 
promoter hypermethylation of both copies of a TGS can switch off the gene function 
and initiate malignancy. In inherited tumors e.g. retinoblastoma, promoter 
hypermethylation of the second copy of a TSG can eliminate the gene function after a 
germ line mutation of the first copy of the gene (Baylin 2005).  
Cancer is generally associated with global hypomethylation of pericentromeric satellites 
and repeated sequences (Das and Singal 2004) especially in tumors with metastasis 
(Bedford and van Helden 1987). This global hypomethylation leads to genome 
instability due to transcriptional activation of transposable elements located in the repeat 
sequences (Wong et al. 2001; Ehrlich 2002). Moreover, hypomethylation of imprinted 
genes results in alteration of their expression, subsequently initiation of malignancy 
(Rainier et al. 1993; Malik and Brown 2000). Global DNA hypomethylation occurs 
simultaneously with localized hypermethylation of CGIs within the promoters of TSGs 
resulting in gene silencing (Kanduri et al. 2009; Baylin et al. 2000; Strathdee and Brown 
2002; Brueckner and Lyko 2004; Davis and Uthus 2004). Genes, which either have 
essential roles in the tumor process or show no definite effects in cancer, can be targets 
for DNA methylation (Issa 2000). In addition, high levels of DNMTs enzymes are 
observed in cancer with DNA hypermethylation (Belinsky et al. 1996; Melki et al. 
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1998). The analysis of DNA hypermethylation and DNA hypomethylation can be used 
in tumor diagnosis and in cancer management (Ehrlich 2002).  
 
 
 
 
Figure ‎1.4 Knudson's two-hit hypothesis 
In sporadic (non-inherited) tumors, somatic mutation of a critical gene e.g. TSG (first 
hit) is followed by deletion or mutation of the second copy of the gene (second hit). 
Instead of gene mutation, promoter hypermethylation of TSG (first hit) is followed by 
either deletion or promoter hypermethylation (biallelic methylation) of the second copy 
of the gene (second hit) to initiate the malignant process (Kim and Deng 2007).   
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1.5 AML and DNA methylation    
 
The altered DNA methylation pattern in the promoter of the calcitonin gene was the first 
reported data of disrupted methylation in AML (Baylin et al. 1987). The calcitonin gene 
was considered a hot spot for methylation in AML (Melki et al. 1999). Being a cancer, 
leukaemia is associated with global hypomethylation of repeated regions together with 
localized promoter hypermethylation of critical genes e.g. TSGs (Melnick 2010; Oki and 
Issa 2010; Peters and Schwaller 2011). The genes that are methylated in leukaemia seem 
to be cancer specific (Melki et al. 1999; Rush et al. 2001). There are two possible 
explanations for this specificity; the first is the presence of certain features in the 
sequence of target genes makes those genes more susceptible to be methylated, for 
instance a repeated region or a unique chromatin structure. The second explanation can 
be concluded from the cells, which have specific methylation pattern, show a 
characteristic disrupted gene expression profile resulting from methylation (Rush et al. 
2001).  
Genes of different functions are found to be hypermethylated in AML. Tumor 
suppressor genes e.g. P15, P73, genes responsible for cellular differentiation e.g. 
MYOD1 and genes encoding transcriptional regulators e.g. PITX2, CEBPα have been 
associated with promoter hypermethylation in AML (Dodge et al. 1998; Wong et al. 
2000; Toyota et al. 2001; Patricia Santos Pereira Lima 2008; Figueroa et al. 2009b). 
Also, promoter hypermethylation of CDH1 (gene encoding calcium dependent cell-cell 
adhesion protein) and DAPK (a gene that induces morphological changes in apoptosis) 
have been identified in AML (Greco et al. 2010). Additionally, promoter 
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hypermethylation of DBC1 is characterized in NK AML which is associated with poor 
prognosis (Alvarez et al. 2010).  
Furthermore, the fusion proteins e.g. AML1-ETO and PML-RARα resulting from 
t(8;21) and t(15;17) translocations respectively recruit the epigenetic modifying 
enzymes e.g. HDAC and DNMT1 in addition to co-repressors including N-CoR and 
Sin3 resulting in silencing of target genes (Galm and Esteller 2004; Plass et al. 2008). 
Similarly, inversion 16 AML with the fusion protein CBFB-MYH11 brings co-
repressors mSin3A and HDAC8 to target genes (Durst et al. 2003).  
As previously mentioned, class III mutations in AML are concerned with genes 
controlling the epigenetic status of the cells. Mutation of TET2 gene, which catalyzes the 
conversion of methylcytosine to 5-hydroxymethylcytosine, was detected in AML 
especially NK AML, and was associated with bad prognosis (Weissmann et al. 2011). 
The methylation profile of IDH1 or IDH2 mutant patients was similar to the methylation 
profile resulting from TET2 mutation, suggesting that both mutations IDH1/2 and TET2 
could have the same effect on the cytosine methylation in haematopoietic cells 
(Figueroa et al. 2010a). Besides, DNMT3A mutation was identified in NK AML with a 
significant worse overall survival than AML patients who lack DNMT3A mutation (Ley 
et al. 2010). Also, EZH2 mutation was detected in MDS patients with a disturbance in 
H3K27 methylation which provokes DNA promoter methylation (Fathi and Abdel-
Wahab 2012).  
Therefore, investigating the relationship between AML subtypes and DNA methylation 
assisted in better understanding the pathogenesis and prognosis of AML. 
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1.6 Methods of DNA methylation analysis 
 
There are many approaches for detecting DNA methylation; most of them rely on one of 
three basic methods: bisulphite conversion of DNA, cutting the DNA using methylation-
sensitive restriction enzymes and immunoprecipitation using antibodies against 
methylation-related proteins.  
 
1.6.1 Bisulphite conversion of DNA 
 
The bisulphite treatment of DNA is the gold standard for DNA methylation analysis 
which facilitates the investigation of DNA methylation at a single base resolution 
(Murrell et al. 2005; Patterson et al. 2011). Sodium bisulphite treatment of DNA 
converts unmethylated cytosine to uracil leaving methylated cytosine unchanged 
through a three-step reaction (Figure 1.5). Bisulphite conversion of DNA can be 
combined with other methods of DNA methylation analysis such as methylation 
sensitive restriction enzymes (Ammerpohl et al. 2009). The major disadvantage of this 
reaction is the incomplete bisulphite conversion, which results in false positive results 
(Grunau et al. 2001; Beck and Rakyan 2008).  
The bisulphite treatment of DNA is involved in the analysis of DNA methylation either 
qualitatively or quantitatively. Methylation-specific PCR (MSP) is a qualitative method, 
which relies on the use of two pairs of primers to amplify either methylated or 
unmethylated alleles after being treated by sodium bisulphite (Herman et al. 1996). 
Chapter 1 
48 
 
Although MSP is highly sensitive (it can detect methylated alleles in the presence of 
1000 of unmethylated alleles), it is not a quantitative method. Therefore, another 
quantitative variant of MSP was developed (MethyLight). MethyLight is also highly 
sensitive method; it can detect methylated alleles in the presence of 10,000-fold excess 
of unmethylated alleles (Eads et al. 2000). MethyLight is based on quantifying the 
amplified DNA by real time PCR using methylated specific primers and a methylated 
specific fluorescent probe (Eads et al. 2000). Other quantitative methods include direct 
bisulphite sequencing of PCR products (Figure 1.6) after being cloned (sequencing-by-
chain termination) (Sanger and Coulson 1975), pyrosequencing which measures the 
ratio of cytosine to thymine during the sequence extension (sequencing-by-synthesis) 
(Ronaghi 2001) and matrix assisted laser desorption ionization/ time of flight mass 
spectrometry (MALDI-TOF MS) which involves analysis of the bisulphite converted 
DNA with the base specific cleavage step of nucleotides by means of mass spectrometry 
(Shen and Waterland 2007).  
The bisulphite converted DNA can also be combined with hybridization on a microarray 
chip to investigate 1,536 independent CpG sites in 96 patients simultaneously. This 
technology is known as GoldenGate methylation assay (Bibikova and Fan 2009). With 
the improvement of the epigenetic analysis tools, HumanMethylation27 BeadChip has 
been introduced which interrogates 27,578 CpG sites corresponding to 14,000 genes in 
12 patients in parallel (Bibikova and Fan 2009). The most advanced BeadChip 
technology is the Infinium Methylation 450K which analyzes 480,000 cytosines 
distributed over the whole genome in 12 patients in parallel (Dedeurwaerder et al. 2011).  
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In addition, Li et al have successfully sequenced bisulphite converted DNA extracted 
from human peripheral blood mononuclear cells using a next-generation sequencing 
technology (NGS); Illumina Genome Analyzer (Illumina GA) (Li et al. 2010).  In this 
Bisulphite-seq study, a global view of the DNA methylation has been achieved with 
92% coverage of total CpG sites present within the human genome. Moreover, a deep 
high-throughput sequencing of bisulphite converted DNA extracted from follicular 
lymphoma cells and CD19
+
 B cells using Roche 454 GS FLX revealed significant 
methylation difference in the regions of interest between malignancy and normal (Choi 
et al. 2010). Both Illumina GA and Roche 454 sequencer interrogate the DNA based on 
single-molecule detection. By contrast, sequencing of the bisulphite converted DNA 
using Applied Biosystems SOLiD system (another high-throughput sequencer) can 
detect two bases at a time by ligation chemistry (Bormann Chung et al. 2010). The main 
limitation of the epigenome-wide association studies (EWASs), which are based on the 
NGS technology, is the cost. That reflected in limited number of the samples 
investigated compared with the number of samples investigated by microarray-based 
studies (Rakyan et al. 2011). Besides, EWASs generate much data that necessitates 
development of software programs for retrieval, alignment to a reference genome and 
visualization of the deep sequencing data (Gupta et al. 2010).  
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Figure ‎1.5 Chemistry of bisulphite conversion of DNA 
DNA is denatured by sodium hydroxide before starting the bisulphite conversion which 
consists of 3 steps. Step 1: Sulphonation of cytosine to form cytosine sulphonate. Step 2: 
Hydrolytic deamination to form uracil sulphonate and Step 3: Alkali-desulphonation to 
remove the sulphonate group. The first 2 steps of the bisulphite conversion are 
performed under acidic conditions while the third step is performed under alkaline 
treatment (Schumacher 2007). 
 
Figure ‎1.6 PCR amplification of a bisulphite converted DNA sequence 
In the bisulphite conversion process, unmethylated cytosine is converted into uracil 
which is amplified as thymine. By contrast, methylated cytosine is protected from the 
bisulphite conversion and is further amplified as cytosine (Frommer et al. 1992). 
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1.6.2 Methylation sensitive restriction enzymes 
 
This method depends on the ability of some restriction enzymes to digest the DNA at a 
specific sequence e.g. CCGG (HpaII – MspI) or CCCGGG (SmaI – XmaI). HpaII and 
SmaI cleave the DNA sequence when the internal cytosine is unmethylated while MspI 
and XmaI cleave the DNA sequence when the internal cytosine is methylated (Jones et 
al. 1990; Sepulveda et al. 2009). The restriction reaction is followed by PCR 
amplification, which amplifies the resultant digested fragments. However, not all 
methylated CpGs are located within CCGG or CCCGGG, hence many potential CpG 
sites are not analyzed by this method. Therefore, using restriction enzymes is considered 
an initial selecting step to be combined with other methods of DNA methylation 
analysis. Restriction landmark genomic scanning (RLGS) is a non-microarray-based 
method that includes using enzymes restricting the DNA followed by running the 
resultant fragments over a two-dimensional electrophoresis (Ando and Hayashizaki 
2006). RLGS is an efficient technique; it can detect thousands of CpG sites in a single 
experiment and is applicable to any organism (Okazaki et al. 1995; Ando and 
Hayashizaki 2006). However, RLGS has limited genome coverage (up to 10% of CGIs) 
and low sensitivity (it requires at least 30% DNA methylation in order to be detectable) 
(Shen and Waterland 2007). Additionally, combination of bisulphite conversion of DNA 
followed by DNA digestion with restriction enzymes (COBRA) has been achieved 
(Xiong and Laird 1997). COBRA (combined bisulphite restriction analysis) is a 
quantitative method, which is applicable to paraffin-embedded tissue samples, and has 
been used to investigate a wide range of tumors (Mund et al. 2005; Hassel et al. 2010). 
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Other methods based on using restriction enzymes include comprehensive high-
throughput arrays for relative methylation (CHARM) approach. CHARM involves DNA 
digestion by McrBC endonuclease enzyme, followed by hybridization on a high density 
array to investigate up to 4.6 million CpG sites across the genome (Irizarry et al. 2008; 
Irizarry et al. 2009). Moreover, HpaII tiny fragment enrichment by ligation-mediated 
PCR (HELP) involves digestion of DNA with HpaII and in parallel, DNA is digested by 
MspI enzyme, the resultant fragments are labelled with specific dyes and hybridized on 
a microarray chip (Khulan et al. 2006). Furthermore, reduced representation bisulphite 
sequencing (RRBS) entails digestion of DNA by MspI enzyme followed by bisulphite 
conversion of the DNA fragments and sequencing using Illumina GA (Gu et al. 2011). 
 
1.6.3 Immunoprecipitation (affinity enrichment) 
 
The third main approach for detecting DNA methylation is to use a specific monoclonal 
antibody against methylated cytosine in single-stranded DNA (MeDIP) or to use a 
methyl-CpG binding domain of the MBD2 protein to capture double-stranded DNA 
(MBDCap). In both MeDIP and MBDCap, capture of the methylated DNA is performed 
on a previously fragmented or sonicated DNA (Figure 1.7).  
MeDIP, a well-established application of the affinity enrichment methods, was 
developed by two groups of scientists at the same time (Weber et al. 2005; Keshet et al. 
2006). The enriched DNA fragments were further hybridized against the input on a 
microarray chip (MeDIP-chip). This monoclonal antibody based approach recognizes 
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methylation in regions with a threshold of CpG density equals 2-3% (Keshet et al. 
2006), with a marked correlation between the MeDIP signals and CpG density (Jia et al. 
2010). Thus, MeDIP detects the mean methylation of a DNA region and does not 
analyze single-site CpG (Ammerpohl et al. 2009). Consequently, MeDIP can detect the 
differences between promoter methylation versus non-promoter methylation in one cell 
type and the differentially methylated regions (DMRs) between different tissue types 
(Rakyan et al. 2008; Tomazou et al. 2008). The main drawback is in the array design, 
which results in inaccurate hybridization signals. In addition, the repeated regions of 
DNA, which have a high methylation level, are not involved on the array and that leads 
to lowering the overall genome coverage (Beck and Rakyan 2008). The combination of 
NGS with MeDIP i.e. MeDIP-seq solves this problem and enables the detection of 
methylated regions in short fragments and in repeated families (Down et al. 2008; Feber 
et al. 2011; Kim et al. 2011). The use of paired-end (PE) sequencing assisted in having 
the precise mapping position of each DNA fragment thus, improving the resolution 
(Down et al. 2008). It was stated that 40 million reads (each read corresponds to a single 
DNA fragment) of MeDIP generated from Illumina GA are enough for a complete 
coverage of the whole genome in any cell type (Beck and Rakyan 2008).  
For interpretation of the DNA methylation signals of MeDIP-seq data, an analytical 
algorithm has been developed; Bayesian Tool for Methylation Analysis (Batman) 
(Down et al. 2008). At 100bp resolution, Batman gives an absolute quantification of the 
methylation signals which are linear to the density of methylated cytosines. Additionally 
and in order to reduce the time for preparing MeDIP-seq libraries, an automated MeDIP 
(AutoMeDIP-seq) has been developed. AutoMeDIP-seq assay can investigate 16 
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samples all at once (Butcher and Beck 2010). Therefore, MeDIP-seq is a technique 
which combines the criteria of being affordable, having sufficient CpG coverage and 
good resolution down to 100bp (Butcher and Beck 2010). 
Notably, MethylCap-seq (MBDCap-seq) assay depends on capturing the sonicated 
methylated DNA using methyl-CpG binding domain of the MBD2 protein followed by 
sequencing the short DNA fragments by Illumina GA (Brinkman et al. 2010). There are 
some differences between MeDIP and MBDCap. The immunoprecipitation (IP) step is 
performed on a single-stranded DNA in MeDIP, while in MBDCap the capture reaction 
is carried out on a double-stranded DNA. In addition, MeDIP identifies methylated 
cytosine regardless of the sequence context while MBDCap detects methylated cytosine 
within the CpG context (Brinkman et al. 2010). Besides, the enrichment of the 
methylated regions is higher in MBDCap than in MeDIP for CpG dense regions. The 
reason for that is during MBDCap, the enriched DNA fragments are eluted using a salt 
concentration gradient, which increases the elution of high dense methylated CpG 
regions with the increase in the salt solution concentration (Robinson et al. 2010) 
(Figure 1.7). Moreover, for identification of DMRs between benign and malignant 
samples, MeDIP can detect hypermethylated DMRs of low and intermediate CpG 
density, while MBDCap can identify hypermethylated DMRs of low density as well as 
DMRs of high CpG density (Nair et al. 2011). 
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Figure ‎1.7 Affinity enrichment DNA methylation methods 
The figure shows that in MeDIP the enrichment of methylated fragments is performed 
after DNA denaturing to obtain a single-stranded DNA. By contrast, in MBDCap, the 
capture reaction is carried out on a double-stranded DNA. In MBDCap, the DNA can 
be eluted either in a high-salt buffer (2 Molar NaCl; 2M NaCl) as a single fraction or in 
separate elutions of increasing concentration of NaCl from 0.2M to 2M to obtain 
different densities of enriched methylated CpGs. MBDElu5 signifies the 1M fraction of 
the elution series (Robinson et al. 2010). 
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1.6.4 Guidance for selecting the appropriate DNA methylation method 
 
In order to choose the correct method to analyze DNA methylation, it is important to 
determine the goal of the study. Figure 1.8 is a simplified „decision tree‟ that describes a 
guide to choose the appropriate technique depending on the target of the experiment 
which could be either a global assay of regions that are not pre-selected or investigating 
pre-identified locus-specific regions (Shen and Waterland 2007).  
 
Figure ‎1.8 DNA methylation methods 
A decision tree demonstrates the different methods of DNA methylation analysis 
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1.7 DNA methylation studies in AML 
 
Studies of DNA methylation in AML can be divided into 2 major groups; studies that 
analyzed individual genes and studies that investigated the DNA methylation on a 
genome-wide scale. Studies concerning candidate genes detected frequently methylated 
genes in AML e.g.  P15, CDH1, ER, DAPK1, CEBPα using different methods such as 
direct bisulphite sequencing (Santana-Lemos et al. 2011), MSP (Aggerholm et al. 1999), 
COBRA (Ekmekci et al. 2004), pyrosequencing (Claus et al. 2011) and MALDI-TOF 
MS (Bullinger et al. 2010).  
Studies investigating DNA methylation in AML on a genome-wide scale were either 
array-based or not array-based. For instance, RLGS (not array-based) identified a 
preferential methylation on chromosome 11 in de-novo AML (Rush et al. 2001). On the 
other hand, array-based studies e.g. the GoldenGate methylation assay detected an 
increase in the promoter methylation in relapse versus diagnostic AML patients (Wilop 
et al. 2011). In addition, MeDIP-chip identified differences in DNA methylation 
between patients with and without DNMT3A mutation in NK AML (Ley et al. 2010) and 
in AML-M5 (Yan et al. 2011). Besides, HumanMethylation27 BeadChip and Infinium 
methylation 450K identified a preferential DNA methylation in genes targeted by 
polycomb group proteins in 118 NK AML patients (Deneberg et al. 2011). A recent 
important study performed by Figueroa et al revealed clustering of AML patients into 16 
groups depending on their DNA methylation signatures (Figueroa et al. 2010b). 5 of 
those 16 groups were new AML subtypes, which did not have either common 
morphological or molecular characteristics but shared a specific DNA methylation 
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pattern in addition to overall survival different from the survival of other well-
established AML subtypes. In this array-based study, Figueroa et al used the HELP 
technique followed by hybridization of HpaII amplifiable fragments on a customized 
promoter array platform covering > 50,000 CpG sites in around 14,000 genes in 344 
AML patients (Figueroa et al. 2010b). 
In summary, many studies have been carried out in AML exploring the changes in DNA 
methylation. However, the previous studies investigated either promoters or CGIs 
methylation. Although CGIs within the promoters are the targets of DNA methylation in 
cancer, DNA methylation could occur outside the CGIs e.g. in CGI shores. In addition, 
the repetitive regions, which undergo global hypomethylation in AML, are difficult to 
be investigated by array-based DNA methylation methods. Therefore, in order to obtain 
a comprehensive view of DNA methylation alterations in AML, genomic regions such 
as CGI shores, gene bodies, repetitive DNA regions in addition to promoters and CGIs 
should be investigated.  
 
 
 
 
 
 
 
Chapter 1 
59 
 
1.8 Aims of the thesis 
 
We planned to study the global DNA methylation alteration in AML using MeDIP-seq 
method (MeDIP followed by next-generation sequencing by Illumina GAII). The 
generated methylation signals are quantified by Batman algorithm in order to obtain 
DNA methylation profiles with a 100bp resolution. The availability of AML 
methylation profiles from different AML subtypes would assist in achieving the 
following goals: 
1. Identification of differences in the global DNA methylation between AML and 
normal bone marrow (NBM). 
2. Detection of DMRs between AML and NBM located in specific genomic regions 
e.g. promoters, gene bodies, CGIs, CGI shores. 
3. Identification of differences in DNA methylation of promoters, gene bodies, 
CGIs and CGI shores between AML subtypes. 
4. Studying the DNA methylation alteration in the repetitive sequences in AML and 
AML subtypes. 
5. Investigating the correlation between DNA methylation of different genomic 
regions and gene expression. 
6. Identification of novel differentially methylated promoters in AML and studying 
their gene expression. 
7. Validation of the MeDIP-seq results by other methods of DNA methylation 
analysis e.g. direct bisulphite sequencing, bisulphite pyrosequencing and 
Illumina Infinium Human Methylation27 BeadChip Arrays. 
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Chapter 2. Materials and Methods 
 
2.1 Patients and samples 
 
Patients‟ samples (peripheral blood or bone marrow) were stored in the tissue bank at St 
Bartholomew‟s Hospital after an informed consent was obtained. The ethical approval to 
access the stored materials and to carry out the study was obtained from East London 
and City Research Ethics Committee (ref 10/H0704/65). The control samples were four 
NBMs; three of them were from healthy donors provided from Stem Cell Laboratory at 
St Bartholomew‟s Hospital. The fourth control was NBM of non-infiltrating follicular 
lymphoma patient in remission. 
 
2.2 Cell lines 
 
7 AML cell lines (Kasumi-1, OCI-AML2, HL60, P31/FUJ, CTS, Kmoe2 and THPI) 
were included in the pyrosequencing validation and in the gene expression study. Two 
cell lines (K562 and MCF7) were involved in the SPHKAP gene transfection experiment 
(Table 2.1). Kasumi cell line, OCI-AML2 cell line, HL60 cell line and Kmoe2 cell line 
were obtained from the Deutsche Sammlung von Mikroorganismen und Zellkulturen -
DSMZ- (German Collection of Microorganisms and Cell Cultures). CTS cell line, THPI 
cell line, P31/FUJ cell line, K562 cell line and MCF7 cell line were provided by Dr. 
Simone Jueliger (Barts Cancer Institute). 
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Table ‎2.1 Details of cell lines investigated 
Cell line name Origin Cell type 
OCI-AML2 From peripheral blood of a 65-
year-old man with AML (AML 
FAB M4) 
Human AML 
Kasumi-1 From peripheral blood of a 7-
year-old Japanese boy with 
AML (AML FAB M2) 
Human AML 
CTS From peripheral blood of a 13-
year-old girl with AML (AML 
FAB M1 in relapse) 
Human AML 
Kmoe2 From peripheral blood of a 2-
year-old girl with acute 
erythremia 
Human acute erythremia 
HL60 From peripheral blood of a 35-
year-old woman with AML 
(AML FAB M2) 
Human AML 
THP-1 From peripheral blood of a 1-
year-old boy with acute 
monocytic leukaemia at relapse 
(AML FAB M5) 
Human acute monocytic 
leukaemia. 
P31/FUJ From peripheral blood of a 7-
year-old Japanese acute 
monocytic leukaemia (AML 
FAB M5) 
Human acute monocytic 
leukaemia. 
K562 Established from the pleural 
effusion of a 53-year-old 
woman with chronic myeloid 
leukaemia (CML) in blast crisis 
CML in blast crisis 
MCF7 From the pleural effusion of a 
69-year-old Caucasian woman 
with metastatic mammary 
carcinoma 
Human breast adenocarcinoma 
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2.3 DNA extraction 
 
The samples (peripheral blood or bone marrow) were provided as liquid nitrogen stored 
vials. Those vials contained leucocytes, which were previously separated by Ficoll and 
cryopreserved. The vials are removed from liquid nitrogen and immediately thawed in 
37C water bath. The content from a vial is emptied into a sterile 15ml falcon tube. 
Phosphate buffered saline (PBS) is added drop by drop to the tube till reaching 10ml. 
The falcon tube is next centrifuged at 1300 rpm for 5 minutes. The supernatant is 
removed and 10ml of PBS is added to the cell pellet. 1ml is kept for counting the cells 
and the rest is centrifuged at 1300 rpm at 4C for 5 minutes. The supernatant is removed 
and maximum of 5 X10
6
 cells are used for DNA extraction by DNeasy Blood & Tissue 
kit (Catalogue number 69506, Qiagen). Cell lines are centrifuged at 1300 rpm for 5 
minutes, the supernatant is removed and the DNA extraction process is performed on the 
cell pellets. In a 1.5ml eppendorf tube, the cell pellet is resuspended in 200l PBS and 
20l Proteinase K is added. 200l of lysis Buffer AL (provided) is next added to the 
tube, the mixture is vortexed and incubated at 56C for 10 minutes. 200l ethanol (96-
100%) is added to the tube and mixed by vortexing. The mixture is then pipetted into 
DNeasy Mini spin column (provided) placed in a 2ml collection tube. The column is 
centrifuged at 8000 rpm for 1 minute and both the flow-through and the collection tube 
are discarded. DNeasy Mini spin column is further placed in a new 2ml collection tube 
and 500l wash buffer AW1 is added. The column is centrifuged at 8000 rpm for 1 
minute and both the flow-through and the collection tube are discarded. DNeasy Mini 
spin column is placed in a new 2ml collection tube and 500l wash buffer AW2 is 
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added. The column is centrifuged at 14,000 rpm for 3 minutes and again the flow-
through and the collection tube are discarded. DNeasy Mini spin column is finally 
placed in a new-labelled 1.5ml eppendorf tube and 200l elution buffer AE is added 
directly onto the DNeasy column membrane. The tube is incubated at room temperature 
for 1 minute followed by centrifugation at 8000 rpm for one minute to elute the DNA. 
 
2.4 MeDIP-seq 
 
2.4.1 MeDIP-seq protocol  
 
We performed a pilot study using Kasumi cell line before starting the analysis of the 
patients‟ samples. Only high quality DNA is subjected for sonication using the Sonic 
Vibracel, model VCX 500. The distribution of the DNA fragments‟ size should be 
between 100-1000bp with a peak size around 300bp (Figure 2.1a). The reasons for 
choosing 300bp as target peak size are firstly for Illumina sequencing since the 
maximum gap between the 2 adaptors over Illumina flow cell should be  500bp. The 
second reason is for better alignment of MeDIP-seq reads, which requires a DNA insert 
size between 120-170bp. The MeDIP-seq libraries are prepared using Paired-End DNA 
Sample Preparation Kit (Catalogue number PE-102-1002, Illumina). 
5g sheared DNA fragments are blunt-ended by incubation at 20C for 30 minutes in 
100µl reaction volume containing 10µl T4 DNA polymerase to fill in 5´overhangs, 1µl 
Klenow enzyme to remove protruding 3´overhangs, 5µl T4 polynucleotide kinase to 
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phosphorylate the 5´-OH, 10µl T4 DNA ligase buffer with 10mM ATP and 4µl of dNTP 
mix. The reaction volume is purified using QIAquick PCR purification kit (Catalogue 
number 28104, Qiagen) and eluted in 32µl elution buffer (EB). In order to allow ligation 
to Illumina paired-end (PE) adaptors, 10µl adenine is added to the 3´ end of DNA 
fragment by 3µl Klenow exo-minus in the presence of 3µl Klenow buffer. The reaction 
mix is incubated at 37C for 30 minutes and then purified by MinElute PCR purification 
kit (Catalogue number 28004, Qiagen) in 10µl EB. Next, 10µl Illumina PE adaptors are 
added to the purified DNA in the presence of 5µl DNA ligase and 25µl DNA ligase 
buffer. The reaction volume is incubated at room temperature for 15 minutes and 
cleaned by QIAquick PCR purification kit in 50µl EB. 50ng ligated purified DNA is set 
aside as an Input fraction and at least 4µg ligated DNA is required for 
immunoprecipitation (IP). 4µg ligated DNA is next diluted with water to reach a final 
volume of 250µl. For proper IP reaction, genomic DNA is denatured by heating at 
100°C for 10 minutes and cooled immediately on ice for 10 minutes. The reason for 
denaturing DNA is that the IP process is more efficient on single-stranded DNA 
(ssDNA) than on double-stranded DNA (dsDNA) (Weber et al. 2005). 250ml 2 X IP 
buffer is added to the denatured DNA sample together with 7.5µl anti-5 methylcytosine 
antibody (1μg/μl) (MAb-081-100, Diagenode) and incubated at 4°C for 2 hours with 
slow rotation. To collect the enriched methylated DNA fragments, magnetic Dynabeads 
are used. 40µl magnetic Dynabeads (Dynabeads M-280 sheep anti-Mouse IgG, 
Invitrogen) are prewashed with 1ml 1 X IP buffer and collected by a magnetic rack. 
Dynabeads are next added to the DNA sample and incubated at 4°C for 2 hours with 
slow rotation. Dynabeads are then collected using a magnet and washed with 750µl 1 X 
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IP buffer for three times. To release the immunoprecipitated DNA, Dynabeads are 
resuspended in 200µl digestion buffer and 5µl Proteinase K (10mg/ml). The suspension 
is incubated at 55°C for 2 hours with shaking to avoid sedimentation of the beads. After 
the incubation, the sample is divided in 2 separate tubes and purified by Zymo DNA 
Clean and Concentrator-5 kit (using 700µl binding buffer) to elute the DNA in 20µl EB. 
For amplification of the DNA, 10µl MeDIP and 10ng Input DNA are subjected to 
limited PCR step using primers provided from Illumina for PE library preparation. PCR 
are performed duplicate for MeDIP and single for the Input. The MeDIP PCR tubes are 
combined together and purified in 20µl EB by Zymo DNA Clean and Concentrator-5 kit 
(Catalogue number D4003, Zymo Research). Real time PCR is carried out to validate 
the enrichment of methylated DNA after the IP step by calculating the change in the Ct 
(cycle threshold) between MeDIP and Input in methylated and unmethylated genes 
(validation of the IP step is described in detail in section 2.4.2). For DNA size selection, 
15µl MeDIP is run over 2% low melting temperature gel (Figures 2.1b, c). MeDIP is 
excised from the gel in the range of 250-300bp (i.e. the insert size of 120-170bp) and 
eluted in 30µl EB using Qiagen Gel Extraction kit (Catalogue number 28704, Qiagen). 
The last step has been modified to use MinElute PCR purification kit‟s columns to 
obtain a more concentrated DNA sample eluted in 10µl EB (Figures 2.1d, e). The 
MeDIP-seq library is now ready to be quantified and sequenced. MeDIP-seq protocol 
steps are summarized in Figure 2.2. 
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a.                                                                                     
 
 
 
 
b.                                                                         c. 
                    
d.                                                                           e. 
          
Figure ‎2.1 MeDIP-seq protocol steps 
a. Sonicated/ fragmented  DNA sample analyzed by Agilent 2100 Bioanalyzer with an average 
peak size around 300bp.  
b, c. Gel size selection of MeDIP-seq library (the sample in the middle) in a range of 250-300bp. 
e, d. Adjustment of the last step of MeDIP-seq protocol since elution of MeDIP-seq library in 
10µl EB (e) revealed a more concentrated DNA library than elution in 30µl EB (d). 
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Figure ‎2.2 Summary of MeDIP-seq steps 
Genomic DNA undergoes sonication in order to obtain short fragments with peak size 
around 300bp. The ends of each fragment are corrected to be suitable for ligation with 
PE adaptors. The IP step is performed on single-stranded DNA using a specific 
monoclonal anti-5 methylcytosine antibody (Ab). The enriched methylated DNA is 
collected by magnetic Dynabeads. Proteinase K is used to separate Dyanabeads-Abs 
from the DNA fragments. MeDIP-seq protocol is followed by gel size selection, library 
quantification, high-throughput sequencing and bioinformatic analysis of the data 
generated. 
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2.4.2 Real time PCR testing of IP efficiency 
 
In order to test the efficiency of the IP step, genes (methylated and unmethylated) (Table 
2.2) were chosen from the Human Epigenome Project (HEP) (Eckhardt et al. 2006) to be 
quantified in both MeDIP and Input DNA by real time PCR (RT-PCR). The reaction 
mix consists of 5l master mix (Fast SYBR® Green Master Mix P/N 4385612), 1l 
forward primer (10M), 1l reverse primer (10M), 2.5l water and 0.5l of either 
MeDIP or Input DNA (10ng). The RT-PCR is run over ABI Prism 7900HT (Applied 
Biosystems) for 25 minutes. Ct values of methylated and unmethylated genes in MeDIP 
and Input are normalized against the reference gene, which is unmethylated gene and 
has the lowest CpG density. To detect the enrichment ratio (Appendix 1 Figure 1), 
these steps are performed:  
1.  Ct MeDIP = (Ct MeDIP - Ct reference) 
2.  Ct Input = (Ct Input - Ct reference) 
3.  Ct = ( Ct MeDIP -  Ct Input) 
4. Enrichment ratio = 2 -  Ct 
 
Table ‎2.2 Genes for real time PCR testing of IP efficiency 
Gene HEP id Chromosome Base 1 Base 2 *CpG 
density 
Methylation 
status 
BRD1 4994 22 48435751 
 
48436242 
 
4.9% methylated 
SLC5A4 6583 22 30949610 
 
30950048 
 
2.1% methylated 
DEPDC5 13478 22 35495486 
 
35495833 
 
7.2% unmethylated 
EIF4ENIF1 5132 22 30209493 
 
30209791 
 
4.0% unmethylated 
TBC1D7 9066 6 13436197 
 
13436521 
 
2.5% unmethylated 
*CpG density % equals the observed number of CpGs in a sequence / the length of this 
sequence. HEP; Human Epigenome Project. 
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2.4.3 MeDIP-seq library quantification 
 
The target of library quantification is to have a library of 10 nanomolar (NM) 
concentration which will be diluted to obtain a 4 picomolar (PM) concentration solution 
over the Illumina flow cell. This concentration is essential to obtain well-identified 
clusters during the cluster generation step of Illumina sequencing process. RT-PCR is 
the method of choice for library quantification. Designed primers and a dual labelled 
probe (DLP) for the Illumina PE adaptor sequences are used (Quail et al. 2008). The 
concept is generating a standard curve of a previously successful sequenced library, for 
which the concentration and the exact cluster number are known. Two different dilutions 
of the newly prepared libraries are next compared to the standard curve. For accurate 
quantification, both standard and new libraries should have the same insert size. 
Primers‟ sequence: AATGATACGGCGACCACCGAGATC, 
CAAGCAGAAGACGGCATACGAGATC. 
DLP‟s sequence: [FAM] CCCTACACGACGCT5CTTCCGATCT [TAMRA].      
 
2.4.4 High-throughput sequencing/ NGS 
 
The quantified dsDNA MeDIP-seq library is subjected to high-throughput 45 base 
paired-end sequencing over the Illumina flow cell, the sequencing was performed by the 
Genome Centre. The flow cell is a glass slide consists of 8 lanes and each lane is divided 
into 100 - 120 tiles. Each library is run over one lane with a preservation of one lane for 
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the standard (PhiX) as a positive control to test the quality and the success of the whole 
run. Preparation for sequencing includes firstly, DNA denaturing by NaOH solution and 
further diluted in HT1 buffer (tris buffer) to end into 4PM (picomolar) concentration 
solution ready to be put over the flow cell. Secondly, the “cluster generation” step, 
which is processed by adding unlabelled nucleotides mixture and DNA polymerase to 
the ssDNA (single-stranded DNA) library. The adaptor oligonucleotides of a DNA 
fragment are complementary to anchor primer sequences present inside the flow cell. 
Each ssDNA fragment is hybridized to the flow cell anchors initiating an amplification 
reaction; „bridge amplification‟ (Voelkerding et al. 2009). This reaction is unique to 
Illumina since the captured DNA strand arches over and hybridized to an adjacent 
anchor oligonucleotide. Subsequently, millions of clusters are generated; each cluster 
represents approximately 1000 amplified clonal molecules of a single DNA fragment. 
Illumina GAII, with the criteria of 1.4-pipeline software and 2.4-system control software 
(SCS) can produce 180,000 – 270,000 clusters/ tile (Figures 2.3 a, b, c). A recent 
advanced pipeline version 1.6 has been used which assisted in filtering highly crowded 
lanes. The actual sequencing step is performed by adding the four labelled nucleotides to 
the flow cell and starting to capture the image of the first base for each fragment with 
giving it identification. A new labelled nucleotide is added to the amplified fragment 
and simultaneously a new image is captured. Illumina starts to sequence from the 
reverse direction in the same way with identifying the first base from the opposite side. 
Following the sequencing steps, the images pass through a pipeline in order to be 
filtered and the reads are produced in a FASTQ format in 2 separate text files, which 
correspond to both directions of sequencing. 
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a.                                                                b. 
 
c. 
 
 
Figure ‎2.3 Clusters generated from Illumina GAII 
 
a, b Two images were taken from 2 different libraries after the cluster generation step. 
The number of clusters in image (a) was around 270,000/ tile, which corresponds to the 
maximum cluster generation capability of Illumina. The clusters in image (b) were > 
300,000/ tile and the filtered clusters were 890/ tile, the low number of filtered clusters 
was because of the overlapped clusters and the poor intensity of images captured. 
 c. Scatter plot of the raw clusters’ number versus the passed filtered clusters. The green 
dots represent the successful runs (raw cluster number range: 120,000 - 270,000/ tile) 
and the red dots are unsuccessful runs, which result in either a low clusters’ number 
(red dot on the left = 15,000/ tile) or a very high cluster number (red dots on the right  
300,000/ tile). The plot shows that, as the number of raw clusters increases, the number 
of passed filtered clusters will increase unless the number of raw clusters exceeds the 
maximum cluster generation capability of Illumina GAII. 
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2.4.5 Sequence alignment by Maq and Bowtie algorithms 
 
Two different algorithms were used for the alignment of the generated reads against the 
reference human genome (NCBI 36/hg18); Maq (Mapping and Assembly with 
Qualities) (Holt et al. 2009) (Figure 2.4) and Bowtie (Langmead et al. 2009). Bowtie 
generated more number of uniquely aligned reads (about one million reads extra) and 
consumed less time in the alignment than Maq. In both Maq and Bowtie, a maximum 
mismatch number of 2 in the first 28 bases was allowed to account for possible 
polymorphisms in the genome. The two FASTQ files for each library were assessed 
through base quality test before performing the alignment. If the base quality was > 30 
that means: 1) The probability of the base being wrong in the sequence is less than 
0.001. 2) The overall base quality of the read is good and that will lead to correct 
alignment. During the alignment, the reads mapping to more than one location are 
removed. PCR duplicates, which could result during the limited PCR amplification step 
in MeDIP-seq protocol, were filtered from the raw reads. The use of PE reads assisted 
in: 1) Better alignment with few mismatches. 2) If one end is matched and another end is 
not, Maq or Bowtie will do the alignment depending on the position of the matched end.  
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Figure ‎2.4 Distribution of the insert size of MeDIP-seq Kasumi cell line library after 
being aligned by Maq 
X axis represents the insert size; Y axis represents the frequency. The insert size is the 
distance between the outer coordinates of each DNA fragment. The figure demonstrates 
that the maximum frequency of reads have an insert size around 120 -170bp. 
 
2.4.6 Batman algorithm 
(A Bayesian Tool for Methylation Analysis) (Down et al. 2008) 
Batman algorithm infers the absolute methylation state for 100bp windows by 
estimating local sequencing read enrichment for methylation taking into account the 
varying densities of methylated CpGs across the genome. Batman relies on some 
aspects: 1) The methylation status of CpG sites within < 1Kb is significantly correlated 
(Eckhardt et al. 2006). 2) DNA methylation in mammals occurs mainly at CpG sites. 3) 
There is no bias in the DNA fragment length distribution. Batman output is in the form 
of GFF files, each GFF file represents a score which equals the median of methylation 
state in a 100bp window. The score ranges between 0 - 1 according to the level of 
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methylation. Batman score > 0.6 implies a high methylated region, a score < 0.4 implies 
a low methylated region and a score between 0.4 and 0.6 implies intermediate 
methylated region (Feber et al. 2011). Before starting the Batman analysis, it is 
important to calibrate each MeDIP-seq sample by estimating how much extra MeDIP-
seq signal is produced by each methylated CpG. In this way, the MeDIP-seq signals are 
compared to CpG density, fitting a linear model and the results are stored in the Batman 
database. In addition, Batman calibration assists in drawing a scatter plot which 
demonstrates the linear correlation between MeDIP-seq signals and density of 
methylated CpGs that is to confirm the efficiency of each MeDIP-seq library before a 
complete Batman analysis is applied (Figure 2.5).  
 
Figure ‎2.5 Batman calibration of Kasumi cell line aligned reads 
The scatter plot shows a linear relationship between MeDIP-seq tags (= the reads 
depth) and the density of methylated CpGs (the blue dots). The blue arrow demonstrates 
the increase in methylation from 0% to 100%. This MeDIP-seq library successfully 
passed the calibration process and a complete Batman analysis can be carried out for 
the total reads. For a given MeDIP-seq sample, calibration process takes few hours, 
while a full Batman analysis takes 9 days (this calibration was performed by Thomas 
Down, Cambridge).   
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2.4.7 MeDIP-seq data statistical workflow 
 
After generating the methylation profiles and in order to detect the differentially 
methylated regions (DMRs) between samples, a MeDIP-seq statistical workflow was 
used. Firstly, to reduce the possible variations among laboratory assays and to facilitate 
the comparison of the genes across all samples, quantile normalization was performed. 
This method is based upon the concept of quantile-quantile plot extended to n 
dimensions (where n is the number of samples) (Bolstad et al. 2003). We next used 
empirical Bayes statistics provided by Bioconductor‟s limma R package to select the 
discriminating genes in each genomic feature investigated e.g. promoters (Gentleman et 
al. 2004). This was performed for every AML cytogenetic group against other groups 
including NBM, and for all AMLs versus all NBMs. The empirical Bayes model was 
used to compute moderated t-statistics and F-statistic. The Benjamini and Hochberg 
false discovery rate (FDR) was used as a multiple testing correction generating adjusted 
P value for each gene.  
For performing the hierarchical clustering analysis and the pair-wise comparison 
between different groups, Pearson correlation coefficient was used to construct the 
distance matrix among samples together with „Ward‟ linkage clustering method (Ward 
1963). 
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2.4.8 Whole genome methylation analysis 
 
To compare the whole (global) genome methylation between all AMLs and all NBMs, 
the DNA methylation was binned into 5 categories; < 0.2, 0.2-0.4, 0.4-0.6, 0.6-0.8 and 
0.8-1.0 Batman scores. Fishers exact test provided with R (Gentleman et al. 2004) was 
used to investigate if there was a statistically significant difference in the proportions of 
the 5 methylation categories between AML and NBM.  
 
2.4.9 Repeats  
 
The list of the investigated repeat elements was obtained from nested RepeatsRM327 
table downloaded from UCSC genome annotation database 
(http://hgdownload.cse.ucsc.edu/goldenPath/hg18/database/).  
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2.5 Bisulphite conversion of DNA 
 
500ng genomic DNA undergoes bisulphite conversion using EZ DNA 
METHYLATION Kit (Catalogue number D5001, Zymo Research). Firstly, a conversion 
reagent (CT) supplied in powder is prepared by adding 750l water and 210l M-
Dilution buffer to the CT tube. The CT tube is vortexed at room temperature for 10 
minutes. During the incubation, 5l M-Dilution buffer is added to the DNA sample and 
the total volume is adjusted to 50l with water. The sample is mixed by pipetting up and 
down and incubated at 37C for 15 minutes to denature the DNA.  Next, 100l prepared 
CT is added to the DNA sample and mixed. The mixture is incubated in darkness at 
50C for 12-16 hours. After the incubation, the reaction tube is placed on ice for 10 
minutes. 400l M-Binding buffer is added to a Zymo-Spin IC Column (provided) and 
the column is placed in a collection tube. The content of the reaction tube (DNA sample 
and CT) is loaded into the previous Zymo-Spin IC Column containing the M-Binding 
buffer and the column is centrifuged at 13,000 rpm for 30 seconds. The flow-through is 
discarded and 100l M-Wash buffer is added to the column. The column is centrifuged 
again at 13,000 rpm for 30 seconds. 200l M-Desulphonation buffer is next added to the 
sample and the column is incubated at room temperature for 20 minutes. The column is 
further centrifuged at 13,000 rpm for 30 seconds. After centrifugation, 200l M-Wash 
buffer is added to the column which is centrifuged at 13,000 rpm for 30 seconds. The 
wash step is repeated followed by placing the column in a labelled 1.5ml eppendorf 
tube. To elute the bisulphite converted DNA, 10l M-Elution buffer is directly added to 
the column matrix. For pyrosequencing experiment, we used EZ-96 DNA Methylation 
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Kit (Catalogue number D5004, Zymo Research). The DNA bisulphite conversion 
process is modified to use Zymo-Spin1-96 binding and collection plates instead of 
separate spin columns. Also, the centrifugation speed and the duration are modified. 
 
2.6 Direct bisulphite sequencing 
 
500ng genomic DNA is bisulphite converted and a PCR amplification of target DNA is 
performed. The primers for each target sequence are designed using MethPrimer website 
(http://www.urogene.org/methprimer/index1.html). Primers details are listed in 
Appendix 1 Table 1. 
PCR reaction mix: 
- 10l PCR master mix (Thermo-Start PCR Master Mix, AB-0938/DC/15A Conc: 
2X, Thermo Scientific). 
- 1l forward primer (10M). 
- 1l reverse primer (10M). 
- 5l bisulphite converted DNA. 
- 3l water 
PCR amplification was obtained from 40 - 42 cycles of 60 seconds at 94°C, 60 seconds 
at 55°C, and 60 seconds at 72°C, after an initial denaturing for 15 minutes at 95°C, and 
final elongation at 72°C for 10 minutes. 
The PCR product undergoes fragment separation using agarose gel electrophoresis. For 
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the insertion of target DNA sequence into a vector: 4l freshly prepared PCR product is 
mixed with 1l TOPO vector (TOPO TA cloning kit pCR 2.1-TOPO vector, lot no. 
933237, Invitrogen) and 1l salt solution. The mixture is incubated at room temperature 
for 5 minutes and next placed on ice. A vial of bacteria (TOP10 E. coli, provided with 
the cloning kit) is placed from -80 C Freezer to be put on ice to be defrosted. The 
inserted PCR product is next cloned into E. coli and incubated on ice for 15 minutes. 
The concentration of PCR product to the added bacteria should be 1: 20. The mixture is 
further placed in a water bath previously warmed to 42°C for 30 seconds without 
shaking (heat shock). 250l L-broth is added to the mixture and incubated in a shaker at 
37°C for one hour. In order to visualize the cloned PCR, 200l of 1:1 mixture of IPTG 
(isopropylthio-β-galactoside) and X-Gal (5-bromo-4-chloro-3-indolyl-β-D-galactoside) 
are spread over the surface of an agar plate. IPTG is an inducer of β-galactosidase 
activity in bacteria while X-Gal is a colourless analog to lactose which is cleaved by β-
galactosidase resulting in blue colour. 200l cloned PCR mixture is spread over the 
surface of the previously prepared agar plate and the plate is next incubated at 37°C 
overnight. Mix of white and blue colonies appears after the incubation and only white 
colonies are picked up for the analysis. To amplify the cloned DNA, a TempliPhi 
amplification step is carried out. 5-10 white colonies are selected and transferred to 
separate tubes. 2.5l sample buffer is added to each tube. The tubes are heated to 95°C 
for 3 minutes that is to lyse the bacteria, subsequently releasing the plasmid. 2.5l 
reaction buffer and 0.1l enzyme are next added to each tube (sample buffer, reaction 
buffer and enzyme are provided in TempliPhi Amplification Kit, product code 25-6400-
10, Amersham Biosciences). The mixture is further incubated at 30°C for 18 hours, 
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followed by heating for 10 minutes at 65°C. Afterwards, 25l water is added to dilute 
the amplified DNA. The sequencing reaction mix is prepared by 5l diluted DNA, 
0.25l Big Dye terminator, 2l 5 X ABI buffer (Applied Biosystems), 0.5l sequencing 
primer and 2.25l water. This sequencing reaction involves initial denaturing at 96°C 
for 1 minute followed by 26 cycles at 96°C for 30 seconds, annealing at 50°C for 15 
seconds and extension at 60°C for 4 minutes before storage at 4°C. ZR DNA 
Sequencing Clean-up Kit (Catalogue number D4050, Zymo Research) is used to remove 
unincorporated dyes and other contaminants. In brief, 240l sequencing binding buffer 
is added to the sequencing reaction. The mixture is transferred to a provided Zymo-spin 
column in a collection tube followed by centrifugation of the column at 13,000 rpm for 
30 seconds. 300l sequencing wash buffer is next added to the column and further 
centrifuged at 13,000 rpm for 15 seconds. The Zymo-spin column is transferred to 1.5ml 
eppendorf and 20l water is directly added to the column matrix to elute the DNA. The 
purified DNA is dried using a vacuum centrifuge (DNA Speed Vac, DNA120; Savant). 
The dried DNA samples are transferred to CRUK for sequencing by capillary 
electrophoresis using the Prism 3730 system (Applied Biosystems). 
 
2.7 Pyrosequencing 
 
Pyrosequencing is a sequencing-by-synthesis method. Pyrosequencing implies a real 
time quantification of nucleotides incorporated in a specific sequence through certain 
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enzymatic reactions that result in release of light. The light is proportional to the number 
of nucleotides incorporated. Pyrosequencing experiment steps include: 
1. Bisulphite conversion of DNA: 500ng genomic DNA is bisulphite converted using 
EZ-96 DNA Methylation Kit (Zymo Research). 
2. Design of the primers: The primers are designed using PyroMark Assay design 2.0 
and synthesized by SIGMA-ALDRICH. The primers are designed in a way to include 
the sequence that has the CpGs investigated. One of the primers is biotinylated to fix the 
PCR products to the streptavidin-coated beads in the subsequent steps. Primers details 
are listed in Appendix 1 Table 2. 
3. PCR amplification of target sequence 
1l bisulphite converted DNA undergoes PCR amplification reaction in 96-well plate. 
The amplification is obtained through 40 PCR cycles of 60 seconds at 94°C, 60 seconds 
at 55°C, and 60 seconds at 72°C, after an initial denaturing at 95°C for 15 minutes, and 
final elongation at 72°C for 10 minutes. In every plate, we include a negative control to 
exclude the possibility of contamination. 
PCR reaction mix: 
- 22l PCR master mix (Thermo-Start Master Mix, AB-0938/15/A Conc: 1.1X, 
Thermo Scientific). 
- 1l forward primer (10M). 
- 1l reverse primer (10M). 
- 1l bisulphite converted DNA 
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4. Sequencing-by-synthesis 
Pyrosequencing was performed using specific reagents and hardwares (PSQ 96 MA, 
Qiagen). The PCR products are denatured and a sequencing primer is hybridized to 
ssDNA, which will act as a template. The four nucleotides are added in a sequential 
manner and as a complementary nucleotide is incorporated at the 3 end of the 
sequencing primer, subsequently a pyrophosphate (PPi) is released. PPi is converted to 
ATP by sulfurylase enzyme. ATP activates luciferase to convert luciferin to oxyluciferin 
which is generated in an excited status. Oxyluciferin is transferred to a ground status 
with emission of light. The amount of light generated is proportional to the amount of 
ATP. Unincorporated nucleotides are removed by apyrase enzyme (Figure 2.6). 
5. Analysis of the results 
The percent methylation at each CpG is calculated using PyroQ-CpG version 1.0.9. At 
each investigated CpG site, the percentage of C (cytosine), which represents methylated 
cytosine and T (thymine), which represents unmethylated cytosine is calculated (Figure 
2.7). 
                      
Figure ‎2.6 Pyrosequencing (sequencing-by-synthesis) 
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a. 
 
 
 b. 
 
  
Figure ‎2.7 Pyrogram produced by pyrosequencing 
Pyrogram produced by pyrosequencing of the promoter of SPHKAP gene methylated in 
AML (a) versus unmethylated SPHKAP in NBM (b). 
Chapter 2 
84 
 
2.8 Illumina Infinium HumanMethylation27 
 
500ng genomic DNA is bisulphite converted and further denatured. The whole genome 
amplification is performed via random hexamer priming using DNA polymerase 
enzyme at 37C for 20-24 hours. The amplified DNA is enzymatically fragmented 
through end-point fragmentation to produce consistent size of terminal fragments. The 
fragmented DNA is precipitated with isopropanol and collected by centrifugation at 4C. 
The DNA is finally resuspended in a buffer to be hybridized on Illumina BeadChip array 
for 16-24 hours at 48C. Infinium Methylation Assay uses two bead type probes for 
detecting a single target CpG site; an unmethylated bead type probe, which matches the 
unmethylated CpG site and a methylated bead type probe that matches the methylated 
CpG site (Figure 2.8). Both methylated and unmethylated bead type probes have the 
same sequence except the last base at the free end. After hybridization, the BeadChip is 
washed and the captured DNA is used as a template to initiate single-base extension by 
hapten-labelled ddNTPs. Both bead types are next fluorescently stained and scanned. A 
beta value is calculated at each target CpG site, which equals the ratio of methylated 
bead type intensity to the combined bead type intensities. Beta value ranges from 0 
(completely unmethylated) to 1 (100% methylated). The GenomeStudio Software was 
used for the methylation analysis. 
Chapter 2 
85 
 
 
Figure ‎2.8 Illumina Infinium Methylation Assay 
Two different bead type probes are used in Illumina Infinium Array  
a. Methylated CpG target site matches with the M (methylated) bead type probe 
initiating single-base extension and detection.  
b. Unmethylated CpG target site matches with the U (unmethylated) bead type probe 
initiating single-base extension and detection (the figure is from the Illumina technology 
website). 
a. 
  b. 
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2.9 Gene expression profiling 
 
2.9.1 RNA extraction 
 
RNA is extracted using RNeasy Plus Mini Kit (Catalogue number 74134, Qiagen). 
Firstly, 10l -mercaptoethanol is added to 1ml lysis buffer (RLT plus). 600l lysis 
buffer is next added to the cell pellet (a total of 10 - 20 X 10
6 
cells) to denature the 
nucleases that might present in the sample. The lysate is pipetted into a QIAshredder 
spin column placed in a 2ml collection tube and centrifuged at maximum speed for 2 
minutes. The QIAshredder spin column homogenized the lysate by shearing high 
molecular weight components to get a less viscid lysate, subsequently improving the 
binding of RNA to the RNeasy spin column in the following steps. To remove the 
genomic DNA, the homogenized lysate is transferred to a gDNA Eliminator spin 
column placed in a 2ml collection tube and then centrifuged at maximum speed for 30 
seconds. The column is discarded and the flow-through is kept. 600l 70% ethanol is 
added to the flow-through and mixed well by pipetting up and down. 700l sample is 
next transferred to an RNeasy spin column placed in a 2ml collection tube. The lid is 
closed gently and the column is centrifuged at maximum speed for 15 seconds. If the 
sample volume exceeds 700l, successive aliquots are centrifuged in the same RNeasy 
spin column. 700l wash buffer (RW1) is added to RNeasy spin column, the lid is 
closed gently and the column is centrifuged for 15 seconds at maximum speed. The 
flow-through is removed and 500l wash buffer (RPE) is added to RNeasy spin column. 
The RNeasy spin column is next centrifuged at maximum speed for 2 minutes. After 
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centrifugation, RNeasy spin column is gently placed in a new labelled 1.5ml collection 
tube. For eluting the RNA, 50l RNase-free water is added directly to the spin column 
membrane. The lid is closed gently and centrifuged at maximum speed for 1 minute.  
 
2.9.2 Array-based gene expression profiling 
 
Applied Biosystems Human Genome Survey Microarray (P/N 4337467) was used for 
the expression profiling (Barbacioru et al. 2006). The microarrays contain 31,700 60-
mer oligonucleotide probes representing 29,098 individual human genes. The 
chemiluminescence (CL) cRNA target preparation was used. Array hybridization was 
performed according to the manufacturer's protocol (P/N 4339629). Signal intensity and 
S/N ratio (signal to noise ratio) for each array were extracted. If S/N was greater than 3, 
it was concluded that the signal detected was a function of the gene expression level 
detected by the probe. The signal values were log2 transformed and normalized across 
the arrays with quantile normalization method. All the statistical analysis was performed 
with the statistical language R (Gentleman et al. 2004). 
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2.9.3 Expression study of candidate genes 
 
2.9.3.1 cDNA synthesis 
 
1g RNA is mixed with 1l Random Hexamers (Catalogue number N8080127, 
Invitrogen) in a microcentrifuge tube. The final volume is adjusted to 12l with RNase-
free water. The tube is next incubated at 65C for 5 minutes followed by placing on ice 
for at least one minute. To generate cDNA, a SuperScript III Reverse Transcriptase kit is 
used (Catalogue number 18080044, Invitrogen). The contents from the previous 
microcentrifuge tube are mixed with 4l of 5 X First-Strand buffer (provided), 1l 0.1M 
DTT (provided), 1l SuperScript III Reverse Transcriptase (200 units/l), 1l 
RNaseOUT Recombinant RNase Inhibitor (Catalogue number 10777019, Invitrogen) 
and 1l dNTPs mix (10mM) (Catalogue number 18427088, Invitrogen). The mixture is 
incubated at room temperature for 5 minutes and next placed in a thermal cycler at 50C 
for 50 minutes followed by heating at 70C for 15 minutes to inactivate the reaction.  
 
2.9.3.2 Relative quantification of gene expression by RT-PCR 
   
The expression of differentially methylated genes identified in AML versus NBM 
(SPHKAP, DPP6 and ID4) is measured relative to normal breast tissue by RT-PCR. 
Expression of a differentially methylated gene in trisomy 8 AML versus the rest of 
groups i.e. HHEX gene is compared between AML subtypes relative to NBM. TaqMan 
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probe and primers are designed for each gene by Applied Biosystems. Primers details 
are listed in Appendix 1 Table 3. All samples are run in duplicates. A reaction mix 
contains 5l TaqMan Universal Master Mix II (Catalogue number 4440040, Applied 
Biosystems), 0.5 assay mix, 3.5l water, 1l cDNA is placed in each well of a 96-well 
reaction plate. RT-PCR reactions are run on the Applied Biosystems 7900HT fast real 
time PCR using the standard thermal cycler protocol with initial step at 95C for 10 
minutes, followed by 40 cycles at 95C for 15 seconds and annealing and extension at 
60C for one minute. Ct (cycle threshold) for each gene is measured which equals the 
mean of Ct duplicates for each sample. The Ct is assessed relative to the Ct of a 
reference (18S). Normal lymph node samples are run on every plate to ensure the 
consistency across the runs. All normal tissues that are used in the expression study e.g. 
breast, lymph node, brain, thymus and heart are provided as RNA from Agilent 
Genomics. NBM used in the expression study is provided as cryopreserved bone 
marrow mononuclear cells from a healthy donor (Catalogue number 2M-125, Lonza). 
For calculating the expression fold change, these steps are performed: 
1.  Ct = (Ct sample - Ct reference) 
2.  CT = ( Ct sample -  Ct calibrator) 
3. Expression fold change = 2 -  Ct 
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2.10 Treatment of AML cell lines with 5-aza-2deoxycytidine 
 
5-aza-2deoxycytidine (DAC) (Catalogue number A3656, Sigma Aldrich) is dissolved 
by dimethylsulfoxide (DMSO) to get 0.1M DAC stock solution. The cell lines are 
centrifuged at 1300 rpm for 5 minutes and the supernatant is removed. The cell pellet 
(10 X10
6
 cells) is resuspended in 20ml of RPMI 1640 with 10% FBS. 1l 0.1M DAC 
stock is added to 20ml of the resuspended cells to get a 5M solution of DAC. The DAC 
treatment is repeated after 48 hours and the gene expression is assayed by RT-PCR after 
72 hours. Control cell lines are treated identically except that they are treated with 
standard media to which DMSO only is added. 
 
2.11 SPHKAP gene transfection 
 
2.11.1 Ligation of SPHKAP cDNA into a vector and cloning into bacteria 
 
SPHKAP cDNA cloned into a vector (pCR-XL-TOPO) (Catalogue number MHS4426-
99240364, Thermo Scientific) is inoculated in LB-Broth contains kanamycin antibiotic 
(50g/ml) and kept in the incubator at 37C overnight with shaking (300 rpm). For 
purification of the plasmid DNA, QIAfilter plasmid purification Maxi kit (Catalogue 
number 12263, Qiagen) is used. DNA concentration is measured and adjusted to reach a 
purified DNA of a concentration of 1g/l. 2l of purified DNA (2g) is digested by 
5l EcoR1 enzyme (12units/l) in the presence of 5l buffer and the reaction volume is 
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adjusted to 50l. The reaction volume is incubated at 37C over night. The digested 
DNA is next run over 0.8% gel and only the cDNA (5Kb) is excised from the gel [away 
from the vector (3.5 Kb)] and then eluted in 10l water. In order to transform the sticky 
ends of the excised cDNA into blunt ends, 10l of excised DNA is filled with 5l 
dNTPs by 1l Klenow enzyme, 5l buffer in an adjusted reaction volume of 50l. The 
reaction volume is incubated at 37C for 15 minutes, followed by heating at 65C for 10 
minutes. The mixture is cleaned by Zymo DNA Clean and Concentrator-5 kit and eluted 
in 10l water (step 1). To prepare for ligation of SPHKAP cDNA with a new vector 
(pIREShyg3, Catalogue number 631620, Clontech), the new vector is digested with StuI 
enzyme to obtain blunt ends to fit with the blunt-ended cDNA fragment. The digestion 
reaction consists of 2l new vector, 5l StuI enzyme (10 units/l, Promega), 5l buffer 
and 38l water. The mixture is further incubated at 37C over night, then purified by 
Zymo DNA Clean and Concentrator-5 kit and eluted in 10l water. To minimize self-
ligation of the vector during the transfection process, Shrimp Alkaline Phosphatase 
enzyme (SAP) (Catalogue number EF0511, Fermentas) is used to remove the 5' 
phosphates, subsequently increasing number of the colonies with the insert. Therefore, 
1l SAP enzyme and 1l of its buffer are added to 10l of the purified vector in an 
adjusted 20l reaction volume. The reaction mix is incubated at 37C for 30 minutes 
followed by heating at 65C for 15 minutes. The vector is next purified in 10l water 
(step 2). For ligation of the cDNA into a vector, 7.5l DNA (step 1) is incubated with 
1l vector (step 2), 0.5l T4 ligase (3 units/l Promega) and 1l buffer at 14C over 
night. The ligated mixture is added to bacteria (E.coli, DH5, Catalogue number 
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18258012, Invitrogen) as was previously mentioned (section 2.6; the steps from heat 
shock of bacteria till plating out over agar plates). The resultant colonies are picked up 
and a TempliPhi amplification step is performed. To check if the correct insert is 
obtained, the amplified plasmid DNA is digested by both XhoI (10 units/l, Promega) 
and BamH1 enzymes (10 units/l, Promega) resulting in 4 fragments. A purification 
step for the plasmid DNA is next carried out using QIAfilter plasmid purification Maxi 
kit. 
 
2.11.2 Transfection of activated SPHKAP into malignant cell lines 
 
The amounts of plasmid DNA and the transfection reagents (Lipofectamine
 TM
 LTX, and 
PLUS reagents, Catalogue number 15338-100, Invitrogen) are optimized to the surface 
area for 24-well format. Opti-MEM I REDUCED Serum Medium (Catalogue number 
31985-062, Invitrogen) is used for diluting the transfection reagents. Before transfection, 
100,000-250,000 MCF7/K562 cells in 500l RPMI 1640 medium are plated in each 
well. 1g plasmid DNA is next diluted with 100l Opti-MEM I REDUCED Serum 
Medium. 1l PLUS reagent is added to the diluted plasmid DNA and mix gently and 
incubated at room temperature for 5 minutes. 5l Lipofectamine TM LTX is added to the 
diluted plasmid DNA and is incubated at room temperature for 30 minutes. Afterwards, 
100l DNA-lipid complex is added drop by drop to the well containing cells. The plate 
is incubated at 37C in a CO2 incubator for 48 hours. To select only the stably 
transfected cells, hygromycin antibiotic will inhibit the growth of untransfected cells. 
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Hygromycin antibiotic is diluted by RPMI 1640 to obtain a concentration of 300 g/ml. 
Transfected MCF7/K562 cell lines are centrifuged at 1500 rpm for 5 minutes. The 
supernatant is removed and the cells are resuspended in 5ml diluted hygromycin 
antibiotic. The drug-containing medium is replaced every 4 days for next 14 days. The 
viability of cells is checked after 2 weeks using the inverted microscope. The stably 
transfected cells are checked for SPHKAP expression before measuring the intracellular 
sphingosine and sphingosine-1-phosphate. In parallel, MCF7/K562 cell lines are 
transfected with empty vector which does not contain the insert (SPHKAP-cDNA).  
 
2.11.3 Liquid chromatography-mass spectrometry simultaneous quantification of 
intracellular sphingosine and sphingosine-1-phosphate (S1P) (Bligh and 
Dyer 1959) 
 
The SPHKAP transfected cells are pelleted by centrifugation. The cell pellet is washed 
twice by PBS. The cell pellet is extracted for sphingosine and S1P and internal standards 
(C17 S1P, C17 sphingosine) by adding 300l chloroform: methanol (1:2) + 1% HCL 
and vortex vigorously for one minute. The extraction tube is left on ice for 30 minutes 
followed by centrifugation at 4C for 10 minutes. 100l water and 100l chloroform are 
added to the mix for phase separation. The tube is centrifuged and the lower organic 
layer is transferred to a new-labelled eppendorf and the extraction step is repeated. The 
supernatant from both extraction steps are combined in one eppendorf. The sample is 
next vacuum dried without heating. The dried extract is reconstituted by a solution (50% 
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methanol and 0.1% formic acid) and 10l is injected into liquid chromatography-mass 
spectrometry (LC-MS) (Waters, USA). 
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Chapter 3. Global DNA methylation study of     
AML and NBM 
 
The aim of this chapter is to develop whole-genome DNA methylation profiles for AML 
and NBM using the MeDIP-seq method. Comparing those methylation profiles should 
allow identification of genomic features that discriminate AML from NBM and different 
AML subtypes. The potential differentially methylated regions (DMRs) should be 
confirmed by other methods of DNA methylation analysis. 
 
3.1 Materials and Methods 
 
12 diagnostic AML patients and 4 NBMs were included in the MeDIP-seq experiment. 
Details of the samples are summarized in Table 3.1. Selected DMRs were validated by 
direct bisulphite sequencing and bisulphite pyrosequencing. In addition, 3 DNA samples 
were subjected to Illumina Infinium HumanMethylation27 BeadChip Array validation 
(studies number 11, 12 and 13). Array-based gene expression profiling for 6 AML 
patients with available RNA (studies number 1, 3, 4, 5, 8 and 9) were also included. The 
MeDIP-seq approach, the validation experiments and the gene expression profiling were 
performed as described in Chapter 2. 
  
 
Chapter 3 
96 
 
Table ‎3.1 Patients and control samples  
Study 
No. 
Risk group Sample 
type 
Sex Age at 
presentation 
FAB type Blast % Survival 
(years) 
1 t(15;17)AML PB M 36 M3 85 5.8 
2 t(15;17)AML PB F 69 M3 80 15.8 
3 t(15;17)AML PB M 30 M3 85 10.0 
4 NK AML BM F 64 M2 60 0.82 
5 NK AML PB M 18 M2 87 6.4 
6 NK AML PB F 56 M1 71 0.53 
7 t(8;21) AML PB F 27 M2 95 13.1 
8 t(8;21) AML BM M 34 M2 88 9.2 
9 t(8;21) AML PB M 67 M2 70 0.16 
10 +8 AML PB M 46 M5 45 2.1 
11 +8 AML PB M 21 M5A 82 0.65 
12 +8 AML PB M 43 NA 73 0.51 
13 Control NBM M 23 NA < 5 NA 
14 Control NBM M 28 NA < 5 NA 
15 Control NBM M 22 NA < 5 NA 
16 Control NBM F 54 NA < 5 NA 
PB; peripheral blood, BM; bone marrow, F; Female, M; Male, NA; not applicable, NBM; normal bone 
marrow, NK; normal karyotype 
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3.2 Results 
 
3.2.1 High-throughput sequencing of MeDIP-seq libraries, alignment and 
saturation analysis 
 
In order to perform a genome-wide analysis of DNA methylation in AML, we applied 
MeDIP-seq to DNA samples from 12 AML patients: 3 with t(8;21) translocation, 3 with 
t(15;17) translocation, 3 with trisomy 8, and 3 with a normal karyotype (NK). The 
choice of the AML subtypes was because of their availability. We used 4 unrelated 
NBMs as control samples. The MeDIP-seq libraries were sequenced by Illumina GAII 
and yielded a total of 7.8 X10
8
 reads. Assessment of the base quality of those reads was 
performed before starting the alignment. That revealed a base quality score higher than 
30 for at least 60 % of the reads generated for each DNA sample, indicating that the 
probability of incorrect base call during the alignment would be 1 in 1000. Running Maq 
and Bowtie algorithms revealed 53% of the total reads were uniquely aligned to the 
human reference genome (NCBI36/hg18) (Table 3.2).  
Before the interpretation of the DNA methylation signals, a saturation analysis was 
performed using MEDIPS software (Chavez et al. 2010). That was to investigate 
whether the number of the uniquely aligned reads was enough to get a reproducible 
whole genome methylation profile by another independent set of a similar number of 
short reads. The saturation analysis confirmed the methylome reproducibility in all 
MeDIP-seq samples (Figure 3.1, Appendix 1 Figure 2). MEDIPS software also 
calculated the percentage of CpG sites covered by MeDIP-seq in the human reference 
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genome for each sample (coverage analysis) (Chavez et al. 2010). The average of CpG 
coverage for all MeDIP-seq samples was 76% of total 28 CpG million sites in the 
human reference genome (Table 3.2). Batman algorithm was next applied to the 
uniquely aligned reads in order to obtain absolute quantification of MeDIP-seq 
methylome data with a 100bp resolution. 
Table ‎3.2 MeDIP-seq reads (sequences) generated from Illumina GAII 
 
*The uniquely mapped reads are reads (sequences) that have unique chromosomal 
location with start and end sites. The raw sequencing data, the alignments files and 
Batman GFF files are available at GEO accession number: GSE28314. 
Study 
No. 
Total 
No. of 
reads 
Quality 
of bases 
> 30 
Forward 
Quality 
of bases 
> 30 
Reverse 
*No. of 
uniquely 
mapped 
reads 
CpG 
coverage 
% 
Pearson r  
True 
saturation 
 
Pearson r 
Estimated 
saturation 
 
1 66 X 10 
6
 74% 73% 26 X 10 
6
 82 0.87 0.93 
2 36 X 10 
6
 64% 64% 21 X 10 
6
 76 0.99 1 
3 40 X 10 
6
 64% 58% 24 X 10 
6
 74 0.99 0.99 
4 30 X 10 
6
 74% 63% 12 X 10 
6
 69 0.78 0.89 
5 38 X 10 
6
 69% 64% 22 X 10 
6
 77 0.99 1 
6 34 X 10 
6
 75% 67% 20 X 10 
6
 74 0.99 0.99 
7 32 X 10 
6
 80% 70% 13 X 10 
6
 63 0.86 0.93 
8 68 X 10 
6
 74% 63% 24 X 10 
6
 80 0.85 0.92 
9 40 X 10 
6
 76% 71% 23 X 10 
6
 76 0.99 1 
10 58 X 10 
6
 81% 77% 24 X 10 
6
 77 0.99 1 
11 66 X 10 
6
 84% 83% 38 X 10 
6
 85 1 1 
12 68 X 10 
6
 84% 82% 41 X 10 
6
 87 1 1 
13 66 X 10 
6
 75% 72% 29 X 10 
6
 84 0.88 0.94 
14 40 X 10 
6
 68% 63% 24 X 10 
6
 77 0.99 1 
15 40 X 10 
6
 67% 63% 24 X 10 
6
 67 0.99 0.99 
16 44 X 10 
6
 88% 87% 26 X 10 
6
 71 1 1 
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Figure ‎3.1 Saturation analysis 
 
In brief, the number of reads covering each 50bp in a chromosome is calculated 
(referred as genome vector in MEDIPS manual). Next, the total number of aligned reads 
are divided randomly but equally into 2 subgroups (A& B). Both sets A and B are 
subdivided into random subsets of equal sizes and a correlation of genome vectors is 
performed between subsets of A and subsets of B (true saturation). We performed this 
analysis using half the number of total mapped reads. Therefore, for the analysis using 
all mapped reads, the total number of reads is doubled and the saturation analysis is 
repeated using this estimated or artificial number of reads (estimated saturation). In this 
figure, it is assumed that Pearson correlation r of the saturation analysis for the full set 
of available short reads will be between the results of the true saturation (the blue line, 
Pearson r = 0.87) and the estimated saturation (the red line, Pearson r = 0.93) in study 
1 and between the results of the true saturation (the blue line, Pearson r = 0.99) and the 
estimated saturation (the red line, Pearson r = 1.0) in study 2. The saturation analyses 
for the rest of MeDIP-seq samples are demonstrated in Appendix 1 Figure 2. 
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3.2.2 Whole-genome DNA methylation analysis 
 
3.2.2.1 Whole-genome DNA methylation comparison between AML and NBM 
 
In order to obtain a global view of differences in DNA methylation between AML and 
NBM, Batman GFF files in 12 AMLs and 4 NBMs were categorized into 5 groups of 
methylation; < 0.2, 0.2-0.4, 0.4-0.6, 0.6-0.8, and 0.8-1.0 (Figure 3.2A). We next used 
Fishers exact test provided with R (Gentleman et al. 2004), which demonstrated no 
significant difference in the global DNA methylation between AML and NBM (P = 
0.96). There was only 2.68% difference in the DNA methylation average; AML DNA 
methylation average was 67.68% while for NBM the DNA methylation average was 
70.36%. Plotting the scores of Batman GFF files opposite to their corresponding density 
(frequency) demonstrated that the frequency of DNA methylation scores > 0.8 was 
lower in AML than NBM (Figure 3.2B). That is because some genomic regions e.g. 
gene bodies and repeat sequences generally lose their DNA methylation in malignancy. 
This is consistent with the global hypomethylation which is a feature of cancer (Ehrlich 
2002). 
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A. 
 
   
 
 
 
  B. 
      
 
Figure ‎3.2 Global DNA methylation comparison between AML and NBM 
A. DNA methylation scores of all AML patients and all NBMs were categorized into 5 
groups of methylation. There was no significant difference in the global DNA 
methylation between AML and NBM (Fisher’s exact test, P = 0.96). 
B. Distribution of DNA methylation in all AMLs (the blue line) versus all NBMs (the 
green line). AML showed lower frequency of DNA methylation scores > 0.8 than NBM. 
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3.2.2.2 Whole-genome DNA methylation comparison among AML subtypes 
 
To assess potential differences in the whole (global) genome DNA methylation among 
AML subtypes, we compared the proportions of categorized DNA methylation groups 
of the triplicate of each AML subtype (Figure 3.3). That revealed a significant 
methylation difference among the 4 AML subgroups (Chi-square test, P = 0.02). t(8;21) 
AML and t(15;17) AML genomes showed the highest percentage of Batman scores > 
0.6 (69%), while trisomy 8 AML genome showed the highest percentage of Batman 
scores < 0.4 (26%) (Figure 3.3).  
 
 
     
Figure ‎3.3 Global DNA methylation comparison among AML subtypes 
DNA methylation scores of the triplicate of each AML subtype were categorized into 5 
groups of methylation. There was a significant difference in the global DNA methylation 
among AML subtypes (Chi-square test, P = 0.02).  
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In order to investigate the global DNA methylation in more detail, the genome was 
divided into 4 features; promoters, gene bodies, CGIs and CGI shores (description for 
each genomic region is summarized in Table 3.3) and 4 repeat classes; satellites, SINEs; 
short interspersed nuclear elements, LINEs; long interspersed nuclear elements and 
LTRs; long terminal repeats.  
Table ‎3.3 Description of the genomic features from MeDIP-seq results 
a
CpG density % equals the number of observed CpGs in a specific sequence / the length 
of this sequence.
  b
TSS; transcription start site. 
c
Promoter bimodal CpG density; 1.5%  
is the average density of promoters with low dense CGIs/ without CGIs, 7.2% is the 
average density of promoters with high dense CGIs (Appendix 1 Figure 3).
 
d
CGIs; CpG islands.
 e
CGI density is found to be  higher when CGI is located closer to 
TSS. 
 
All the genome annotation is based on (NCBI 36/hg18).  
The methylation for each genomic region equals the average of all Batman scores 
arising from this genomic region. 
Genomic 
feature 
 
Description 
a
CpG density of aligned 
genomic feature 
No. of regions 
detected by 
MeDIP-seq  
Promoter bTSS  1 Kb 
c
Bimodal (1.5%, 7.2%) 19,571 
Gene body All available exons 
and introns from 
2
nd
 exon onward 
1.9% 19,412 
d
CGI GC > 50%,  
CpG obs/exp ratio > 
0.6 in a sequence 
length ≥ 200bp 
(Gardiner-Garden 
and Frommer 
1987) 
e
19.4% (CGIs 
inside/overlapped the 
promoters), 18.2% (CGIs 
≥ 1 Kb outside the 
promoters) 
23,318 
CGI shore 2 Kb from either 
side of a CGI 
2.3% upstream shores & 
downstream shores. 
26,978 upstream 
shores, 26,977 
downstream 
shores 
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We found among the genomic regions and repeats, the gene bodies showed the highest 
percentage of DNA methylation scores > 0.6 in AML (82%) and in NBM (85%) (Figure 
3.4B). By contrast, CGIs showed the lowest percentage of DNA methylation scores > 
0.6 in AML (16%) and in NBM (13%) (Figure 3.4C). The global hypomethylation in 
AML was observed mainly in SINEs since SINEs showed the highest percentage 
difference in Batman DNA methylation scores > 0.8 between NBM and AML (20%) 
(Figure 3.4F).        
 
 
Figure ‎3.4 DNA methylation of different genomic regions in AML subtypes and NBM 
(A-H) In each genomic feature and repeat, DNA methylation of AML triplicate average 
and 4 NBMs average were categorized into 5 groups of methylation. SINEs (F) showed 
the highest difference in DNA methylation scores > 0.8 between NBM and AML. 
Chapter 3 
105 
 
3.2.3 Identification of DMRs  
 
3.2.3.1 MeDIP-seq statistical workflow 
 
We next searched for specific DMRs that could differentiate between AML and NBM 
and between AML subtypes. We used the MeDIP-seq statistical workflow as was 
described in Chapter 2. However, due to small sample size, not many genes remained 
statistically significant when multiple testing corrections were applied. Assuming a 
random distribution, the frequency of uncorrected P values < 0.05 for differential 
methylation was found higher than expected. Therefore, this uncorrected P value 
distribution indicated a differential methylation pattern between specified groups 
(Schulte et al. 2010) (Figure 3.5). 
 
3.2.3.2 Determination of cutoff values for DMRs and for the cluster analysis 
 
In order to set a cutoff value for selecting DMRs between groups, we used the 
distribution of the absolute methylation differences in all covered genomic regions 
(618,556) between normal and leukaemic samples. Since the 99th percentile of the 
differences in methylation scores corresponds to 0.23, the minimal difference in 
methylation between groups required for calling DMRs was rounded to 0.25. Therefore, 
a DMR was defined as a differentially methylated region with uncorrected P < 0.05 and 
an absolute methylation difference > 0.25 Batman score (equals to at least 25% 
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difference in DNA methylation). Additionally, in order to reduce the data for clustering 
purposes, we selected DMRs with P value < 0.001 for which we noticed particular 
enrichment (Figure 3.6). For estimating the FDR in the DMR calling, we used a mixture 
model approach (Allison et al. 2002). DMRs identification based on P value < 0.05 and 
absolute methylation difference > 25% gave a FDR of 2.4% across investigated genomic 
features and repeats. That was comparable to a FDR of 3.7% in DMRs identified by a 
recent MeDIP-seq study (Feber et al. 2011). The steps of MeDIP-seq workflow are 
summarized in Figure 3.7. 
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A. t(8;21) AML versus the rest of groups    
 
B. t(15;17) AML versus the rest of groups 
 
 
Figure ‎3.5 Histograms of uncorrected P values after testing the equality of promoter 
methylation averages between groups 
(A-B) X-axis represents uncorrected P values of the averages of promoters methylation 
compared between groups; Y-axis represents the frequencies of those P values. When 
investigating data with equal averages between groups, the P values were expected to 
be uniformly distributed across the unit interval (blue line). (A) Comparing the 
distribution of uncorrected P values to the uniform distribution expected for random 
data revealed enrichment of P value < 0.05 (red line) in t(8;21) AML versus the rest of 
the groups. (B) There was less observed enrichment of P values < 0.05 (red line) in 
t(15;17) AML versus the rest of the groups.. Histograms of the distribution of 
uncorrected P values in each investigated genomic region were demonstrated in 
Appendix 1 Figure 4. 
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Figure ‎3.6 Distribution of uncorrected P values of DMRs in all covered genomic 
regions between normal and leukaemic samples 
The frequency of P values < 0.05 (red line) is higher than expected with particular 
enrichment of P values < 0.001. 
 
Figure ‎3.7 MeDIP-seq workflow 
HTS; High-throughput sequencing  
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3.2.3.3 Detection of DMRs between AML and NBM and between AML subtypes in 
promoters, gene bodies, CGIs and CGI shores 
 
Using the previous criteria of DMRs, we detected a total of 1,191 DMRs between all 
AMLs and all NBMs in the 4 genomic features; promoters, gene bodies, CGIs and CGI 
shores (Table 3.4). 74% of the total DMRs were hypermethylated in AML versus NBM. 
The highest number of DMRs was identified associated with CGIs where 80% of those 
islands were located outside the promoters (35% within the gene bodies and 45% were 
intergenically located). That was observed with 2-fold increase in the differentially 
methylated CGIs located within the promoters between NBM and AML. In order to 
identify which genomic feature was the strongest predictor, we performed a two-
dimensional cluster analysis (Figure 3.8) and a pair-wise comparison (Figure 3.9). That 
indicated, of the 4 genomic features, the CGIs could cluster all AML samples most 
tightly and discriminate them from NBM. 
Moreover, the examination of the differentially methylated promoters identified some 
previously noted targets for epigenetic alteration in haematological disorders. For 
example, ID4 has been shown to act as a putative tumour suppressor gene in AML (Yu 
et al. 2005), DCC is hypermethylated in follicular lymphoma (Bennett et al. 2009) and 
mutation of TERT increases the risk of familial AML (Kirwan et al. 2009). This gene list 
also included genes that have roles in a variety of other cancers e.g. DPP6 is 
downregulated in melanoma (Jaeger et al. 2007), SPHKAP plays a role in the 
sphingosine phosphorylation pathway that induces tumor progression and invasion 
(Lacana et al. 2002; Pyne and Pyne 2010). Additionally, differentially methylated gene 
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bodies, intragenic CGIs (within promoters/ inside gene bodies) and intragenic CGI 
shores identified a number of genes belonging to potentially important transcription 
factor families e.g. MYOD1, SOX14, FOXA2, FOXB2, RUNX1 and PAX1.  
 
Table ‎3.4 DMRs discriminating between all AMLs and all NBMs in 4 genomic features 
List of differentially methylated promoters, gene bodies, CGIs and CGI shores between 
AML and NBM are provided in Appendix 2. The full lists of DMRs between AML and 
NBM and for each AML subtype are provided as Dataset excel files in the supporting 
information at:  
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0033213#s5 
 
 
 
 
 
Genomic 
features 
 
DMRs between 
AML and NBM 
 
Hypermethylated 
DMRs in AML 
Hypomethylated DMRs 
in AML 
Promoters 105 102 3 
Gene 
bodies 
72 57 15 
CGIs 704 470 234 
CGI shores 310 258 52 
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Figure ‎3.8 Hierarchical clustering analysis of AML versus NBM in 4 genomic features 
In each cluster analysis, each column represents AML patient/ NBM and each row 
represents a single DMR. Colour represents methylation level (red = high methylation; 
green = low methylation). AML patients were clustered more tightly in CGIs (C) than in 
promoters (A), gene bodies (B) and CGI shores (D). 
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Figure ‎3.9 Pair-wise comparison of the methylation profiles between AML and NBM in 
4 genomic features  
The red and yellow colours indicate high and low similarity level respectively. CGIs (C) 
showed the highest similarities in the methylation profiles between AML patients and a 
clear discrimination from NBMs among the rest of the genomic features; promoters (A), 
gene bodies (B), CGI shores (D). 
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Since 12 AML patients of 4 different cytogenetic subtypes were included, it was 
important to investigate if the previous 4 genomic features could discriminate each 
AML subtype. The highest number of identified DMRs was found in t(8;21) AML. By 
contrast, trisomy 8 AML showed the lowest number of recognized DMRs (Tables 3.5A, 
B). Additionally, 60% of the total DMRs were hypermethylated in each AML subtype 
except in trisomy 8 AML where only 40% of the total DMRs were hypermethylated. For 
all AML subtypes, most of the hypermethylated DMRs were located in CGIs where the 
preferential methylation was found in CGIs present outside the promoters (within gene 
bodies or intergenically located). Additionally, there were very few overlapped DMRs 
between AML subtypes with no common DMRs were detected between the all 4 AML 
subtypes (Figure 3.10). Most of those DMRs were unique for each AML subtype e.g. 
DMRs associated with MEIS1/2, TOP3B, CDH13, ST6GAL2 in t(8;12) AML, DOK6, 
NCOR2 in t(15;17) AML, ELK1, VMO1 in NK AML, SNX16, HHEX in trisomy 8 
AML. Performing a two-dimensional cluster analysis (Figure 3.11) and a pair-wise 
comparison (Figure 3.12) showed that each AML subtype could be distinguished using 
the identified genomic features. Notably, the t(8;21) AML subgroup was clustered 
distantly from the other AMLs.  
Furthermore, we investigated if specific chromosome/chromosomes were frequently 
represented in the intragenic DMRs (within promoters/ inside gene bodies) in AML 
subtypes using David Bioinformatics (Huang da et al. 2009). Chromosomes, other than 
those involved in the translocations, were frequently represented in t(8;21) AML and 
t(15;17) AML, while chromosome 8 was the most frequent representative chromosome 
in the hypermethylated DMRs in trisomy 8 AML  (Table 3.5C). 
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Table ‎3.5 DMRs and representative chromosomes identified in AML subtypes in 4 
genomic features  
(A, B) DMRs in AML subtypes (C) The most frequent representative chromosome in the 
intragenic DMRs in each AML subtype 
A. 
Genomic 
features 
 
t(8;21) AML 
hypermethylated 
DMRs 
t(8;21) AML 
hypomethylated 
DMRs 
t(15;17) AML 
hypermethylated 
DMRs  
t(15;17) AML 
hypomethylated 
DMRs 
Promoters 191 32 29 4 
Gene 
bodies 
57 44 30 29 
CGIs 710 358 255 118 
CGI 
shores 
331 314 88 70 
 
 
B. 
 
Genomic 
features 
 
NK AML 
hypermethylated 
DMRs 
NK AML 
hypomethylated 
DMRs 
Trisomy 8 AML 
hypermethylated 
DMRs 
Trisomy 8 AML 
hypomethylated 
DMRs 
Promoters 54 11 12 61 
Gene 
bodies 
35 35 15 44 
CGIs 240 174 177 151 
CGI 
shores 
109 60 31 110 
       
C. 
AML subtypes Hypermethylated DMRs Hypomethylated DMRs 
t(8;21) AML Chr 18 P = 9.7E-4 
 
Chr 19 P = 2.8E-12 
Chr 16 P = 2.1E-04 
 
t(15;17) AML Chr 19 P = 2.0E-03 
 
Chr 16 P = 1.6E-02 
 
NK AML Chr 7 P = 1.2E-02 
 
 
Chr 14 P = 2.3E-04 
Chr 19 P = 1.1E-02 
Trisomy 8 AML Chr 8 P= 9.0E-04 
 
Chr 21 P = 2.3E-02 
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 Hypermethylated DMRs Hypomethylated DMRs 
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Figure ‎3.10 Characters of DMRs in AML subtypes 
Venn diagrams showed few overlapped DMRs between AML subtypes with no common 
DMRs were identified between the all 4 AML subtypes. 
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Figure ‎3.11 Hierarchical clustering analysis of AML subtypes in 4 genomic features 
In each cluster analysis, each column represents AML patient/ NBM and each row 
represents a single DMR. Colour represents methylation level (red = high methylation; 
green = low methylation). AML subtypes were clearly discriminated in the 4 genomic 
features; promoters (A), gene bodies (B), CGIs (C) and CGI shores (D) with high 
number of methylated DMRs identified in t(8;21) AML. 
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Figure ‎3.12 Pair-wise comparison of the methylation profiles between AML subtypes in 
4 genomic features 
The red and yellow colours indicate high and low similarity level respectively. The 
methylation profiles of t(8;21) AML subtype was discriminated distantly from the other 
AML subtypes in promoters (A), gene bodies (B), CGIs (C) and in CGI shores (D). 
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3.2.3.4 Detection of DMRs associated with repeat sequences between AML and 
NBM and between AML subtypes 
 
A considerable advantage of next-generation sequencing is the ability to investigate 
repeated elements, which would cross-hybridize on a microarray chip (Beck and Rakyan 
2008). We used the uniquely mapped reads which have specific start and end sites to 
determine the methylation pattern of repeated elements (Feber et al. 2011; Kim et al. 
2011). 40% of the aligned satellites were centromeric, 53% of the aligned SINEs were 
Alu repeats and 60% of the aligned LINEs were LINE1 family (Table 3.6A). 
Additionally, SINEs showed the highest CpG density among aligned repeats; average 
CpG density was 3% in SINEs, 0.8% in LINEs, 1% in LTRs and 1.2% in satellites. 
Dividing the aligned repeats in each MeDIP-seq sample into promoter located and non-
promoter located repeats showed that the non-promoter located repeats (within gene 
body or intergenically located) exhibited significantly higher methylation level than the 
promoter located repeats (Kruskal-Wallis test followed by Dunn‟s multiple comparison 
tests, P < 0.05). 
In order to detect DMRs that could discriminate between AML and NBM, we carried 
out the analysis using the MeDIP-seq statistical workflow as was previously described. 
The methylation pattern of the selected SINEs, LINEs and LTRs discriminated clearly 
AML from NBM (Table 3.6A, Figures 3.13, 3.14). The clearest distinction between 
AML and NBM was obtained with SINE methylation; 62% of those SINEs were of the 
Alu family (43% AluJb, 40% AluSx). These discriminating repeats had a significantly 
high CpG density compared with the rest of the Alu subfamilies (Mann-Whitney test, P 
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= 0.002) and with the rest of SINEs (Mann-Whitney test, P < 0.0001). As regards AML 
subtypes, it was evident that for LINEs, SINEs and LTRs the feature that discriminated 
AML subgroups was hypomethylation of a particular group of repeats which were not 
associated with specific chromosomes. Most of those distinctive hypomethylated repeats 
were intergenically located in LTRs and in LINEs (65% found in LINE1). However, 
most of the distinctive hypomethylated SINEs belonged to the Alu family and were 
intragenically located (Tables 3.6B, C, Figures 3.15, 3.16). For satellites, few DMRs (P 
< 0.05 and > 25 % absolute methylation difference) were found differentiating AML 
from NBM and discriminating each AML subtype. 
Since characteristic hypomethylated repeats differentiating each AML subtype were 
identified, we investigated whether the expression of genes overlapping those repeats 
could also discriminate AML subtypes and if this discrimination would be related to a 
specific repeat element. As previously mentioned, array-based gene expression profiling 
for 6 AML patients was available; 2 t(8;21) AML patients, 2 t(15;17) AML patients, 2 
NK AML patients. Correlating the gene expression to the hypomethylated repeat 
clusters revealed number of genes which overlapped the hypomethylated repeats in each 
AML subtype; 751 genes in t(8;21) AML, 653 genes in t(15;17) AML, 550 genes in NK 
AML. The expression of those genes related to each repeat element was compared 
among AML subtypes. That revealed no significant expression difference detected 
between AML subtypes in any of the repeats investigated (Figure 3.17). The array 
expression profiles for the 6 AML patients are available at GEO accession number: 
GSE34722. 
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Table ‎3.6 DMRs discriminating between AML and NBM and between AML subtypes in 
repeat sequences  
(A) DMRs associated with repeats between AML and NBM  (B, C) DMRs associated 
with repeats between AML subtypes  
A. 
 
B. 
 
C. 
Lists of differentially methylated repeats between AML and NBM and for each AML 
subtype are provided as Dataset excel files in the supporting information at: 
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0033213#s5 
Repeats No. of aligned 
repeats 
DMRs between 
AML and NBM  
Hypermethylated 
DMRs in AML 
Hypomethylated 
DMRs in AML 
Satellites 1,213 1 0 1 
SINEs 75,793 721 444 277 
LTRs 132,581 455 325 130 
LINEs 292,703 713 488 225 
Repeats t(8;21) AML 
hypermethylated 
DMRs 
t(8;21) AML 
hypomethylated 
DMRs 
t(15;17) AML 
hypermethylated 
DMRs  
t(15;17) AML 
hypomethylated 
DMRs 
Satellites - - - 1 
SINEs 421 764 273 567 
LTRs 228 631 128 485 
LINEs 445 902 231 757 
Repeats NK AML 
hypermethylated 
DMRs 
NK AML 
hypomethylated 
DMRs 
Trisomy 8 AML 
hypermethylated 
DMRs 
Trisomy 8 AML 
hypomethylated 
DMRs 
Satellites - 3 9 4 
SINEs 516 730 436 949 
LTRs 366 567 399 612 
LINEs 615 1008 626 1004 
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Figure ‎3.13 Hierarchical clustering analysis of AML versus NBM in repeat sequences 
 In each cluster analysis, each column represents AML patient/ NBM and each row 
represents a single DMR. Colour represents methylation level (red = high methylation; 
green = low methylation).  DMRs associated with SINEs (A), LINEs (B) and LTRs (C) 
clearly discriminated AML from NBM.  
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Figure ‎3.14 Pair-wise comparison of the methylation profiles between AML and NBM in 
repeat sequences 
The red and yellow colours indicate high and low similarity level respectively. SINEs 
(A) showed the highest similarities in the methylation profiles between AML groups in 
the comparison with LINEs (B) and LTRs (C). 
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Figure ‎3.15 Hierarchical clustering analysis of AML subtypes in repeat sequences 
In each cluster analysis, each column represents AML patient/ NBM and each row 
represents a single DMR. Colour represents methylation level (red = high methylation; 
green = low methylation). Distinguished clusters of hypomethylated SINEs (A), LINEs 
(B) and LTRs (C) clearly discriminated each AML subtype.  
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Figure ‎3.16 Pair-wise comparison of the methylation profiles between AML subtypes in 
repeat sequences 
The red and yellow colours indicate high and low similarity level respectively. Clear 
separation of the methylation profiles of AML subtypes was observed in SINEs (A), 
LINEs (B) and LTRs (C). 
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Figure ‎3.17 Comparison of the expression of genes overlapping the distinctive 
hypomethylated repeat clusters among AML subtypes 
Each box plot illustrates the expression levels of genes overlapping the hypomethylated 
DMRs associated with each transposable element (TE) (Figure 3.15) in individual AML 
subtype. Overall, there was no significant expression difference detected among genes 
overlapping the distinctive hypomethylated repeat clusters in AML subtypes. 
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3.2.4 Correlation between DNA methylation and gene expression 
 
We next investigated the relationship between DNA methylation of different genomic 
regions and gene expression. Therefore, the DNA methylation of 6 AML patients, for 
whom the array expression profiles were available, was categorized into 4 groups (< 0.4, 
0.4-0.6, 0.6-0.8, > 0.8 Batman scores). The average of each methylation group was 
correlated to corresponding gene expression average. That revealed strong significant 
inverse correlation between DNA methylation and gene expression in promoters (13,690 
genes) (Pearson r = -0.97, P < 0.0001), CGIs (within the promoters of 8,745 genes) 
(Pearson r = -0.89, P < 0.0001) and their parallel upstream CGI shores (Pearson r = -0.8, 
P < 0.0001) (Figures 3.18A, B, C). In addition, the intragenic interspersed repeats 
(within promoters or within gene bodies) showed significant inverse correlation with 
gene expression. SINEs (1,285 intragenic repeats) showed the strongest inverse 
correlation (Pearson r = -0.82, P < 0.0001) followed by LTRs (541 intragenic repeats) 
(Pearson r = -0.63, P = 0.001) and finally LINEs (11,242 intragenic repeats) (Pearson r = 
-0.54, P = 0.006) (Figures 3.18D, E, F).   
Moreover, we examined the potential correlation between differential gene expression 
and differential promoter DNA methylation in AML subtypes. Consequently, the 
promoter MeDIP-seq results were integrated into the gene expression profiles of AML 
subtypes established by previous studies (Virtaneva et al. 2001; Debernardi et al. 2003; 
Valk et al. 2004). We found that DNA methylation of overexpressed genes was 
significantly less than DNA methylation of underexpressed genes in t(8;21) AML, NK 
AML and trisomy 8 AML (Mann-Whitney test, P = 0.005, P = 0.044, P = 0.01 
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respectively). However, there was no significant methylation difference between the 
distinctive genes in t(15;17) AML (P = 0.53). This analysis showed that differential 
promoter DNA methylation was correlated with differential gene expression in most 
AML subtypes (Figure 3.18G, the distinctive expressed genes and their methylation 
scores are listed in Appendix 1 Tables 4A, B).  
Figure ‎3.18 Correlation between DNA methylation and gene expression 
(A-F) For AML patient, the average of each methylation category (< 0.4, 0.4-0.6, 0.6-
0.8, > 0.8 Batman scores) was correlated to corresponding gene expression average in 
promoters (A), CGIs (B), CGI shores (C), SINEs (D), LINEs (E), LTRs (F). (G) Box 
plots represent promoter DNA methylation of over- and underexpressed genes in each 
triplicate of t(8;21), t(15;17), NK and trisomy 8 AMLs. N represents the number of 
genes investigated in each AML subtype. Mann-Whitney test between the two sets of 
genes demonstrated a significant methylation difference between the medians in t(8;21) 
AML, NK AML and trisomy 8 AML.  
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3.2.5 MeDIP-seq validation 
 
MeDIP-seq data was validated by two approaches; validation of candidate genes/ 
genomic regions by bisulphite sequencing and validation of some MeDIP-seq samples 
using a genome-wide approach e.g. Illumina Infinium Array.  
 
3.2.5.1 Direct bisulphite sequencing validation 
 
We performed direct bisulphite sequencing of 4 of the most significant DMRs between 
AML and NBM; 3 DMRs were hypermethylated in AML versus NBM (promoter of 
DPP6, promoter of SPHKAP and an intergenic CGI shore) and one DMR was 
hypomethylated in AML versus NBM (CGI within the gene body of LAMA5). The 
bisulphite sequencing was performed on the MeDIP-seq DNA samples and analyzed by 
QUMA (Quantitative Method for Methylation Analysis, http://quma.cdb.riken.jp) 
(Appendix 1 Figures 5A—E). The bisulphite sequencing results confirmed the MeDIP-
seq data for the 4 genomic regions investigated (Table 3.7). The correlation between the 
direct bisulphite sequencing results and the corresponding Batman scores for the 
investigated MeDIP-seq samples in the 4 selected genomic regions is demonstrated in 
Appendix 1 Figure 5F.  
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Table ‎3.7 Direct bisulphite sequencing validation of candidate genomic regions 
 
Genomic 
region 
Location No. 
of 
CpGs 
MeDIP-seq 
results 
(absolute 
methylation 
difference) 
P value 
(MeDIP-seq 
versus 
bisulphite 
sequencing) 
 
Pearson R
2 
(MeDIP-seq 
versus 
bisulphite 
sequencing) 
DPP6  
(Promoter) 
Chr7:153214701-
153215064 
36 0.45601 0.0005 0.84 
SPHKAP 
(Promoter) 
Chr2:228754201-
228754550 
23 0.44987 0.02 0.5 
CGI 
(Present 
within the 
gene body 
of LAMA5) 
Chr20:60319301-
60319515 
14 0.62537 0.008 0.72 
CGI shore 
(sequence a) 
(Intergenic 
CGI shore) 
Chr7:8448450-
8448726 
18 0.30308 0.002 0.82 
CGI shore 
(sequence b) 
(Intergenic 
CGI shore) 
Chr7:8448727-
8448894 
13 0.30308 <0.0001 0.96 
 
 
3.2.5.2 Bisulphite pyrosequencing validation 
 
We extended the validation to include bisulphite pyrosequencing of 63 AML patients of 
different cytogenetic abnormalities, 7 AML cell lines (Kasumi-1 (in duplicates), OCI-
AML2, HL60, P31/FUJ, CTS, Kmoe2 and THPI) and 5 NBMs. Pyrosequencing 
validation included 2 DMRs discriminating AML from NBM; promoter of DPP6, 
promoter of SPHKAP, 2 DMRs that were specific for 2 AML subtypes; promoter of 
ST6GAL2 in t(8;21) AML (absolute methylation difference = 0.42, P = 1.45 X 10
-5
), a 
CGI within the gene body of HHEX in trisomy 8 AML (absolute methylation difference 
= 0.74, P = 9 X 10
-6
) and finally an AluJb repeat within the gene body of ZNF398 that 
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was differentially hypomethylated in t(8;21) AML (absolute methylation difference = 
0.46, P = 0.0009). 
Pyrosequencing results revealed statistically significant methylation differences among 
the groups (Kruskal-Wallis test followed by Dunn‟s multiple comparison tests P < 0.05). 
AML cell lines showed high methylation levels in all genomic regions investigated 
except Alu repeat (Tables 3.8, 3.9, Figures 3.19, 3.20). 
Table ‎3.8 Pyrosequencing validation of selected genomic regions in AML and NBM 
*Percentage = average of methylation of all CpGs sequenced as calculated by pyrosequencing  
 
Genomic 
region 
No. of  
CpGs  
investigated 
MeDIP-seq results AML patients  AML 
cell lines 
NBMs 
 SPHKAP 
chr2: 
228753601-
228753665 
(sequence a) 
9 AML > NBM 
(promoter) 
*53% *82% *17% 
SPHKAP  
chr2: 
228753760-
228753852 
(sequence b) 
8 AML > NBM 
(promoter) 
27% 59% 7% 
DPP6 chr7: 
153214816-
153214843 
4 AML > NBM 
(promoter) 
23% 61% 3% 
ST6GAL2 
chr2: 
106869095-
106869136 
8 t(8;21) AML > 
AML & NBM 
(promoter) 
t(8;21) AML 
average = 43% 
Other AMLs 
average = 12% 
68% 1% 
HHEX chr10: 
94442251-
94442377 
9 Trisomy 8 AML > 
AML & NBM (CGI) 
Trisomy 8 AML  
average  = 42% 
Other AMLs  
average  = 14% 
50% 6% 
AluJb chr7: 
148474346-
148474580 
3 t(8;21)AML < AML 
& NBM (within the 
gene body of 
ZNF398) 
t(8;21)AML  
average  = 7%, 
other AMLs  
average  = 23% 
12% 29% 
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Table ‎3.9 Pyrosequencing validation of selected genomic regions in different AML 
subtypes 
The pyrosequencing results of each AML group/ NBM in the genomic regions 
investigated are demonstrated in Appendix 1 Figures 5G-L 
Samples ID SPHKAP 
(sequence a) 
SPHKAP 
(sequence b) 
DPP6 St6GAL2 HHEX Alu repeat 
t(8;21) AML *65/6 36/6 41/6 43/6 3/5 7/7 
t(15;17)AML 63/10 29/10 27/10 20/9 22/4 25/4 
Inv 16 AML 63/3 34/3 15/3 15/3 3/6 12/6 
+8 AML 45/5 18/4 19/5 17/5 42/10 15/10 
+21 AML 49/3 26/3 9/3 8/3 - - 
t(9;22) AML 42/1 20/1 3/1 2/1 - - 
t(6;9) AML 50/1 - 32/1 11/1 - - 
t(v;11q23)AML 48/2 18/2 20/2 12/2 - - 
t(9;11) AML 20/2 14/2 6/1 7/2 - - 
Complex AML 60/5 28/5 23/5 4/5 35/5 24/5 
NK AML 50/24 27/21 22/20 9/22 8/30 15/30 
AML cell lines 82/8 59/6 61/6 68/5 50/8 12/8 
NBMs 17/5 7/4 3/4 1/4 6/5 29/5 
*65/6; 65 is the average of methylation percentage of all CpGs sequenced as calculated by 
pyrosequencing, 6 is the number of patients investigated in this AML subtype.  
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Figure ‎3.19 Pyrosequencing validation of DMRs between AML and NBM 
In each figure, the dots are the average CpG methylation percentage as calculated by 
pyrosequencing, the horizontal line represents the mean of those dots, and N is the 
number of samples investigated. There was significant methylation difference among the 
groups in all genes investigated (Kruskal-Wallis test, P < 0.0001). Additionally, there 
was significant methylation difference between AML patients and NBMs in SPHKAP 
(sequences a & b) and in DPP6 (Dunn’s multiple comparison tests, P < 0.05). Also, 
there was significant methylation difference between AML patients and AML cell lines 
in SPHKAP (a) and in DPP6 (Dunn’s multiple comparison tests, P < 0.05). 
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Figure ‎3.20 Pyrosequencing validation of DMRs between AML subtypes  
The dots are the average methylation percentage as calculated by pyrosequencing, N is 
the number of samples investigated. There was significant methylation difference among 
the groups in all investigated genes/ Alu repeat (Kruskal-Wallis test, P < 0.0001). 
Additionally, there was significant methylation difference between AML patients and 
AML cell lines in all genes investigated (Dunn’s multiple comparison tests, P < 0.05) 
except Alu repeat. Also, significant methylation difference between t(8;21) AML and the 
rest of AML patients in ST6GAL2 and Alu repeat was detected (Mann-Whitney test, P= 
0.001, 0.002 respectively). For HHEX gene, there was significant methylation difference 
between trisomy 8 AML and the rest of AML patients (Mann-Whitney test, P= 0.001).  
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3.2.5.3 Illumina Infinium Array 
 
The Illumina HumanMethylation 27 BeadArray was applied to 3 MeDIP-seq samples 
[studies No. 11, 12, 13 (Table 3.1)]. The Illumina Infinium Array interrogates 
approximately 27,000 CpG sites in 14,000 genes. Since the Infinium Array assayed a 
single CpG in average 124bp, we determined from MeDIP-seq data a 100bp window 
that included this CpG in its centre. Correlating the average Batman score to each 1% 
Infinium Array bin revealed strong significant positive correlation between both 
methods in the three MeDIP-seq samples (R
2= 0.89, 0.9, 0.8 respectively, Pearson‟s) 
(Figure 3.21).  
 
 
Figure ‎3.21 Correlation between MeDIP-seq and Illumina Infinium Array in 3 MeDIP-
seq samples 
Strong significant positive correlation was identified between MeDIP-seq and Illumina 
Infinium Array in the three samples investigated. 
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3.2.5.4 Comparison between the current study and AML array-based study  
 
It was of interest to compare our MeDIP-seq results of t(8;21) AML and t(15;17) AML 
to corresponding results of a recent array-based study of DNA methylation in AML 
subtypes (Figueroa et al. 2010b). We found 48 genes with the same methylation status 
were in common between the array-based study (equals 16% of the total number of 
differentially methylated genes) and the MeDIP-seq study (equals 5% of the 
differentially methylated genes). There was a difference in the localization of the 
sequences investigated by each study for each gene. Figueroa et al used amplified 
fragments derived from digestion of HpaII sites and hybridized onto a custom human 
promoter array (HELP technique) (Khulan et al. 2006). The fragments were annotated to 
the nearest TSS up to 5Kb distance of approximately 14,000 genes. In the current study, 
we used a specific monoclonal antibody to methylated cytosines followed by sequencing 
the whole genome and further identified the gene promoter methylation as an average of 
the methylation scores of 2 Kb centered at the TSS. Despite such major differences 
between both techniques, a common list of genes could be readily identified (the 
common genes between both studies are listed in Appendix 1 Tables 5A, B). 
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3.3 Discussion 
 
DNA methylation plays an important role in pathogenesis, diagnosis and prognosis of 
AML (Schoofs and Muller-Tidow 2011). Since recent improvements have been 
introduced to the methods detecting DNA methylation, new AML subtypes have been 
identified using only their DNA methylation signatures (Figueroa et al. 2010b). A 
significant difference was also found between the survival of the new AML subtypes 
and the survival of other well-established AML subtypes (Figueroa et al. 2010b). 
However, due to technical reasons, previous studies performed on DNA methylation in 
AML focused on either alterations in promoters or CGIs. Therefore, in the current study 
we used a global method for investigating the AML methylome; MeDIP-seq. MeDIP-
seq has been used successfully for mapping methylomes in normal tissue (Chavez et al. 
2010; Maunakea et al. 2010), a colon tumour (Bock et al. 2010), a pool of 10 benign and 
a pool of 10 malignant peripheral nerve sheath tumors (Feber et al. 2011).  
Batman was the first algorithm developed to obtain an absolute quantification of 
MeDIP-seq data with a 100bp resolution (Down et al. 2008). Recently, Chavez et al 
developed another software „MEDIPS‟ to get an absolute quantification of MeDIP-seq 
(Chavez et al. 2010). MEDIPS has some advantages over Batman. Firstly, MEDIPS 
investigated the reproducibility of the methylation profiles which revealed we had 
sufficient numbers of short reads to generate reliable methylome profiles for each DNA 
sample. Secondly, MEDIPS calculated the percentage of CpG coverage in the whole 
genome which indicated that the current MeDIP-seq study covered around 76% of 28 
million CpG sites present in the human reference genome. This CpG coverage goes 
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above a recent MeDIP-seq coverage in peripheral nerve sheath tumors (67%) (Feber et 
al. 2011).  Also, MEDIPS can identify DMRs between the samples investigated. 
However, both Batman and MEDIPS share the same problem of consuming much time 
in calling methylation signals from the regions of interest.  
Consequently, we were able to develop whole-genome DNA methylation profiles with a 
view to the identification of epigenetic changes relevant to the development of AML and 
some of its subtypes. Methylomes from 12 AML samples were created including 4 
different cytogenetic subtypes (Grimwade et al. 1998) and from 4 NBMs. The 100bp 
resolution methylation map for each leukaemia and NBM enabled us to identify the 
differences in methylation of promoters, gene bodies, CGIs and CGI shores between 
AML and NBM. That revealed DMRs which were associated with not only previously 
identified methylated genes in AML e.g. ID4 and DCC but also previously unidentified 
methylated genes in AML e.g. SPHKAP and DPP6.  
For validation of MeDIP-seq data, we used the gold standard for DNA methylation 
analysis; bisulphite sequencing. Direct bisulphite sequencing confirmed the MeDIP-seq 
results as was previously shown (Down et al. 2008). In the current study, all DMRs 
validated by bisulphite sequencing were of high CpG density (10%) with different levels 
of methylation in AML. This was in contrast to what was reported for MeDIP as a better 
detector of hypermethylated DMRs of low and intermediate CpG density than DMRs of 
high CpG density (Nair et al. 2011). This might be due to Batman algorithm models the 
effect of varying densities of methylated CpGs on MeDIP enrichment allowing 
quantitative measurement of DNA methylation across a wide range of CpG densities 
(Down et al. 2008). In addition, bisulphite pyrosequencing extended the MeDIP-seq 
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validation to include 63 AML patients of different subtypes and AML cell lines. AML 
cell lines showed a higher level of DNA methylation of target genes than AML patients 
e.g. average DNA methylation of SPHKAP was 53% in AML patients and 82% in AML 
cell lines, average DNA methylation of DPP6 was 23% in AML patients and 61% in 
AML cell lines. The DNA methylation difference between AML cell lines and AML 
patients might be due to the significant increase of the 5 methylcytosines in cell lines 
over primary tumors (Smiraglia et al. 2001). Furthermore, the strong correlation 
between MeDIP-seq and Illumina Infinium Array (R
2 
= 0.8, 89, 0.9) is consistent with 
and slightly higher than previous studies which verified the strong correlation between 
both methods (R
2
= 0.84) (Bock et al. 2010), (R
2
= 0.8) (Feber et al. 2011). 
Since 40 - 45% of the human genome is repetitive and consists of interspersed repeats 
derived from autonomous and non-autonomous transposable elements and tandem 
repeats of simple sequences (satellite DNA), it was important to extend the analysis to 
include such sequences. Both the hyper- and hypomethylated DMRs associated with 
LINE, SINE and LTR repeat families discriminated AML from NBM. This 
discrimination was less clear in the satellite repeat family. Differences between satellite 
methylation and interspersed repeat methylation were previously reported in leukaemia 
and in bladder cancer (Choi et al. 2009). Additionally, hypomethylated clusters of 
interspersed repeats distinguished each AML subtype (Figure 3.15), such discrimination 
was not found for the satellite repeat members. Previous studies have identified the 
importance of the hypomethylation of repeat elements being a feature in cancer (Wilson 
et al. 2007). For example, hypomethylation of LINEs has been observed in several 
cancer types with an increase in the hypomethylation parallel to the severity of 
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malignancy (Hoffmann and Schulz 2005). Also, hypomethylation of LINEs has been 
associated with the phases of chronic myeloid leukaemia and is shown to have 
prognostic value (Roman-Gomez et al. 2005). Besides, the significant inverse 
correlation between DNA methylation of interspersed repeat elements and gene 
expression (Figures 3.18D - F) confirmed the impact of DNA methylation of SINEs, 
LINEs and LTRs on regulating the gene transcription (Roman-Gomez et al. 2005; 
Mansour 2007; Lee et al. 2008; Wolff et al. 2010).  
In summary, generating methylation maps with a 100bp resolution assisted in detecting 
hypomethylated repeat sequences that distinguished each AML subgroup. This result is 
the first to show that cancer subtypes can be classified according to their repeats 
hypomethylation. This raises some questions concerning the role of those repeats as 
diagnostic markers in addition to a possible association with the survival of AML 
patients.     
.
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Chapter 4. Study of the expression of SPHKAP,             
DPP6 and ID4 genes in AML 
 
4.1 Introduction 
 
The previous analysis of MeDIP-seq data of the promoter DNA methylation in AML 
and NBM revealed novel differentially methylated genes in AML e.g. the DPP6 and 
SPHKAP genes.  
 
4.1.1 SPHKAP (A- kinase anchor protein, SKIP; SPHK1-interacting protein)  
 
The study of SPHKAP in more depth was of special interest since SPHKAP’s promoter 
was one of the most significant differentially methylated promoters in AML versus 
NBM (absolute methylation difference = 0.45, P = 0.0002). Also, SPHKAP acts as a 
modulator of sphingosine kinase 1 (SPHK1), which is an important element in the 
sphingolipid pathway (Lacana et al. 2002; Pyne and Pyne 2010).  
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4.1.1.1 Sphingolipid pathway 
 
The sphingolipid pathway consists of groups of bioactive molecules that regulate 
physiological and pathological processes. Two kinds of elements are included in this 
pathway: pro- and anti-apoptotic (Figure 4.1). The pro-apoptotic elements are two 
sphingolipids; ceramide and sphingosine, while the anti-apoptotic components involve 
SPHK1 enzyme and sphingosine-1-phosphate (S1P). In brief, ceramide located in the 
cell membrane is hydrolyzed from sphingomyelin by sphingomyelinase enzyme. 
Ceramide induces its apoptotic effect through certain intracellular targets; ceramide  
activated protein kinase (CAPK), cathepsin D, phosphoprotein phosphatase 1 (PP1) 
(Pettus et al. 2002). Ceramide is converted to sphingosine by ceramidase enzyme. 
Sphingosine is rapidly phosphorylated to produce S1P by SPHK1 enzyme. S1P 
promotes both cell proliferation and cell survival. Therefore, the sphingolipid pathway 
can be directed towards either apoptosis or cell survival depending on the balance of the 
concentrations between ceramide/sphingosine and SPHK1/S1P inside the cell (Maceyka 
et al. 2002). This dynamic balance between those metabolites is known as sphingolipid 
„rheostat‟, which is under the control of certain factors (Jessup et al. 2011). For example, 
cell stress, chemotherapy and irradiation mediate the ceramide synthesis through 
activation of sphingomyelinase enzyme. On the other hand, some growth factors e.g. 
vascular endothelial growth factor (VEGF) and protein kinases e.g. PKC activate 
SPHK1 enzyme to produce S1P thus aggravating cell survival and cell migration 
(Visentin et al. 2006). 
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4.1.1.2 Roles of SPHK1 and S1P in cancer 
 
The SPHK1 gene is overexpressed in tumors and in cancer cell lines. Its high expression 
level is associated with an increase in the tumor grade and with a decline in the patient 
survival (Van Brocklyn et al. 2005; Liu et al. 2010). Therefore, SPHK1 can act as an 
oncogene without presence of a known mutation (Pyne and Pyne 2010). Notably, 
SPHK2 enzyme is another isoform of SPHK, which is located mainly in the nucleus. 
SPHK2, in contrast to SPHK1, inhibits the DNA synthesis (Maceyka et al. 2005; Ryland 
et al. 2011). However, the role of SPHK2 in malignancy is not yet clear (Vadas et al. 
2008). Moreover, the role of S1P in tumor progression is well-established through 
extracellular and intracellular effects (Pyne and Pyne 2010; Huang et al. 2011). The 
extracellular effect is through 5 G-protein coupled receptors (S1PR1-5). S1P couples to 
G proteins, resulting in activation of Ras-MAPK, phosphatidylinositol 3-kinase (PI3K) 
and phospholipase C (PLC) pathways. The intracellular effect of S1P is through the 
activation of growth factors e.g. VEGF, epidermal growth factor (EGF), tumor necrosis 
factor- (TNF-) and transcriptional factors that protect against apoptosis e.g. AP-1 and 
NK-KB (Maceyka et al. 2002). Additionally, S1P increases the expression of anti-
apoptotic proteins e.g. BCL2 and inhibits the expression of pro-apoptotic proteins e.g. 
BAD and BAX (Huang et al. 2011). In order to control the sphingolipid metabolites in 
cancer, potential therapeutic agents have been developed. For example, suppression of 
malignancy was achieved through inhibition of SPHK1 (Kennedy et al. 2011a), or 
inhibition of S1P (Visentin et al. 2006) or blocking of S1PRs (Kennedy et al. 2011b). 
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4.1.1.3 The link between SPHKAP and SPHK1 
 
The study, which illustrated the relationship between SPHKAP and SPHK1, was 
performed on NIH 3T3 fibroblasts as cell transfection with SPHKAP reduced the 
activity of SPHK1 without affecting its expression (Lacana et al. 2002). Also, SPHKAP 
reduced the activated extracellular receptor kinase (ERK), which was stimulated due to 
overexpression of SPHK1. Additionally, transfection of NIH 3T3 fibroblasts with both 
tagged SPHKAP and SPHK1 showed that both SPHKAP and SPHK1 were co-localized 
in the cytoplasm (Lacana et al. 2002). Recently, SPHKAP was identified as a member of 
the A-kinase-anchoring proteins (AKAPs) (Kovanich et al. 2010). The importance of 
AKAPs is in directing protein kinase A (PKA) towards a precise site of action. The 
presence of SPHK1 in the cytoplasm while its substrate (sphingosine) is located in the 
cell membrane suggests that SPHKAP, as an AKAP, directs SPHK1 to its substrate to 
trigger its function (Lacana et al. 2002).  
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Figure ‎4.1 Sphingolipid pathway 
Two types of elements are included in the sphingolipid pathway; pro-apoptotic (Cer; 
ceramide and Sph; sphingosine) and anti-apoptotic (SK1; SPHK1 and S1P). S1PR; S1P 
receptor [the figure is adapted from (Pyne and Pyne 2010)]. 
 
4.1.2 DPP6 (Dipeptidyl-peptidase 6) 
 
DPP6 (dipeptidyl peptidase-like protein-6, also known as DPPX) was the second gene 
of interest since the promoter of DPP6 was one of the most significant differentially 
methylated promoters in AML versus NBM (absolute methylation difference = 0.46, P = 
0.0007). The DPP6 gene is one member of dipeptidyl peptidase IV family. However, 
DPP6 has no enzymatic activity since it lacks the serine residue in the catalytic region of 
the protein (Clark et al. 2008). Its function is most probably through protein-protein 
interaction (Yu et al. 2010). DPP6 is a vital controller of nervous system excitability. 
This control is achieved through acting as an associated subunit of the potassium 
channel Kv4 and by increasing the conductance of the leak channels and Na current 
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amplitude (Nadin and Pfaffinger 2010). Moreover, DPP6 gene has roles in the 
pathogenesis of some degenerative neurological diseases such as progressive spinal 
muscular atrophy (van Es et al. 2009) and amyotrophic lateral sclerosis (Blauw et al. 
2010). In cancer, DPP6 was detected as a biomarker of melanoma (Jaeger et al. 2007) 
where it was downregulated. In addition, DPP6 was hypomethylated in colon cancer 
(Irizarry et al. 2009). 
Therefore, the aim of this chapter is to assess the expression of two of the most 
significant differentially methylated genes in AML: DPP6 and SPHKAP with 
investigating the potential correlation between SPHKAP methylation and SPHK1 and 
S1P. The promoter methylation of DPP6 and SPHKAP was validated in Chapter 3 by 
direct bisulphite sequencing and bisulphite pyrosequencing. Parallel to those genes, ID4 
gene expression is also investigated since a significant methylated DMR was found in its 
promoter in AML versus NBM (absolute methylation difference = 0.28, P = 0.003). 
 
4.2 Materials and Methods 
 
AML patients‟ samples with available RNA were obtained from the tissue bank at St 
Bartholomew‟s Hospital. The expression of SPHKAP, DPP6, ID4 and SPHK1 was 
measured relative to normal breast by RT-PCR as described in Chapter 2. Before the 
RT-PCR, a conventional PCR was initially performed to assess the SPHKAP expression 
in cancer cell lines. The reaction mix consisted of 1l cDNA, 0.1l forward primer 
(100M), 0.1l reverse primer (100M) and 18.8l ReddyMix PCR Master Mix (AB-
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0575/LD/A, Thermo Scientific). PCR amplification was obtained from 30 cycles of 30 
seconds at 95°C, 30 seconds at 55°C, and 30 seconds at 72°C, after an initial denaturing 
for 2 minutes at 95°C, and final elongation for 5 minutes at 72°C.   
SPHKAP forward primer: CTGCATCTGGACCGCCTAC, reverse primer 
CAGTTCCAAGAGCCAGTCAA.  
Treatment of AML cell lines with DAC (5-aza-2deoxycytidine) was carried out as 
described in Chapter 2. Cloning of SPHKAP cDNA into a vector, transfecting human 
chronic myeloid leukaemia cell line (K562) and human breast cancer cell line (MCF7) 
with this construct and subsequent measuring S1P and sphingosine by LC-MS were all 
performed as described in Chapter 2. 
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4.3 Results 
 
4.3.1 SPHKAP assessment in AML 
 
4.3.1.1 SPHKAP gene expression in cancer cell lines and normal tissues 
 
First, we investigated the expression of SPHKAP in AML cell lines, other cancer cell 
lines and normal tissues by PCR. SPHKAP was expressed in all normal tissues 
investigated. By contrast, SPHKAP was repressed in all cancer cell lines investigated 
including AML cell lines (Figure 4.2, Table 4.1).  
 
          
SPHKAP  
 
GAPDH  
 
 
 
Figure ‎4.2 SPHKAP gene expression in cancer cell lines and normal tissues by PCR 
Table ‎4.1 SPHKAP gene expression in cancer cell lines and normal tissues by PCR 
SPHKAP expression was absent in all cancer cell lines, while in normal tissues 
SPHKAP expression was evident. The blue arrow indicates the direction of the wells. 
Well No. Sample tested 
1 Ladder 
2 Nomo-1 (AML cell line) 
3 P31/FUJ (AML cell line) 
4 Kasumi (AML cell line) 
5 OCI-AML2 (AML cell line) 
6 Kmoe2 (AML cell line) 
7 CTS (AML cell line) 
8 HL60 (AML cell line) 
9 THP1 (AML cell line) 
10 MCF7 (Breast cancer cell line) 
11 T47D (Breast cancer cell line) 
12 SkBr 3 (Breast cancer cell line) 
13 Normal lymph node 
14 Normal thymus 
15 Normal brain 
16 Normal ovary 
17 Normal kidney 
18 Normal breast 
19 Ladder 
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In order to confirm the previous results, SPHKAP gene expression was assessed using 
RT-PCR. The RT-PCR results confirmed the absence of the gene expression in cancer 
cell lines, while SPHKAP expression was evident in normal tissues investigated (Figure 
4.3A). SPHKAP showed a notable gene expression level in normal heart tissue (Figure 
4.3B).       
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4 
149 
 
A.  
    
         
B. 
 
 
Figure ‎4.3 SPHKAP gene expression in cancer cell lines and normal tissues by RT-PCR 
A. X-axis represents relative expression of SPHKAP gene and Y-axis represents the 
samples investigated. SPHKAP expression was undetectable in cancer cell lines, 
while in normal tissues SPHKAP expression was evident (mean ± SD).  
B. SPHKAP gene showed a high expression level in normal heart tissue.  
The expression was calculated using relative quantitative real-time PCR. The Ct (cycle 
thresold) of SPHKAP in each sample was normalized using a reference gene (18S). 
Next, the  Ct is compared to the  Ct of a calibrator (normal breast tissue). Therefore, 
the relative gene expression in any sample is calculated relative to 18S relative to 
normal breast tissue. For full details, refer to Chapter 2 section 2.9.3.2. 
Relative Expression 
Relative Expression 
Chapter 4 
150 
 
4.3.1.2  SPHKAP gene expression in AML patients 
  
SPHKAP gene expression was next investigated in 60 AML patients by RT-PCR; all 
AML patients had a normal karyotype. Additionally, SPHKAP expression was 
investigated in 3 normal tissues [mononuclear cells NBM from a healthy donor (MNCs 
NBM), normal kidney and normal thymus]. The results showed that SPHKAP 
expression was undetectable in 57 AML samples. The relative expression for the 3 
positive AML and the normal tissues are shown in Figure 4.4. 
                       
Figure ‎4.4 SPHKAP gene expression in the only 6 positive samples by RT-PCR 
The relative gene expression in any sample is calculated relative to 18S relative to 
normal breast tissue. 
 
4.3.1.3 Correlation between SPHKAP gene expression and promoter methylation 
 
Matching SPHKAP gene expression results with pyrosequencing results of SPHKAP 
from 2 different sequences in its promoter (Chapter 3, Figure 3.19) revealed 24 matched 
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samples; 19 AML patients, 4 AML cell lines and a NBM (Table 4.2). All AML patients 
had a normal karyotype. Comparing SPHKAP methylation between samples expressing 
and samples not expressing SPHKAP revealed a significant methylation difference 
between both groups (Mann-Whitney test, P = 0.01) (Figure 4.5). 
Table ‎4.2 SPHKAP promoter methylation and expression results 
 *% CpG methylation as measured by pyrosequencing 
 
Sample ID *% CpG methylation 
(SPHKAP sequence a) 
*% CpG methylation 
(SPHKAP sequence b) 
SPHKAP 
expression 
AML patient 
61.23 35.63 
Negative 
AML patient 69.59 34.27 Negative 
AML patient 46.4 16.26 Negative 
AML patient 34.89 7.65 Negative 
AML patient 60.88 21.08 Negative 
AML patient 55.55 55.49 Negative 
AML patient 48.12 20.99 Negative 
AML patient 23.95 9.85 Negative 
AML patient 
32.27 28.45 
Negative 
AML patient 28.09 23.11 Negative 
AML patient 48.42 38.8 Negative 
AML patient 34.2 21.05 Negative 
AML patient 47.17 22.09 Negative 
AML patient 59.39 20.08 Negative 
AML patient 46.43 26.03 Negative 
AML patient 
57.59 61.8 
Negative 
AML patient 
46.4 16.26 
Positive  
AML patient 
32.1 12.59 
Positive  
AML patient 
32.27 28.45 
Positive 
MNCs NBM 9.73 6.38 Positive 
OCI-AML2 cell line 71.62 30.57 Negative 
HL60 cell line 90.05 88.79 Negative 
P31/FUJ cell line 80.28 67.36 Negative 
Kasumi cell line 86.66 85.37 Negative 
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Figure ‎4.5 Comparison of DNA methylation between samples expressing SPHKAP and 
samples not expressing SPHKAP 
There was a significant SPHKAP promoter methylation difference between both groups 
(Mann-Whitney test, P = 0.01, Mean  SD). 
 
4.3.1.4 SPHK1 methylation as identified by MeDIP-seq 
 
Since SPHKAP is an important modulator of SPHK1 (Lacana et al. 2002), therefore we 
identified the promoter methylation of SPHK1 and S1PRs using MeDIP-seq database. In 
contrast to SPHKAP, SPHK1 and S1PRs promoter methylation levels were less than 0.6 
Batman scores in both AML and NBM (Figures 4.6A, B). S1PR2, S1PR4 and S1PR5 
were the S1PRs which were covered by MeDIP-seq. 
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A.  
B.  
Figure ‎4.6 Promoter DNA methylation of SPHKAP, SPHK1, SPHK2 and S1PRs in 
MeDIP-seq samples 
A. Promoters of SPHK1, SPHK2, S1PR2 and S1PR4 were low methylated in both AML 
and NBM (Batman scores < 0.4). Promoter of S1PR5 was intermediate methylated (0.4-
0.6 Batman scores). B. SPHKAP showed a methylated DMR in its promoter in AML 
patients versus NBMs (absolute methylation difference = 0.45, P = 0.0002). 
 
4.3.1.5 SPHK1 expression in cancer cell lines and normal tissues 
 
The expression of SPHK1 was next investigated in cancer cell lines and normal tissues 
by RT-PCR. SPHK1 expression was variable with more expression levels were 
identified in cancer cell lines than normal tissues. The highest SPHK1 expression was 
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detected in HT1080 (human fibrosarcoma cell line) and in HD-MYZ (human Hodgkin 
lymphoma cell line) (Figure 4.7) 
      
     Figure ‎4.7 SPHK1 expression in cancer cell lines and normal tissues by RT-PCR 
    SPHK1 was expressed in both cancer cell lines and normal tissues with a higher          
SPHK1 expression level was found in cancer than in normal. The relative gene 
expression in any sample is calculated relative to 18S relative to normal breast tissue. 
                           
4.3.1.6  Comparison between SPHK1 and SPHKAP gene expression  
 
SPHK1 gene expression was compared to SPHKAP gene expression in 30 AML patients 
of different cytogenetic subtypes, cancer cell lines and normal tissues by RT-PCR. Most 
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of AML patients, who showed expression of SPHK1, did not show SPHKAP expression. 
SPHK1 was also expressed in all cancer cell lines investigated, while SPHKAP 
expression was undetectable in all cancer cell lines investigated. However, both 
SPHKAP and SPHK1 were expressed in normal tissues (Figure 4.8). 
Figure ‎4.8 Gene expression comparison between SPHKAP and SPHK1 in AML patients, 
cancer cell lines and normal tissues 
The relative gene expression in any sample is calculated relative to 18S relative to 
normal breast tissue. 
4.3.1.7 Measurement of S1P and sphingosine in AML by LC-MS 
 
In order to investigate the possible correlation between SPHKAP methylation and S1P, 
the intracellular level of S1P was measured in 26 AML patients by LC-MS. Sphingosine 
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(SPH), which is the substrate for SPHK1, was also measured. In parallel, we assessed 
SPHKAP methylation by pyrosequencing and SPHKAP gene expression by RT-PCR in 
those patients (Table 4.3). There was a significant positive correlation between the 
intracellular level of S1P and SPH (Spearman r = 0.5, P = 0.02). However, there was no 
significant correlation detected between SPHKAP methylation and S1P (P = 0.5). 
Measurement of S1P was performed intracellularly since the extracellular S1P was 
difficult to assess due to lack of availability of patients‟ plasma. 
Table ‎4.3 Levels of sphingosine (SPH), S1P, and S1P/SPH ratios in AML patients 
measured by LC-MS 
Samples Cytogenetic 
abnormality 
*Pyro % SPH (ng/10
6 
cells) 
S1P (ng/ 10
6 
cells) 
S1P/SPH SPHKAP 
expression 
AML patient +8,  80.4 41.6 8.6 0.2  Unexpressed 
AML patient +8,  65.27 47.9 179.3 3.7 Unexpressed 
AML patient inv 16 55.77 16.1 246.8 15.3 Unexpressed 
AML patient inv 16 52.21 11.3 10.1 0.9 Unexpressed 
AML patient inv 16 58.34 101.48 1029.6 10.1 Unexpressed 
AML patient inv 16 60.37 147.3 128.4 0.9 Unexpressed 
AML patient NK 23.57 21.1 326.9 15.5 Unexpressed 
AML patient NK 44.59 29.7 1048.2 35.3 Unexpressed 
AML patient NK 42.23 11.1 321.3 29 Unexpressed 
AML patient NK 38.81 43.8 725.1 16.6 Unexpressed 
AML patient NK 27.95 72.8 1385.8 19 Unexpressed 
AML patient NK 81.24 19.57 395.5 20.2 Unexpressed 
AML patient NK 73.66 27.1 498.5 18.4 Unexpressed 
AML patient NK 25.32 20.9 408.3 19.5 Unexpressed 
AML patient NK 19.34 4.9 442.1 90.6 Unexpressed 
AML patient NK 32.1 18 16.7 0.9 Expressed 
AML patient NK 66.55 102 84.2 0.8 Unexpressed 
AML patient NK 32.27 53.9 29.6 0.6 Expressed 
AML patient NK 34.89 120.4 36.2 0.3 Unexpressed 
AML patient NK 38.81 15.2 21.4 1.4 Unexpressed 
AML patient t(15;17) 62.32 62.3 528 8.5 Unexpressed 
AML patient t(15;17) 80.2 47.3 167.1 3.5 Unexpressed 
AML patient t(8;21) 84.22 11.2 248.4 22.2 Unexpressed 
AML patient t(8;21) 80.19 71.7 9.2 0.2 Unexpressed 
AML patient t(8;21) 70.66 23.1 25.9 1.1 Unexpressed 
AML patient t(8;21) 50.92 59.5 1260.6 21.2 Unexpressed 
*Pyro % equals average CpG methylation of SPHKAP (sequence a) as measured by pyrosequencing.  
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4.3.1.8 Transfection of SPHKAP cDNA into cancer cell lines 
 
To investigate whether activation of SPHKAP could affect S1P level, we transfected 
K562 cell line with a vector that expresses SPHKAP. The intracellular S1P and 
sphingosine (SPH) were measured in the transfected cells and S1P/SPH ratio was 
calculated. The S1P/SPH ratio was compared to corresponding S1P/SPH ratio in K562 
cell line transfected with an empty vector (without SPHKAP cDNA). That revealed 2 
times increase in the intracellular SIP level and S1P/SPH ratio in K562 cell line after the 
transfection with SPHKAP cDNA. The measurement was performed in duplicate using 
LC-MS (Table 4.4). Since MCF7 cell line showed high SPHKAP promoter methylation 
by pyrosequencing (SPHKAP sequence a = 68%, SPHKAP sequence b = 51%) and 
unidentified SPHKAP expression by PCR (Figure 4.2), we repeated the SPHKAP 
transfection experiment using MCF7 cell line. That revealed 2 times and 10 times 
increase in the intracellular S1P level and S1P/SPH ratio respectively after the activation 
of SPHKAP gene (Table 4.4).  
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Table ‎4.4 S1P/SPH ratio in cancer cell lines transfected with vector expressing 
SPHKAP 
Sample ID SPH conc (ng/10
6 
cells) 
S1P conc (ng/ 10
6 
cells) 
S1P/SPH Ratio 
K562 cell line 
transfected with an 
empty vector 
43.9 15.7 0.4 
K562 cell line 
transfected with an 
empty vector 
45.9 13.1 0.3 
K562 cell line 
transfected with a vector 
containing  SPHKAP 
cDNA 
33.0 34 1.0 
K562 cell line 
transfected with a vector 
containing SPHKAP 
cDNA 
28.5 23.0 0.8 
MCF7 cell line 
transfected with an 
empty vector 
195.5 488.0 2.5 
MCF7 cell line 
transfected with a vector 
containing SPHKAP 
cDNA 
46.8 1350.3 28.8 
MCF7 cell line 
transfected with a vector 
containing SPHKAP 
cDNA 
53.5 1099.9 20.6 
SPH; sphingosine, S1P; sphingosine-1-phosphate, conc; concentration 
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4.3.2 DPP6 assessment in AML 
                                   
The second gene of interest was DPP6 as its promoter was one of the most significant 
differentially methylated promoters in AML versus NBM. Figure 4.9 demonstrated 
DPP6 promoter DNA methylation as detected by MeDIP-seq. 
 
Figure ‎4.9 Promoter DNA methylation of DPP6 in MeDIP-seq samples 
The X-axis represents MeDIP-seq samples and Y-axis represents the corresponding 
promoter methylation calculated by Batman algorithm. The figure shows a significant 
methylated DMR was found in the DPP6 gene promoter in AML patients versus NBMs 
(absolute methylation difference = 0.46, P = 0.0007). 
 
4.3.2.1 DPP6 expression in AML and normal tissues 
 
DPP6 gene expression was assessed in 30 AML patients, cancer cell lines including 
WM (melanoma cell line) and normal tissues using RT-PCR. DPP6 expression was 
undetectable in all AML patients and in some AML cell lines. By contrast, DPP6 was 
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expressed in normal tissues investigated (Figure 4.10A). Notably, the highest DPP6 
gene expression was identified in normal brain tissue (Figure 4.10B). 
A. 
 
B. 
 
 
 Figure ‎4.10 DPP6 gene expression in AML, cancer cell lines and normal tissues 
A. Absence of DPP6 expression in all AML patients and in some cancer cell lines. 
B. DPP6 showed a high gene expression level in normal brain tissue.  
The relative gene expression in any sample is calculated relative to 18S relative to 
normal breast tissue. 
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4.3.2.2 Correlation between DPP6 gene expression and promoter methylation 
 
Relating the previous gene expression results with DPP6 pyrosequencing results 
(Chapter 3 Figure 3.19) revealed 17 matched samples (13 AML patients, 3 AML cell 
lines and a MNCs NBM) (Table 4.5). All samples did not show DPP6 gene expression 
except the Kasumi cell line. The range of DPP6 promoter methylation in samples not 
expressing the gene was between 1.52% and 88.56%. DPP6 promoter methylation in 
Kasumi cell line (the only sample expressing DPP6 gene) was 87.69% (Table 4.5). 
Table ‎4.5 DPP6 gene expression and promoter methylation 
 
 
 
 
 
 
 
 
 
 
 
*%CpG methylation as measured by pyrosequencing 
 
 
 
Sample ID *% CpG methylation DPP6 expression 
AML +8 44.72 Negative 
AML +8 22.03 Negative 
AML inv 16 20.72 Negative 
AML inv16 14.58 Negative 
AML NK 45.98 Negative 
AML NK 17.77 Negative 
AML t(15;17) 38.68 Negative 
AML t(15;17) 29.7 Negative 
AML t(15;17) 26.23 Negative 
AML t(8;21) 59.31 Negative 
AML t(8;21) 58.11 Negative 
AML t(8;21) 19.88 Negative 
AML t(8;21) 66.36 Negative 
Kasumi cell line 87.69 Positive 
KMOE2 cell line 67.08 Negative 
MNCs NBM 1.52 Negative 
OCI-AML2 cell line 88.56 Negative 
Chapter 4 
162 
 
4.3.3 ID4 assessment in AML 
 
Since we identified novel genes that were methylated and downregulated in AML 
(DPP6 and SPHKAP), it was important to compare the previous results to those of ID4 
gene which is well-known to be methylated in AML (Zhao et al. 2008; Uhm et al. 2009; 
Xu et al. 2011). Figure 4.11 illustrated the promoter DNA methylation of ID4 gene as 
detected by MeDIP-seq. 
 
Figure ‎4.11 Promoter DNA methylation of ID4 in MeDIP-seq samples 
The X-axis represents MeDIP-seq samples and Y-axis represents the corresponding 
promoter methylation calculated by Batman algorithm. The figure shows a significant 
methylated DMR was found in the ID4 gene promoter in AML patients versus NBMs 
(absolute methylation difference = 0.28, P = 0.003). 
 
ID4 gene expression was investigated in 30 AML patients and in normal tissues by RT 
PCR. ID4 gene expression was absent in all AML patients. By contrast, ID4 was 
expressed in normal tissues (Figure 4.12). Opposite to both SPHKAP and DPP6 genes, 
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we did not find specificity for ID4 gene expression in any of the investigated normal 
tissues. 
 
 
Figure ‎4.12 ID4 gene expression in AML patients and normal tissues 
The relative gene expression in any sample is calculated relative to 18S relative to 
normal breast tissue. 
 
4.3.4 Effect of 5-aza-2-deoxycytidine on candidate methylated genes in AML 
 
The effect of a demethylating drug; DAC (5-aza-2-deoxycytidine) on the expression of 
SPHKAP, DPP6 and ID4 genes was investigated in 2 AML cell lines (OCI-AML2 and 
CTS). This confirmed that the demethylating treatment was able to restore the 
expression of DPP6 and SPHKAP (Figure 4.13). 
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Figure ‎4.13 SPHKAP, DPP6 and ID4 expression in CTS and OCI-AML2 cell lines 
before and after addition of DAC 
Restoration of gene expression was observed in SPHKAP and DPP6 genes after treating 
the cell lines with DAC. 
 
4.4 Discussion 
 
In this chapter, we assessed the expression of 2 of the most significant differentially 
methylated genes detected in AML e.g. SPHKAP and DPP6. SPHKAP (SKIP) is 
important as a modulator of SPHK1 (Lacana et al. 2002). The latter is a controller of 
S1P, which promotes cancer progression and metastasis (Guillermet-Guibert et al. 
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2009). Recently, SPHKAP has been identified as an AKAP (A-kinase-anchoring 
protein), which directs cytoplasmic SPHK1 enzyme to its substrate (sphingosine) 
located in cell membrane (Kovanich et al. 2010). The role of SPHKAP has also been 
recognized in heart diseases (Aye et al. 2011). However, to date, no studies have been 
reported concerning the possible role of SPHKAP methylation in malignancy. In our 
study, SPHKAP was methylated and repressed in AML. Additionally, SPHKAP 
expression was restored after treatment of AML cell lines with DAC. Furthermore, 
transfection of K562 cell line (haematopoietic cell line) and MCF7 cell line (breast 
cancer cell line) with vector containing SPHKAP cDNA led to 2 and 10 times increase in 
the S1P/sphingosine ratio respectively. These results suggested a potential role of 
SPHKAP methylation in suppressing high levels of S1P in cancer. It was reported that a 
persistent exposure to high doses of S1P resulted in cell shrinkage and a decrease in cell 
migration (Davaille et al. 2002; Shin et al. 2007). Moreover, the apoptotic response of 
MCF7 cell line to a persistent exogenous exposure to S1P was recognized as a sigmoid-
shaped response. This response was in contrast to the bell-shaped apoptotic response of 
MCF12 (normal mammary gland epithelial cell line) to the same persistent exogenous 
exposure to S1P (Ling et al. 2011) (Figure 4.14). Those data suggested that S1P level 
had to be controlled in malignancy in order to ensure enhanced cell proliferation without 
the apoptotic effects. This S1P control was thought to be self-protective (Ling et al. 
2011). However, we have another explanation for the control of S1P level in cancer. 
Combining the apoptotic effect of continual exposure to high doses of S1P with our 
results, we can propose that SPHKAP methylation is important in suppressing the 
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production of high doses of S1P in malignancy. This suppression was reversed after 
transfection of cancer cell lines with vector expressing SPHKAP gene. 
 
 
 
Figure ‎4.14 Difference in the apoptotic response of normal and malignant cell lines 
exposed to persistent high doses of S1P 
In both figures, X axis represents treatment with different concentrations of S1P for 24 
hours, Y axis represents the percentage increase (mean ± standard deviation) of cell 
apoptosis in MCF12A (figure on the left) and in MCF7 (figure on the right). The 
apoptotic response of the normal cell line (MCF12A) to persistent increase in S1P is 
bell-shaped, while the apoptotic response of the malignant cell line (MCF7) to the same 
S1P exposure is sigmoid-shaped [The figure is adapted from (Ling et al. 2011)].  
 
The second differentially methylated gene of interest, which was also repressed in all 
AML patients and some cancer cell lines, was the DPP6 gene. DPP6 gene expression 
was restored in AML cell lines after addition of DAC. Notably, DPP6 was 
overexpressed in normal brain tissue as was previously observed (Clark et al. 2008). 
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DPP6 was reported as a hypomethylated gene in colon cancer (Irizarry et al. 2009) and 
at the same time was considered a biomarker for melanoma (Jaeger et al. 2007). DPP6 
gene became hypermethylated in some tumors and hypomethylated in other types of 
tumors as its promoter hypomethylation is important in activating some oncogenes and 
in provoking loss of imprinting (Portela and Esteller 2010).  
Finally, it was important to compare the expression of SPHKAP and DPP6 genes to the 
expression of a well-known methylated gene in AML e.g. ID4 (Zhao et al. 2008; Uhm et 
al. 2009; Xu et al. 2011). ID4 also exacerbates the transformation of MDS into AML 
(Wang et al. 2010). MeDIP-seq results confirmed the previous identified methylation 
status of ID4 in AML. In addition, the downregulation of ID4 gene in AML patients 
opposite to normal tissues was demonstrated using an independent expression study 
(Figure 4.12). These results suggest that ID4 acts as a putative tumor suppressor gene in 
AML (Yu et al. 2005). 
Overall, the MeDIP-seq analysis identified novel methylated targets which were also 
repressed in AML e.g. DPP6 and SPHKAP. Surprisingly, the methylation of SPHKAP 
appeared to suppress high levels of S1P in cancer. Subsequent studies have begun in our 
department to explore the implications of the SPHKAP activation in malignancy. 
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Chapter 5. Study of the epigenomic impact of   
trisomy 8 in AML 
 
5.1 Introduction 
 
Trisomy 8 is the most common numerical aberration in AML (Huret 2007).  It occurs as 
a sole abnormality in 6% of AML and co-exists with other numerical aberrations in 16% 
of AML (Paulsson and Johansson 2007). The prognosis of AML with sole trisomy 8 is 
intermediate to poor (Byrd et al. 1998; Wolman et al. 2002). However, the presence of 
trisomy 8 associated with other leukaemic aberrations was found not to affect the 
underlying AML prognosis (Schoch et al. 1997). The extra chromosome 8 has been 
shown to affect not only the expression of genes located on chromosome 8 (Virtaneva et 
al. 2001) but also has a global gene expression impact (Paulsson and Johansson 2007; 
Nawata et al. 2011). Additionally, there was an absence of a consistent pattern of genes 
that showed a high expression level in all AML subtypes with trisomy 8 (Schoch et al. 
2006). This heterogeneity of trisomy 8 AML patients might be due to the presence of 
cryptic cytogenetic abnormalities responsible for the incidence of AML and trisomy 8 is 
considered a secondary event which modifies the AML pathology (Paulsson et al. 2006). 
In Chapter 3, we found DNA methylation of different genomic features e.g. promoters, 
gene bodies, CGIs and CGI shores clearly clustered trisomy 8 AML. Also, clusters of 
hypomethylated interspersed repeats; SINEs, LINEs and LTRs obviously distinguished 
trisomy 8 AML from the other AML subtypes. Moreover, comparing the whole genome 
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DNA methylation among different AML subtypes revealed that trisomy 8 AML genome 
showed the highest percentage of low methylated Batman scores (26% of the genome 
had Batman scores < 0.4).  
Therefore, the aim of this chapter is to investigate the possible impact of the extra 
chromosome 8 on DNA methylation distribution in trisomy 8 AML. DNA methylation 
of trisomy 8 AML is compared to DNA methylation of non-trisomic AML and NBM 
with a further focus on the DMRs that differentiate between them. In addition and 
because of the availability of the relapse samples for trisomy 8 AML, DNA methylation 
is compared between diagnostic and corresponding relapse samples. This may provide a 
view of DNA methylation changes between diagnostic and relapse trisomy 8 AML. 
 
5.2 Materials and Methods 
 
MeDIP-seq DNA methylation analysis was carried out on 3 pairs of trisomy 8 AML 
patients (diagnostic and relapse). The diagnostic samples were described in Chapter 3 
(Table 3.1). The relapse DNA samples were obtained from the tissue bank at St 
Bartholomew‟s Hospital. DNA methylation of trisomy 8 AML was compared to DNA 
methylation of non-trisomic AML patients and NBMs (Table 3.1). For detecting DMRs 
between groups, the MeDIP-seq statistical workflow was applied as described in 
Chapter 3. Infinium HumanMethylation27 BeadChip Array validation was carried out 
on the available DNA from 2 pairs of trisomy 8 AML. Validation of a differentially 
methylated CGI present within the gene body of HHEX in trisomy 8 AML was 
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performed by pyrosequencing. The corresponding expression of HHEX gene in AML 
relative to NBM was assessed by RT-PCR. The validation experiments and the 
expression study were performed as described in Chapter 2. 
 
5.3 Results 
 
5.3.1 High-throughput sequencing, CpG coverage and reproducibility of trisomy 
8 AML 
 
We applied MeDIP-seq protocol to 3 paired diagnostic-relapse trisomy 8 AML samples. 
The total number of reads generated from Illumina GAII was 3.82 X 10
8 
reads. Mapping 
those reads to the human reference genome (NCBI/hg18) resulted in 2.15 X 10
8 
uniquely 
aligned reads (Table 5.1).
 
In order to investigate the percentage of CpG coverage and the 
reproducibility of the methylation profiles, the MEDIPS software was used (Chavez et 
al. 2010). The average coverage of CpG sites was 84% of total 28 million CpG sites 
present within the human reference genome. Pearson correlation r of both true and 
estimated saturation analyses for the uniquely aligned reads were nearly 1 in diagnostic 
(Appendix 1 Figure 2) and in relapse trisomy 8 AML (Figure 5.1).  
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Table ‎5.1 Criteria of trisomy 8 AML samples 
A recent Illumina pipeline version 1.6 was used for filtering the reads generated from 
sequencing trisomy 8 AML libraries. This assisted in filtering more high quality bases, 
subsequently improving the CpG coverage and the reproducibility of the whole genome 
analysis.  
 
*Relapse (relapse for study 10), ●Relapse (relapse for study 11), ¤Relapse (relapse for study 12) 
 
 
Study 
No. 
Total  No. 
of reads 
Quality 
of bases  
> 30 
Forward 
Quality 
of bases 
> 30 
Reverse 
No. of 
uniquely 
mapped 
reads 
% CpG 
Coverage 
Pearson r 
True 
saturation  
Pearson r 
Estimated    
saturation 
Study 10 58 X 10 6 81% 77% 24 X 10 6 77 0.99 1 
*Relapse  60 X 10 6 78% 78% 30 X 10 6 84 1 1 
Study 11 66 X 10 6 84% 83% 38 X 10 6 85 1 1 
●Relapse  68 X 10 6 84% 83% 38 X 10 6 85 1 1 
Study 12 68 X 10 6 84% 82% 41 X 10 6 87 1 1 
¤Relapse  62 X 10 6 85% 84% 44 X 10 6 86 1 1 
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Study 10 (Relapse) 
 
 Study 11 (Relapse)  
 
Study 12 (Relapse) 
 
 
Figure ‎5.1 Saturation analyses of trisomy 8 AML relapse samples 
It is assumed that Pearson correlation r of the saturation analysis for the full set of 
available short reads will be between the results of the true saturation (the blue line, 
Pearson r = 1) and the estimated saturation (the red line, Pearson r = 1) in the three 
relapse trisomy 8 AML samples. This analysis indicated that the genome-wide 
methylation profiles of those patients could be perfectly reproduced using another 
independent set of a similar number of short reads. 
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5.3.2 Comparing DNA methylation distribution between trisomic and non-
trisomic DNA samples 
 
In order to demonstrate the potential epigenomic impact of extra chromosome 8, DNA 
methylation distribution was firstly compared between chromosome 8 and the rest of the 
chromosomes in a trisomy 8 AML patient. Chromosome 8 showed a higher frequency of 
Batman scores > 0.8 and a lower frequency of Batman scores < 0.4 than the rest of the 
chromosomes (Figure 5.2). To explore whether this pattern of DNA methylation 
distribution is specific to trisomy 8 AML, we repeated the comparison using the 
methylation scores of all trisomy 8 AML samples (3 diagnostic and 3 relapse), the 
average of the methylation scores of 9 non-trisomic AML patients and the average of the 
methylation scores of 4 NBMs. Unlike trisomy 8 AML (Figure 5.3C), there was no 
difference in the DNA methylation distribution between chromosome 8 and the rest of 
the chromosomes in either non-trisomic AML (Figure 5.3A) or NBM (Figure 5.3B).  
The chromosomal DNA methylation distribution was next compared between trisomic 
and non-trisomic DNA samples. Instead of investigating all the chromosomes, we chose 
3 random chromosomes e.g. 1, 6 and 11 in addition to chromosome 8 to do the 
comparison. Chromosomes 1, 6 and 11 showed a higher frequency of Batman scores < 
0.4 in trisomy 8 AML than non-trisomic DNA samples (Figure 5.4). That was in 
contrast to chromosome 8 which showed a higher frequency of Batman scores > 0.8 in 
trisomy 8 AML than non-trisomic DNA samples (Figure 5.4). Investigating the DNA 
methylation distribution in individual trisomy 8 AML patients (diagnostic & relapse), 3 
individual non-trisomic AML patients and 3 NBM samples confirmed the previous 
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observed differences in the DNA methylation distribution pattern between trisomic and 
non-trisomic DNA samples (Appendix 1 Figures 6-9). 
Collectively, it could be suggested that the presence of extra chromosome 8 led to an 
increase in the chromosome 8 methylation signals. These extra methylation signals 
seemed to disrupt the whole genome methylation by an increase in the hypomethylation 
signals from the rest of the chromosomes in trisomy 8 AML. That was observed when 
comparing trisomic versus non-trisomic DNA samples since Batman scores > 0.8 in 
chromosome 8 were of a higher frequency in trisomy 8 AML than non-trisomic DNA 
samples. By contrast, Batman scores < 0.4 in the remaining chromosomes (other than 
chromosome 8) were of a higher frequency in trisomy 8 AML than non-trisomic DNA 
samples.  
In order to localize the site of chromosome 8 extra methylation signals, DNA 
methylation of trisomy 8 AML (3 diagnostic and 3 relapse) is compared to DNA 
methylation of 4 NBMs in the following section of this chapter. 
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Figure ‎5.2 Differences in the DNA methylation distribution between chromosome 8 and 
the rest of the chromosomes in trisomy 8 AML 
The scores of Batman GFF files (X-axis) were plotted against their density (frequency) 
(Y-axis) in chromosome 8 (blue line) and in the rest of the chromosomes (green line). 
Chromosome 8 showed a higher frequency of Batman scores > 0.8 and a lower 
frequency of Batman scores < 0.4 than the rest of the chromosomes (other than 
chromosome 8). This analysis was performed in a trisomy 8 AML patient (study No.10) 
using R package (Gentleman et al. 2004). 
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Figure ‎5.3 Comparison of the DNA methylation distribution between chromosome 8 and 
the rest of the chromosomes in AML (non-trisomic), NBM and trisomy 8 AML  
In non-trisomic AML (A), and NBM (B), there was no difference in the DNA methylation 
distribution between chromosome 8 (blue line) and the rest of the chromosomes (green 
line). The plots on the right showed linear correlation between the frequencies of the 
methylation scores in chromosome 8 (X-axis) and the rest of the chromosomes (Y-axis) 
in (A) and (B). In trisomy 8 AML (C), the plot on the right showed deviation of the linear 
correlation towards chromosome 8 (X-axis), indicating an increase in the methylation 
scores in chromosome 8 over the rest of the chromosomes (Y-axis). 
A. 
B. 
C. 
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             Chromosome 1                                                          Chromosome 6 
 
                  
             Chromosome 11                                                     Chromosome 8 
Figure ‎5.4 Differences in DNA methylation distribution of chromosomes 1, 6, 11 and 8 
between AML (non-trisomic), NBM and trisomy 8 AML 
Chromosomes 1, 6, 8 and 11 showed similar DNA methylation distribution between 
AML (non-trisomic) (green line) and NBM (red line) with a lower frequency of Batman 
scores > 0.8 in AML than NBM. By contrast, trisomy 8 AML (blue line) showed a higher 
frequency of Batman scores > 0.8 in chromosome 8 and a higher frequency of Batman 
scores < 0.4 in chromosomes 1, 6, 11 than NBM  and AML (non-trisomic). 
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5.3.3 Localization of chromosome 8 extra methylation signals 
 
In order to localize the site of chromosome 8 extra methylation signals, the DNA 
methylation of six trisomy 8 AML samples (diagnostic & relapse) were compared to 4 
NBMs in the 4 genomic features described in Chapter 3-Table 3.3 and in the repeat 
sequences (satellites and interspersed repeats). Most of the DMRs associated with 
promoters or gene bodies were hypomethylated in trisomy 8 AML. That was in contrast 
to CGIs and CGI shores where most of the DMRs were hypermethylated in trisomy 8 
AML (Table 5.2). The two-dimensional cluster analysis and the pair-wise comparison 
showed that each genomic feature clearly distinguished trisomy 8 AML from NBM with 
the clearest discrimination was observed in the promoters (Figures 5.5, 5.6).  
Using David Bioinformatics (Huang da et al. 2009), different chromosomes were 
frequently found in the intragenic DMRs (within promoters or inside gene bodies) with a 
notable representation of chromosome 8 in the intragenic differentially hypermethylated 
CGI shores in trisomy 8 AML (Table 5.2). Chromosomes 1 and 19 were the most 
frequent representative chromosomes in the intergenic differentially hypermethylated 
CGIs and CGI shores respectively in trisomy 8 AML. 
Additionally, the majority of DMRs associated with repeats were hypomethylated in 
trisomy 8 AML except LTRs (Figures 5.7, 5.8). Chromosome 8 was the most frequent 
representative chromosome in the intragenic differentially hypermethylated SINEs, 
LINEs and LTRs in trisomy 8 AML (Table 5.2). Moreover, chromosome 8 was the most 
frequent representative chromosome in the intergenic differentially hypermethylated 
SINEs, LINEs and LTRs in trisomy 8 AML (11%, 14% and 20% of the total 
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representative chromosomes respectively). Overall, it could be suggested that 
chromosome 8 extra methylation signals were localized mainly in CGI shores and 
interspersed repeats in trisomy 8 AML. 
 
Table ‎5.2 DMRs identified between trisomy 8 AML (diagnostic & relapse) and NBM 
 
D; diagnostic, R; relapse 
 
 
 
 
 
Genomic 
features 
 
DMRs 
between 
trisomy 
8(D& R) 
and NBM 
 
Hypermethylated 
DMRs in trisomy 
8 (D& R) versus 
NBM 
Most frequent 
chromosome  
Hypomethylated 
DMRs in trisomy 
8 (D& R) versus 
NBM 
Most 
frequent 
chromosome 
Promoters 128 49 Chr 5, 
P= 0.0041 
79  Chr X,  
P= 0.00001 
 
Gene 
bodies 
72 37 Not detected 47 Chr 22, 
P=0.00007 
CGIs 563 343 Chr 5,  
P=3.40E-03 
 
220 Chr16,  
P= 5.70E-04 
 
CGI 
shores  
466 244 Chr 8,  
P=4.00E-04 
 
222 Chr 19, 
P=1.70E-02 
 
Satellites 28 3 Not detected 25 Not detected 
SINEs 1895 818 Chr 8,  
P= 2.60E-07 
 
1077  Chr 20,  
P= 6.00E-03 
 
LINEs 1828 725 Chr 8,  
P=4.10E-08 
 
1103 Chr X,  
P= 3.80E-07 
 
LTRs 2687 1566 Chr 8,  
P=2.60E-011 
 
1121 Chr X,  
P= 9.90E-05 
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Figure ‎5.5 Hierarchical clustering analysis of trisomy 8 AML versus NBM in 4 genomic 
features 
In each cluster analysis, each column represents AML patient/ NBM, each row 
represents a DMR. Colour represents methylation level (red = high methylation; green 
= low methylation). Trisomy 8 AML D; diagnostic, trisomy 8 AML R; relapse. In the 4 
genomic features; promoters (A), gene bodies (B), CGIs (C) and CGI shores (D), 
diagnostic and relapse trisomy 8 AML were clustered together away from NBM with a 
high number of hypermethylated CGIs and CGI shores was observed in trisomy 8 AML. 
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Figure ‎5.6 Pair wise comparison of the methylation profiles between trisomy 8 AML and 
NBM 
The red and yellow colours indicate high and low similarity level respectively. 
Promoters (A) showed the highest similarity in the methylation profiles between trisomy 
8 AML samples (diagnostic & relapse) and a clear discrimination from NBM. Gene 
bodies (B), CGIs (C) and CGI shores (D). 
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Figure ‎5.7 Hierarchical clustering analysis of trisomy 8 AML versus NBM in repeat 
sequences 
In each cluster analysis, each column represents AML patient/ NBM, each row 
represents a DMR. Colour represents methylation level (red = high methylation; green 
= low methylation). Trisomy 8 AML D; diagnostic, trisomy 8 AML R; relapse. Trisomy 
8 AML showed more hypomethylated DMRs than NBM in SINEs (A) and LINEs (B). 
Additionally, clusters of hypomethylated repeats clearly distinguished diagnostic and 
relapse trisomy 8 AML in SINEs, LINEs and LTRs (C). 
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Figure ‎5.8 Pair-wise comparison of the methylation profiles between trisomy 8 AML 
and NBM in repeat sequences 
The red and yellow colours indicate high and low similarity level respectively. All the 
interspersed repeats; SINEs (A), LINEs (B) and LTRs (C) showed a clear discrimination 
in the methylation profiles between trisomy 8 AML and NBM.   
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5.3.4 Comparison of the DNA methylation between diagnostic and relapse 
trisomy 8 AML 
 
Because of the availability of relapse samples, we investigated the DNA methylation 
differences between diagnostic and relapse trisomy 8 AML with an expected increase in 
the CGIs DNA methylation in relapse (Kroeger et al. 2008). CGI shores showed a 
higher number of DMRs between diagnostic and relapse trisomy 8 AML than 
promoters, gene bodies and CGIs (Table 5.3). Most of those differentiating CGI shores 
were hypomethylated in relapse. By contrast, most of the DMRs located in promoters, 
gene bodies and CGIs were hypermethylated in relapse. Moreover, different 
chromosomes, not including chromosome 8, were frequently represented in the 
hypermethylated intragenic DMRs in relapse (Table 5.3). Chromosome 1 was the most 
frequent representative chromosome in the intergenic differentially hypermethylated 
CGIs and CGI shores in relapse; 14% and 10% respectively. For the hypermethylated 
intragenic DMRs in diagnostic samples, chromosome 7 was the most frequent 
representative chromosome (Table 5.3). Although the two-dimensional cluster analysis 
and the pair-wise comparison (Appendix 1 Figures 10, 11) showed clear discrimination 
between diagnostic and relapse in the 4 genomic features e.g. promoters, gene bodies, 
CGIs and CGIs shores, few DMRs passed the significance test P < 0.001 and > 25% 
absolute methylation difference.  
Furthermore, SINE, LINE and LTR associated DMRs were more hypomethylated in 
relapse (Table 5.3). Similar to the previous genomic features, few DMRs associated with 
repeats passed the significance test P < 0.001 and absolute DNA methylation difference 
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> 25% (Appendix 1 Figures 12, 13). Also, there were different frequently 
representative chromosomes, not including chromosome 8, in the differentiating repeats 
in relapse (Table 5.3).  
Overall, this analysis revealed little significant methylation difference between 
diagnostic and relapse trisomy 8 AML, with most of the DMRs were more 
hypomethylated in relapse. 
Table ‎5.3 DMRs identified between diagnostic and relapse trisomy 8 AML 
List of DMRs between diagnostic and relapse trisomy 8 AML is provided in Appendix 2. 
 
 
Genomic 
features 
 
DMRs 
between 
trisomy 8 
diagnostic 
and relapse  
Hypermethylated 
DMRs in  
trisomy 8 
diagnostic versus 
relapse 
Most 
frequent 
chromosome 
Hypomethylated 
DMRs in  
trisomy 8 
diagnostic versus 
relapse 
Most  
frequent 
chromosome 
Promoters 103 44 Chr 7, 
P= 0.02 
59 Chr 20,P=0.027 
Chr14,P=0.039 
Gene 
bodies 
59 25 Not detected 34 Chr14,P=0.028 
CGIs 178 87 Chr 7, 
P= 4.1E-02 
 
91 Chr 17,P 
=8.6E-02 
CGI 
shores  
453 241 Chr 7, 
P= 2.7E-04 
 
212 Chr 17,P 
=1.7E-02 
Satellites 8 3 Not detected 5 Not detected 
SINEs 2635 1319 Chr 19,  
P=1.0E-03 
 
1316 Chr 17,P= 
9.7E-03 
 
LINEs 3450 1782 Chr 7, 
P=3.5E-04 
 
1668 Chr 3,P=3.8E-
08 
 
LTRs 4659 2487 Chr 18,  
P= 1.6E-05 
 
2172 Chr 2, P=1.3E-
02 
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5.3.5 Validation of trisomy 8 AML DNA methylation by Illumina Infinium Array 
 
DNA from two diagnostic trisomy 8 AML patients (study No.11 and study No. 12) and 
their relapse samples were available for validation by Illumina Infinium Array. 
Correlating the average Batman score to each 1% Infinium Array bin revealed a strong 
positive correlation between both methods in the samples investigated (Figure 5.9). 
          
Figure ‎5.9 Validation of trisomy 8 AML by Illumina Infinium Array 
A strong positive correlation was detected between MeDIP-seq and Illumina Infinium 
Array in all samples investigated. Studies No.11, 12 are trisomy 8 AML, study No.13 is a 
NBM (Table 3.1), R; relapse. 
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5.3.6 Hematopoietically expressed homeobox (HHEX) gene methylation and 
expression in trisomy 8 AML 
 
In Chapter 3, we identified a specific CGI within the gene body of HHEX that was 
significantly hypermethylated in trisomy 8 AML (diagnostic) versus the other AML 
subtypes and NBM (absolute methylation difference = 0.74, P = 9 X 10
-6
). By 
comparing trisomy 8 AML (diagnostic and relapse) to NBMs, the same CGI located in 
chromosome 10 (chromosome 10: 94442180-94442408) (Figure 5.10) was detected as 
the most significant differentially hypermethylated CGI in trisomy 8 AML versus NBM 
(absolute methylation difference = 0.83, P = 7.88X 10
-11
). Therefore, in this section, we 
focus on this CGI and investigate if the DNA methylation of this island could affect 
HHEX gene expression.  
 
 
Figure ‎5.10 Location of the identified methylated CGI within the gene body of HHEX  
The significant methylated CGI (green coloured block) is located between exon 2 and 
exon 3 (blue coloured blocks) of HHEX gene. The blue arrow indicates the direction of 
the gene (the figure is adapted from UCSC Genome Browser). 
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Firstly, from MeDIP-seq results, we checked HHEX gene promoter and gene body 
methylation in all 15 AML patients [9 non-trisomic AML, 3 diagnostic and 3 relapse 
trisomy 8 AML] and 4 NBMs. There was no significant methylation difference detected 
between trisomy 8 AML and the rest of the samples in either HHEX promoter or gene 
body (Figure 5.11). 
 
Figure ‎5.11 HHEX gene methylation in MeDIP-seq samples 
X-axis represents AML patients and NBMs; Y-axis represents Batman scores for each 
sample. The significant difference in HHEX gene methylation between trisomy 8 AML 
and the rest of the samples was observed in a CGI located within the gene body of 
HHEX. 
 
5.3.6.1 HHEX gene methylation in trisomy 8 AML 
 
The size of that island is 228bp and contains 21 CpG sites. Since the CGI has a high 
CpG density (around 9.2%), it was important to divide the island into shorter sequences 
in order to facilitate the pyrosequencing validation. Sequence 1 started from CpG 
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number 8 to CpG number 16 and sequence 2 started from CpG number 17 to CpG 
number 21. 
The pyrosequencing results revealed that both sequences (1 and 2) showed significant 
methylation differences among the groups investigated (Kruskal-Wallis test, P = 0.0004, 
P = 0.0009 respectively). However, in sequence 1 (CpG 8-16), trisomy 8 AML showed 
significant methylation differences with t(8;21) AML, inversion 16 AML and NBMs 
(Dunn‟s multiple comparison tests, P < 0.05) (Figure 5.12A, B). For sequence 2 (CpG 
17-21), trisomy 8 AML showed a significant methylation difference only with NBMs 
(Dunn‟s multiple comparison test, P < 0.05) (Figure 5.13A, B). 
A.                                                                                    B. 
        
Figure ‎5.12 Pyrosequencing results of the intragenic CGI sequence 1 (CpG 8-16) 
A. Trisomy 8 AML methylation was significantly higher than the DNA methylation of 
t(8;21) AML, inversion 16 AML and NBMs (Kruskal-Wallis test followed by Dunn’s 
multiple comparison tests, P < 0.05). PB; peripheral blood from 4 healthy donors. 
B. Significant methylation difference was detected between trisomy 8 AML and the rest 
of AML patients (Mann-Whitney test, P= 0.004). In each figure, the dots represent the 
average methylation percentage as calculated by pyrosequencing, the horizontal line 
represents the mean of those dots, N; the number of samples investigated. 
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A.                                                                             B. 
          
 
Figure ‎5.13 Pyrosequencing results of the intragenic CGI sequence 2 (CpG 17-21) 
A. Trisomy 8 AML methylation was significantly higher than the DNA methylation of 
NBMs (Kruskal-Wallis test followed by Dunn’s multiple comparison tests, P < 0.05).  
B. Significant methylation difference was detected between trisomy 8 AML and the rest 
of AML patients (Mann-Whitney test, P= 0.03). In each figure, the dots represent the 
average methylation percentage as calculated by pyrosequencing, the horizontal line 
represents the mean of those dots, N; the number of samples investigated and PB; 
peripheral blood from 4 healthy donors.  
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5.3.6.2 HHEX gene expression in trisomy 8 AML 
 
To investigate the impact of DNA methylation of the identified intragenic CGI on gene 
expression, HHEX gene expression was investigated by 2 sets of primers. Primers set 1 
was across exon boundaries 1 and 2 [referred as HHEX1] and primers set 2 was across 
exon boundaries 3 and 4 [referred as HHEX2].  
The RT-PCR results revealed that there was a significant expression difference among 
the groups investigated in both HHEX1 and HHEX2 (Kruskal-Wallis test, P = 0.02, P = 
0.04 respectively). Performing Dunn‟s multiple comparison tests showed that trisomy 8 
AML expression was significantly less than the expression of t(8;21) AML in both 
HHEX1 and HHEX2 (P < 0.05) (Figure 5.14A, B). 
Correlating the previous CGI pyrosequencing results to the expression results of HHEX 
gene revealed that CGI methylation (sequence 1, CpG 8-16) showed moderate but 
significant inverse correlations with HHEX1 and HHEX2 sequence expression 
(Spearman r = -0.5, P = 0.006, Spearman r = -0.43, P = 0.02 respectively) (Figure 
5.15A, B). However, CGI methylation (sequence 2, CpG 17-21) did not show such 
correlation with either HHEX1 or HHEX2 sequence expression (P = 0.22, P = 0.24 
respectively). 
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A.                                                                          B. 
          
 
Figure ‎5.14 HHEX gene expression in AML samples 
(A, B) There was a significant expression difference among samples investigated in 
HHEX1 and HHEX2 (Kruskal-Wallis test, P = 0.02, P = 0.04 respectively). HHEX gene 
expression was significantly less in trisomy 8 AML than t(8;21) AML in both (A) and (B) 
(Dunn’s multiple comparison tests, P < 0.05).  
In each figure, each dot represents HHEX expression, the horizontal line represents the 
mean of those dots, N; the number of samples investigated and PB; peripheral blood 
from 4 healthy donors. HHEX gene expression was tested relative to NBM. 
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A.                                                                      B. 
               
 
Figure ‎5.15 Correlation between the intragenic CGI methylation and HHEX expression 
(A, B) X axis represents the percentage CpG methylation as calculated by 
pyrosequencing; Y axis represents the relative expression of HHEX gene. There was a 
moderate but significant inverse correlation between CGI methylation (CpG 8-16) and 
HHEX gene expression; HHEX1 (across exon 1 and exon 2) and HHEX2 (across exon 3 
and exon 4) (Spearman r = -0.5, P = 0.006, Spearman r = -0.43, P = 0.02 respectively). 
The red dots represent trisomy 8 AML patients with HHEX gene methylation > 60%. 
 
5.4 Discussion 
 
Extra chromosome 8 is the commonest trisomy found in AML (Huret 2007). Since the 
epigenomic homeostasis is affected by both genetic and environmental factors (Rakyan 
et al. 2011), presence of extra chromosome 8 could possibly affect the epigenomic status 
in trisomy 8 AML. Recently, an introduction of chromosome 8 into a normal human cell 
revealed an increase in the average level of gene expression on chromosome 8 compared 
to a diploid normal human cell (Nawata et al. 2011). Additionally, in the same study, the 
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average level of gene expression of all non-trisomic chromosomes in the artificial 
trisomy 8 cell decreased (Nawata et al. 2011). In the current study, we demonstrated that 
there was no difference in the DNA methylation distribution between chromosome 8 
and the rest of the chromosomes in either non-trisomic AML patients or NBMs. By 
contrast, there was a difference in the DNA methylation distribution in trisomy 8 AML 
i.e. an increase in the hypermethylated Batman scores > 0.8 in chromosome 8 and an 
increase in the hypomethylated Batman scores < 0.4 in the remaining non-trisomic 
chromosomes. Considering the previous evidence of the global impact of trisomy 8 on 
gene expression, it could be suggested that presence of extra chromosome 8 affects not 
only chromosome 8 methylation but also has a global DNA methylation impact. In 
addition, comparing DNA methylation between trisomy 8 AML and NBM showed that 
the extra methylation signals of chromosome 8 were localized mainly in CGI shores and 
interspersed repeats.  
Furthermore, the MeDIP-seq analysis enabled us to detect differences in the DNA 
methylation between diagnostic and relapse trisomy 8 AML throughout the genome. 
Most of the DMRs identified between diagnostic and relapse samples were more 
hypomethylated in relapse e.g. DMRs associated with CGI shores and interspersed 
repeats. By contrast, DMRs located in promoters, gene bodies and CGIs were more 
hypermethylated in relapse versus diagnostic. Applying the criteria for selecting DMRs 
for clustering purpose; P < 0.001 & > 25% absolute methylation difference revealed few 
DMRs that passed this test. Overall, there was a little significant methylation difference 
identified between diagnostic and relapse trisomy 8 AML with localized genomic 
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regions showed an accentuation in their DNA methylation in relapse status (Kroeger et 
al. 2008; Wilop et al. 2011). 
 
HHEX gene [also known as proline-rich homeodomain (PRH)] located on chromosome 
10 is a member of the homeobox family of transcription factors and can act as 
transcriptional repressor (Soufi and Jayaraman 2008). HHEX gene becomes a 
transcriptional activator on fusion with proteins e.g. NUP98 (Jankovic et al. 2008) or 
V16 (Brickman et al. 2000). HHEX plays important roles in the development of 
haemangioblast from mesoderm during embryogenesis (Paz et al. 2010) and in the 
maturation of early haematopoietic progenitors (Bedford et al. 1993). However, HHEX 
is repressed in terminal myeloid differentiation and T-cell lineage (Mack et al. 2002). 
Moreover, HHEX is involved in the pathogenesis of AML since HHEX interacts with 
the promyelocytic leukaemia protein (PML). This interaction is important for PML 
protein‟s role in growth control. In t(15;17) AML, the fusion protein „PML–RARα‟ 
disrupts HHEX-PML interaction hence contributing to the pathogenesis of AML (Topcu 
et al. 1999). Also, fusion of HHEX gene with NUP98 gene resulted in HHEX- NUP98 
protein, which produced a gene expression profile similar to HOXA9- NUP98 fusion 
protein that is highly leukaemogenic (Jankovic et al. 2008). In addition, overexpression 
of HHEX in K562 cell line resulted in repression of vascular endothelial growth factor 
(VEGF) and VEGF receptor genes (Noy et al. 2010). Our results revealed an intragenic 
CGI associated DMR within the gene body of HHEX that was significantly 
hypermethylated in trisomy 8 AML versus the other groups of AML & NBMs (P = 9 X 
10
-6
). The significant difference in methylation increased when more trisomy 8 AML 
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patients were included (P = 7.88 X 10
-11
). Furthermore, the DNA methylation of that 
island was inversely correlated with HHEX gene expression. It is established that CGIs 
located within promoters are more susceptible to DNA methylation in tumorigenesis and 
that is correlated with gene silencing (van Vlodrop et al. 2011). However, some studies 
showed that CGIs located outside the promoters could also act as alternative promoters, 
hence hypermethylation of those islands could affect the gene function (Xin et al. 2008; 
Maunakea et al. 2010). Therefore, in our study, the identified CGI located within the 
gene body of HHEX is considered an example of a non-promoter CGI whose 
methylation status is associated with nearby gene repression. 
Our results also showed that HHEX gene was less expressed in trisomy 8 AML than 
t(8;21) AML. A previous study by Topisirovic et al reported that HHEX gene expression 
was altered in AML depending on the FAB criteria (Topisirovic et al. 2003). Topisirovic 
et al observed that HHEX gene was downregulated in M4/M5 AML (11 AML patients, 
one of them was +8), while HHEX gene expression showed a similar level to NBM in 
M1/M2 AML [5 AML patients, 4 of them were t(8;21) AML]. However, in our study, 
trisomy 8 AML patients, who showed a significant decrease in HHEX expression, had 
different phenotypic criteria; 4 of them were M4/M5 AML and 4 of them were M1/M2 
AML. Additionally, in the current study, t(8;21) AML patients, who showed significant 
increase of HHEX gene expression, were all M2 AML. Therefore, the significant 
decrease in HHEX gene expression in trisomy 8 AML did not depend only on the 
phenotypic criteria of those patients. There could be another factor that might contribute 
to the downregulation of HHEX gene in trisomy 8 AML, which is eIF4E (eukaryotic 
translation initiation factor 4E). It was noted that eIF4E was overexpressed in AML 
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patients who showed downregulation of HHEX gene (Topisirovic et al. 2003). This is 
particularly important since eIF4E overexpression is associated with upregulation of 
MYC gene (De Benedetti and Harris 1999), which an increase in its copy number was 
linked to the pathogenesis of trisomy 8 AML (Wolman et al. 2002). 
In summary, the MeDIP-seq approach assisted in identification of differences in DNA 
methylation distribution between trisomic and non-trisomic DNA samples. Additionally, 
the analysis of the whole genome revealed a differentially methylated intragenic CGI 
within the gene body of HHEX in trisomy 8 AML. The methylation of this island was 
inversely correlated with HHEX gene expression which was also differentially repressed 
in trisomy 8 AML. 
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Chapter 6. Discussion 
 
 
AML is a progressive blood disorder characterized by abnormal clonal proliferation of 
haematopoietic stem cells and leads eventually to bone marrow failure. 55% of AML 
patients have chromosomal abnormalities, which initiate the malignant process 
(Marcucci et al. 2004). Parallel to the genetic abnormalities of leukaemic blast cells, 
other epigenetic changes, which affect the DNA structure without affecting the DNA 
sequence, are also present. The epigenetic alterations in AML include frequent DNA 
hypermethylation of promoters of tumor suppressor genes and genes encoding cell 
adhesion molecules e.g. P15, P73, E-cadherin (Claus and Lubbert 2003; Galm et al. 
2006), while the repeat sequences are generally thought to undergo global 
hypomethylation resulting in genome instability (Wilson et al. 2007). Previous array-
based analysis of DNA methylation in AML investigated several thousands of genes in 
hundreds of samples (Figueroa et al. 2010b; Deneberg et al. 2010; Deneberg et al. 
2011). In spite of this large number of investigated samples, the CpG sites were limited 
to promoters or to CGIs. By contrast, studies based on next-generation sequencing 
(NGS) technology investigated the whole AML genome for detection of genetic 
mutations in a limited number of samples (Ley et al. 2008; Mardis et al. 2009; Ley et al. 
2010). To date, there is no comprehensive genome-wide study of DNA methylation in 
AML and AML subtypes using NGS technology. For this reason, we applied the 
MeDIP-seq approach (methylated DNA immunoprecipitation followed by next-
generation sequencing) to 12 AML patients of 4 different cytogenetic subtypes and 
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compared the DNA methylation profiles of those patients to the DNA methylation 
profiles of NBMs. Also, we applied a recently developed algorithm „Batman‟ to obtain 
an absolute quantification of MeDIP-seq signals in each 100bp of the genome (Down et 
al. 2008).  
There were some limitations in the present MeDIP-seq study. Firstly, the number of 
samples was low; 15 AML patients (12 diagnostic AML and 3 relapse trisomy 8 AML) 
versus 4 NBMs. The reason for that was the cost of the libraries preparation and running 
those libraries over the Illumina GAII (each lane costs 300 GBP). Also, the extensive 
bioinformatic manipulation of the sequencing data and the interpretation of the 
methylation signals by Batman algorithym consumed much time in order to obtain the 
methylation profiles before starting the comparison between different samples. This 
limitation is clear in other studies based on next-generation sequencing technology e.g. 
one AML patient was sequenced by Illumina GA (Ley et al. 2008; Mardis et al. 2009; 
Ley et al. 2010) and 5 AML patients were recently sequenced by reduced representation 
bisulphite sequencing (Akalin et al. 2012). Secondly, we used DNA extracted from the 
mononuclear cells of NBMs as control samples. The reason for that was: to start 
MEDIP-seq protocol we need 5µg genomic DNA to prepare a single MeDIP-seq library 
and at least 4µg of the adapted ligated DNA for the immnuoprecipitation step. Because 
of the difficulty of obtaining such large amount of DNA from separated cells, therefore, 
we could not use DNA extracted from isolated cells i.e. CD34
+
 as a control for AML 
patients. In spite of these restrictions, we succeeded in comparing different MeDIP-seq 
samples using a statistical method that was used in a previous next-generation 
sequencing study of microRNAs compared between 5 favorable and 5 unfavorable 
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neuroblastoma patients (Schulte et al. 2010). Additionally, the pair-wise and the two-
dimensional cluster analyses we performed showed that the methylation profiles of the 
controls (4 NBMs) were very similar and were clustered away from AML patients in all 
genomic regions investigated. Moreover, the DMRs identified between AML and NBMs 
included many well-known methylated targets in AML e.g. DCC, ID4, TERT, MEIS. 
 
6.1 Global DNA methylation study of AML and NBM 
 
 
The most methylated genomic feature observed in our study was the gene body in both 
AML and NBM. This has been previously reported through a genome-wide study of 
human leukaemia-derived cell line M091 (Brenet et al. 2011). However, the current 
study revealed that the gene expression was strongly associated with the promoter DNA 
methylation (Pearson r = -0.97, P < 0.0001) more than with the DNA methylation of any 
of the other genomic regions investigated. This confirms the impact of DNA 
methylation around TSS in altering the related gene expression (Bird 2002; Veyrieras et 
al. 2008; Koga et al. 2009; Pai et al. 2011).  
Comparing the whole genome methylation between AML and NBM revealed no 
significant difference identified between the 5 categories of DNA methylation (< 0.2, 
0.2-0.4, 0.4-0.6, 0.6-0.8, > 0.8 Batman scores) between leukaemia and normal. The 
average of the whole genome methylation in AML was 3% less than the average of the 
whole genome methylation in NBM. This limited global hypomethylation is in contrast 
to a previous suggestion that 10-20% of the genome became hypomethylated in cancer 
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(Ehrlich 2002; Wilson et al. 2007). However, using MeDIP-seq method, Feber et al 
observed a similar limited global hypomethylation of 0.7% between malignant and 
benign peripheral nerve sheath tumors (Feber et al. 2011).  
Our study also revealed clear discrimination between AML and NBM based on the 
DNA methylation of promoters and CGIs. That was previously observed by Figueroa et 
al in de-novo and secondary AMLs (Figueroa et al. 2009a). As the whole DNA 
methylation profiles were available, we were able to compare between AML and NBM 
in other genomic regions; gene bodies and CGI shores which clearly distinguished 
leukaemia from normal. The highest number of identified DMRs between AML and 
NBM was found in CGIs. Most of those differentiating CGIs (80%) were located 
outside the promoters (within gene bodies or intergenically placed). Although CGIs 
located within the promoters are at risk of DNA methylation in cancer (van Vlodrop et 
al. 2011), some studies confirmed the susceptibility of CGIs located outside the 
promoters to DNA methylation in malignancy. This has been associated with gene 
repression (Asada et al. 2003), but also may not affect the function of the related gene 
(Kaneda et al. 2002; Ushijima 2005). In addition, it has been suggested that DNA 
methylation in malignancy occurs in a non-random pattern (Chong et al. 2003; Dawson 
et al. 2007). That includes CGI DNA methylation alterations among different kinds of 
tumors. For instance, Kim et al observed that CGIs DNA methylation could not 
differentiate between normal and malignant prostatic tissues (Kim et al. 2011) while, 
Illingworth et al found that DNA methylation increased mainly in CGIs located within 
the promoters in colorectal tumors (Illingworth et al. 2010). The differential localization 
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of CGI methylation in tumors might be caused by molecular defects in the protective 
mechanisms of all CGIs or of CGIs located inside the promoters (Ushijima et al. 2003). 
Moreover, comparing the whole genome methylation between AML subtypes revealed a 
significant methylation difference among groups. The highest percentage of methylated 
genome was present in t(8;21) AML and t(15;17) AML (69% of the genome had 
Batman scores > 0.6). By contrast, trisomy 8 AML showed the highest percentage of 
hypomethylated genome (26 % of the genome had Batman scores < 0.4). It was reported 
that AML associated with chromosomal translocations; t(8;21) and t(15;17) showed 
high levels of DNA methylation (Galm and Esteller 2004; Blum and Marcucci 2005; 
Uribesalgo and Di Croce 2011). This increase in DNA methylation was related to the 
effect of fusion proteins, resulting from chromosomal translocations, in recruiting the 
DNMTs to target genes (Plass et al. 2008).  
Using the DNA methylation of specific genomic regions, we were able to clearly cluster 
AML subtypes based on the significant changes in DNA methylation of promoters, gene 
bodies, CGIs and CGI shores. t(8;21) AML showed the highest number of methylated 
DMRs and could be clustered away from the rest of AML subtypes, while trisomy 8 
AML showed the lowest number of methylated DMRs. Figueroa et al were the first to 
cluster AML subtypes according to their promoter DNA methylation with identification 
of new AML subtypes shared common DNA methylation signatures (Figueroa et al. 
2010b). Moreover, the epigenetic changes were correlated to the survival of AML 
patients (344 patients) of different cytogenetic groups in this array-based study 
(Figueroa et al. 2010b). However, due to limited number of AML patients, we could not 
compare the patients‟ survival among AML subtypes.  
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Additionally, investigating the MeDIP-seq promoter methylation of genes which 
showed distinctive expression pattern in AML subtypes (Virtaneva et al. 2001; 
Debernardi et al. 2003; Valk et al. 2004) revealed that differential promoter DNA 
methylation was correlated to differential gene expression in 3 AML subtypes; t(8;21) 
AML, NK AML and trisomy 8 AML (Figure 3.18G). However, there was no such 
correlation in t(15;17) AML suggesting additional modifying factors might affect the 
gene expression in this subtype e.g. microRNA (Dixon-McIver et al. 2008; Jongen-
Lavrencic et al. 2008; Li et al. 2008). 
Interestingly, DMRs located intragenically as well as DMRs located intergenically both 
were good discriminators between AML and NBM and between AML subtypes. The 
importance of intergenic regions in addition to intragenic regions in distinguishing DNA 
methylation has been recently observed in LINEs in prostatic tumors (Kim et al. 2011) 
and in satellites in peripheral nerve sheath tumors (Feber et al. 2011).  
Additionally, in our study, repeats located outside the promoters (within gene bodies or 
intergenically located) were significantly hypermethylated compared to repeats located 
within the promoters in both AML and NBM. This was previously observed by Xie et al 
in human cerebellum where Alu repeats were less methylated when being closer to TSS 
(Xie et al. 2009). Comparing the methylation of different repeats between AML and 
NBM revealed that SINEs were the best discriminators between the methylation profiles 
of leukaemia and normal. Also, SINEs showed the highest difference in the global DNA 
methylation between AML and NBM (Figure 3.4F), indicating that the AML global 
hypomethylation was mainly occurring at CpG sites of high methylation density 
(Arnaud et al. 2000). Since SINEs, especially Alu family, are rich in transcription factor 
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binding sites (Polak and Domany 2006), this may explain why DNA methylation of 
SINEs among other repeats showed the strongest inverse correlation with the expression 
of the associated genes (Pearson r = -0.82, P < 0.0001).  
The most striking result was the evidence of hypomethylated repeat clusters that could 
distinguish each AML subtype. Those hypomethylated repeats were neither linked to a 
specific chromosome nor correlated to differential gene expression. That raised a 
question concerning the potential role of those repeats in AML. Those hypomethylated 
repeats could be used as diagnostic markers (Hsiung et al. 2007; Wilson et al. 2007; 
Wolff et al. 2010) or prognostic markers (Choi et al. 2007) or indicators of cancer 
progression and metastasis (Hoffmann and Schulz 2005; Roman-Gomez et al. 2005; 
Cho et al. 2007) for each AML subtype. That will necessitate extension of the analysis 
to include more patients‟ samples together with remission and relapse samples of those 
AML patients to confirm this conclusion. 
 
6.2 SPHKAP and AML 
 
One of the significant results of my study was identification of SPHKAP (SKIP) gene as 
a methylated and silenced gene in AML. Treating AML cell lines with a demethylating 
drug (DAC) restored SPHKAP expression. It was reported that SPHK1 is upregulated in 
leukaemia (Le Scolan et al. 2005) and its inhibitor (Dimethylsphingosine, DMS) 
induced apoptosis (Paugh et al. 2008). Additionally, overexpression of RUNX gene, 
which plays a role in the pathology of t(8;21) AML, increases the extracellular 
Chapter 6 
205 
 
sphingosine-1-phosphate (S1P) (Kilbey et al. 2010). However, no studies have been 
reported concerning the possible role of SPHKAP gene methylation in malignancy.  
Based on the current results, the increase of S1P level and S1P/sphingosine ratio at least 
twice on transfection of cancer cell lines with vector expressing SPHKAP suggested a 
role of SPHKAP gene methylation in suppressing high S1P levels, since persistent 
exposure to high doses of S1P leads to apoptosis instead of cell survival. The apoptotic 
effect of S1P was observed by Shin et al who exposed mouse B16 melanoma cell line to 
5μM S1P for 24 hours (Shin et al. 2007). This resulted in cell shrinkage and cell 
detachment through continual activation of extracellular receptor kinase (ERK) pathway 
and through an activation of Caspase-3 (Shin et al. 2007). Davaille et al reported the 
same observation on treatment of  human hepatic fibroblast with 15μM S1P for 16 hours 
(Davaille et al. 2002). Additionally, S1P could be released from apoptotic cells as a lipid 
signal to attract phagocytic cells to remove the cell debris thus inhibiting cell necrosis 
(Gude et al. 2008). Also, S1P assists in extrusion of apoptotic cells through the 
contraction of the actin–myosin extrusion ring at the live-dying cell interface (Gu et al. 
2011). Therefore, there is a growing body of evidence confirming the role of S1P in 
apoptosis.  
However, how SPHKAP methylation suppresses high levels of S1P is not yet clear. 
Notably in our study, most AML samples, that did not show SPHKAP expression, 
showed expression of SPHK1. In addition, it has been suggested that SPHK1 and 
SPHK2 could have compensatory or overlapping functions (Maceyka et al. 2009). Thus, 
it would be important to perform more studies including both SPHK1 and SPHK2 to 
investigate their impacts on SPHKAP-S1P interrelationship. Since Dimethylsphingosine 
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(DMS), which is a SPHK1 inhibitor, induced apoptosis in Jurkat cell lines (Gude et al. 
2008), it would be also important to compare the metabolomic changes resulting from 
SPHKAP transfection to that resulting from addition of DMS to cancer cell lines.  
The observed increase of both S1P and S1P/sphingosine ratio after transfection of K562 
cell line with vector expressing SPHKAP is particularly important since SPHK1/S1P 
promotes imatinib resistance in K562 CML cell line (Salas et al. 2011). Therefore, 
activation of SPHKAP could possibly alter imatinib resistance in CML cell lines. 
Besides, K562 cell lines are resistant to doxorubicin which is a strong inducer of 
apoptosis (Gude et al. 2008). This resistance was overcome by a combinational therapy 
of doxorubicin and curcumin (Misra and Sahoo 2011). Measuring the cell viability of 
transfected K562 cells with activated SPHKAP after adding doxorubicin is an indicator 
of a possible impact of SPHKAP on doxorubicin resistance in those cells. 
 
6.3 Epigenomics of trisomy 8 AML  
 
Finally, the present study investigated the epigenomics of trisomy 8 AML by applying 
the MeDIP-seq approach. The current results revealed unequal DNA methylation 
distribution between chromosome 8 and the rest of the chromosomes in trisomy 8 AML. 
An increase in the hypermethylation signals of chromosome 8 was accompanied by an 
increase in the hypomethylation signals of the rest of the chromosomes in trisomy 8 
AML. By contrast, there was no difference in the DNA methylation distribution pattern 
between chromosome 8 and the rest of the chromosomes in non-trisomic DNA samples 
(non-trisomic AML and NBM). The effect of DNA methylation of the extra copy of 
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chromosome 8 mimics the global gene expression impact of plus 8 chromosome in 
increasing the expression of genes located on chromosome 8 and in decreasing the 
average gene expression level on the remaining chromosomes (Nawata et al. 2011). 
Although, our MeDIP-seq study could not determine which copy of chromosome 8 was 
more methylated in trisomy 8 AML, comparing trisomy 8 AML to NBM revealed that 
chromosome 8 extra methylation signals were localized mainly in CGI shores and 
interspersed repeats.  
In addition, studying the DNA methylation of diagnostic and relapse trisomy 8 AML 
showed that most of the DNA methylation of diagnostic samples was preserved in 
relapse samples with an increase in the DNA methylation of specific regions related to 
promoters, gene bodies and CGIs. Interestingly, DMRs located within CGI shores 
showed the highest number among other DMRs associated with promoters, gene bodies 
and CGIs. Most of those CGI shores were hypomethylated in relapse. This is 
particularly important as in Chapter 3 we confirmed the significant inverse correlation 
between CGI shores DNA methylation and related gene expression (Pearson r = -0.8, P 
< 0.0001) (Doi et al. 2009; Irizarry et al. 2009). Also, interspersed repeats were more 
hypomethylated in relapse versus diagnostic, which implicated more genome instability 
and a therapeutic resistance in the relapse status (Roman-Gomez et al. 2006; Verma et 
al. 2010). 
Since the MeDIP-seq analysis produced a whole-genome methylation profile, we were 
able to detect a significant methylated CGI located within the gene body of HHEX 
(PRH) in both diagnostic and relapse trisomy 8 AML. The DNA methylation of this 
intragenic CGI was associated with HHEX gene repression in trisomy 8 AML. HHEX 
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gene is involved in the pathogenesis of different haematological diseases. For instance, 
HHEX was downregulated in M4/M5 AML (Topisirovic et al. 2003). Besides, AML 
with a t(10;11) translocation resulted in HHEX- NUP98 fusion protein which 
deregulated HHEX target genes in haematopoietic progenitor cells (Jankovic et al. 
2008). Moreover, overexpression of HHEX gene resulted in induction of B-cell and T-
cell leukaemias and lymphomas (Soufi and Jayaraman 2008).  
eIF4E (eukaryotic translation initiation factor 4E) might explain the identified HHEX 
gene repression in trisomy 8 AML since the downregulation of HHEX gene was 
associated with overexpression of eIF4E in AML (Topisirovic et al. 2003). eIF4E 
overexpression is linked to upregulation of MYC gene (De Benedetti and Harris 1999), 
which an increase in its copy number was thought to be important in the pathogenesis of 
trisomy 8 AML (Wolman et al. 2002). However, the role of MYC in the development of 
leukaemia is controversial. Although overexpression of MYC induced leukaemia in mice 
(Felsher and Bishop 1999), another study based on a microarry analysis showed 
downregulation of MYC in trisomy 8 AML as compared to CD34+ (Virtaneva et al. 
2001). Collectively, the persistence of HHEX gene methylation in both diagnostic and 
relapse trisomy 8 AML and subseqent gene repression indicated the importance of 
HHEX gene methylation in the pathogenesis of trisomy 8 AML. However, the 
explanation for the role of HHEX  gene particulary in trisomy 8 AML is not yet clear.  
 
6.4 Conclusions and future directions 
 
This study is the first to use MeDIP-seq as a global method in AML to obtain a 
comprehensive view of the DNA methylation alterations. The DNA methylation 
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differences between AML and NBM and among AML subtypes were not limited to 
changes in the promoters or CGIs but also extended to other genomic regions including 
CGI shores and gene bodies. In addition, DNA hypomethylation of specific repeated 
sequences notably distinguished each AML subtype. These repeat clusters may have a 
functional role in controlling the expression of nearby genes. To confirm this potential 
role, more studies are required including RT-PCR of the expression of the related genes 
and investigating the enrichment of these repeated sequences with factors that are 
important for transcription e.g. H3K4me3 and RNA polymerase II. Moreover, designing 
pyrosequencing primers to these specific hypomethylated repeated sequences in each 
AML subtype and further investigating the repeats hypomethylation in a larger number 
of de novo AML patients may assist in exploring the role of those repeats as diagnostic 
markers. Besides, the survival could be compared between patients with and without 
repeats hypomethylaion to demonstrate if the DNA hypomethylation of these repeated 
sequences is accompanied by poor survival i.e. prognostic markers.  
The current results also revealed hundreds of DMRs discriminating AML from NBM 
and distinguishing each AML subtype, which appeared to be unique for each subgroup. 
Studying one of the novel significant methylated promoters in AML e.g. SPHKAP 
revealed a link between SPHKAP and S1P. SPHKAP (SKIP) gene activation increases 
the intracellular level of S1P by two times. Therefore, SPHKAP is not only an important 
modulator of SPHK1 but also can control the intracellular level of S1P. Since S1P has a 
pro-apoptotic impact in micromolar concentration, which is a receptor-independent 
effect, S1P could be used as a potential chemotherapeutic drug either solely or in 
combination with other therapeutic agents.  
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Furthermore, the present MeDIP-seq study revealed a global analysis of the DNA 
methylation of trisomy 8 AML. Since an intragenic CGI within HHEX body was 
significantly and differentially methylated in both diagnostic and relapse samples of 
trisomy 8 AML (P = 7.88 X 10
-11
), HHEX gene might be a potential diagnostic marker 
for trisomy 8 AML which is associated with poor survival. This will require 
investigating the methylation of this significant intragenic CGI by pyrosequencing in a 
larger number of trisomy AML patients and correlate the DNA methylation level to the 
survival of those patients. 
 
The current results and results of other microarray-based studies will assist in        
exploring, interpreting and obtaining a full-scale human epigenomic profile that will 
improve our understanding of the pathology of cancer in general and the pathology of 
AML in particular. 
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Figure 1 Enrichment ratios of the investigated HEP (Human Epigenome Project) genes 
in MeDIP-seq samples  
X-axis represents the CpG density %; Y-axis represents the enrichment ratio (mean  
SEM; standard error of the mean). The green and yellow colours correspond to 
methylated and unmethylated genes respectively. The figure demonstrates that 
methylated genes show higher enrichment ratios (after the IP step) than unmethylated 
genes. Additionally, for the methylated genes the enrichment ratio increases with the 
increase of CpG density. 
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Table 1 Bisulphite sequencing primers 
 
Genes Primers No of PCR  
cycles 
SPHKAP Forward: GTGTGAAATTTTTTTAAGTTGTGTT 
Reverse: CAATAAATAACAACTCCCTACTCTC 
42 cycles 
CGI Forward:TTGTTAGGTTTTGTTTATTATTTTTTTT 
Reverse: CAAACCCAATCTCTCCATACAC  
42 cycles 
CGI shores (a) Forward: AGTGTTTTTTTAGAAATTGGTTTG  
Reverse:AAAAATTTCTTACTTCTTATAAAAAAC 
42 cycles 
CGI shores (b) Forward: TTTAGTTGGGGTTGGTTGTTAATTA  
Reverse: AAAACATATCAACACCTCCTTAAAC  
42 cycles 
DPP6 Forward:GTTAATTTAGAGTGTAATTATGGAGA 
Reverse: AAACTAAACTAAACTAAAAAACCTC 
40 cycles 
 
  Table 2 Pyrosequencing primers 
*Primer is biotinylated 
 
 
Gene Primers 
SPHKAP chr2: 
228753601-228753665 
(sequence a) 
F:GGTTTTATTTAGGGTAGAGTAGATT 
*R:CCCCCTTCTTTCTATACCCAATACCATATC 
S:ACCAACTTACCCCAA 
SPHKAP chr2: 
228753760-228753852 
(sequence b) 
*F:GGGAGTAATAGTATTTTTGGTT 
R:TCCCCCAACCCAACAAATAACCT 
S:GGAGTAATAGTATTTTTGGTTTT 
DPP6 chr7: 153214816-
153214843 
F:TGGGTAAAGAGGGTAGTTTTTTTTTAG 
*R:TTCCCCACCTCTCCCTTCTCT 
S:AGTTTTTTTTTAGATATTTT 
ST6GAL2 chr2: 
106869095-106869136 
F:GGAGGTTGTAGAGTTATTAAGAAAGG 
*R:AAAACCCCCACCAAAATCCCA 
S:AGGAGTGAGTGTTATATTTTATTTT 
HHEX (sequence 1) 
chr10: 94442251-
94442377 
F:GGAAGAGTTTGGTTAAGATGTTGTAGT 
*R:ACCAAAAAACAAAATAACTCCT 
S:GGTTAAGATGTTGTAGTTTAG 
HHEX (sequence 2)  
chr10: 94442377-
94442408 
F:GTTTTAGGGGAAGGGAAGGTTT 
*R:TCCATACCTATTTTAATCTCCTCCATTT 
S:GAGGAGAGGAGTTATTTTGT 
AluJB chr7: 148474346-
148474580 
F: AAGTTAGATTTTTGTTGTTTTTAGGAATTT 
*R: TCCACCCCCCTTAACCTCCCAAAATA 
S: GTTTGTAGTTTAAGATGT 
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Table 3 Primers of the RT-PCR gene expression study  
Gene Assay ID Exon boundary Reporter Quencher 
SPHKAP Hs00919511_m1 8-9 FAM Non-fluorescent 
DPP6 Hs00157265_m1 16-17 FAM Non-fluorescent 
ID4 Hs02912975_g1 2-3 FAM Non-fluorescent 
SPHK1 Hs01116528_m1 1-2 FAM Non-fluorescent 
HHEX1 Hs00242160_m1 1-2 FAM Non-fluorescent 
HHEX2 Hs01074519_m1 3-4 FAM Non-fluorescent 
18S 4308329  VIC TAMRA 
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Figure 2 Saturation analyses of MeDIP-seq samples   
(A, B, C) The saturation analysis investigates whether the number of uniquely aligned 
reads is sufficient to generate a saturated and reproducible methylation profile of the 
reference genome. The higher the Pearson correlation coefficients (r), the more 
assurance of the reproducibility of the methylation proﬁles. Sample study number is 
identified in Chapter 3 Table 3.1. 
Figure 2A 
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Figure 2B 
                  
                      
                  
                            
                    
                         
Appendix 1 
216 
 
Figure 2C 
            
                    
 
            
                       
                       
 
                        
Appendix 1 
217 
 
A.  
 
B. 
          
Figure 3 Bimodal distributions of promoter CpG densities 
A. Batman scores of the promoters in study No.1 were plotted against their 
corresponding CpG densities. The CpG densities were clustered into 2 regions; 
a region of high CpG density and a region of low CpG density. 
B. Batman scores of the gene bodies in study No. 1 were plotted against their 
corresponding CpG densities. The CpG densities were clustered into one region 
of low CpG density. In both A and B figures, there was a significant inverse 
correlation between DNA methylation and CpG density (P < 0.0001). 
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Figure 4 Histograms of uncorrected P values after testing the equality of methylation 
averages in 4 genomic regions (A) and in repeats (B). In each figure, X-axis represents 
P values and Y-axis represents the frequencies of P Values. When comparing the data 
with equal averages between groups, the P values were expected to be uniformly 
distributed across the unit interval (blue line). Comparing the distribution of 
uncorrected P values to the uniform distribution expected for random data revealed 
enrichment of P value < 0.05 (red line), indicating a differential methylation pattern.  
 
Figure 4A 
Promoters  
 
Gene bodies 
                
 
CGIs 
        
CGI shores 
          
      t(8;21) versus                 t(15;17) versus             NK versus              Trisomy 8 versus            All AMLs versus  
         all groups                      all groups                   all groups                     all groups                     all NBMs      
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Figure 4B 
Satellites, opposite to other repeats investigated, did not show a specific distribution of 
uncorrected P values across the samples. 
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Table 4A DNA methylation of over- and underexpressed genes (Debernardi et al. 2003) 
in t(8;21), t(15;17) & NK AML subgroups that were included in MeDIP-seq study  
Genes ID Promoter location Batman methylation scores 
  Patient 1 Patient 2 Patient 3 
t(8;21) 
overexpressed genes 
 t(8;21)-patient 1 t(8;21)-patient 2 t(8;21)-patient 3 
TRH Chr3:131175254:131177253 0.2388 0.30795 0.35145 
POU4F1 Chr13:78074696:78076695 0.2488 0.17785 0.13375 
NEUROD1 Chr 2:182252626:182254625 0.68575 0.3379 0.4336 
PRAME Chr22:21230696:21232695 0.38615 0.5156 0.41565 
PGDS Chr4:95482050:95484049 0.56635 0.6688 0.4108 
RGS10 Chr10:121291212:121293211 0.0901 0.08475 0.06675 
GPM6B Chr23:13865758:13867757 0.158 0.1776 0.2579 
t(8;21) under 
expressed  genes 
 t(8;21)-patient 1 t(8;21)-patient 2 t(8;21)-patient 3 
HOXA9 Chr7:27174794:27176793 0.4054 0.4528 0.51105 
HOXA4 Chr7:27135877-2713783653 0.227 0.6091 0.6251 
SPINK2 Chr4:57381654:57383653 0.5383 0.43805 0.513 
CAPG Chr2:85490187:85492186 0.4027 0.7297 0.6955 
t(15;17) 
overexpressed genes 
 t(15;17)-patient 1 t(15;17)-patient  2 t(15;17)-patient 3 
CPA3 Chr3:150064772:150066771 0.76785 0.57075 0.58205 
SLPI Chr20:43315620:43317619 0.83215 0.82165 0.8381 
FGF13 Chr23:137893912:137895911 0.78655 0.69755 0.8783 
DLX2 Chr2:172674724:172676723 0.14465 0.12035 0.18775 
CST7 Chr20:24876867:24878866 0.56995 0.2691 0.4761 
RUNX3 Chr1:25163088:25165087 0.57155 0.6533 0.73955 
FGFR1 Chr8:38444509:38446508 0.3452 0.4579 0.47255 
PPARG Chr3:12303071:12305070 0.2521 0.18545 0.31525 
t(15;17) under 
expressed genes 
 t(15;17)-patient 1 t(15;17)-patient  2 t(15;17)-patient 3 
SLC7A7 Chr14:22357840:22359839 0.7648 0.7801 0.8007 
HOXA9 Chr7:27174794:27176793 0.3395 0.32935 0.4532 
ITPR1 Chr3:4509035:4511034 0.17325 0.1999 0.15125 
MEF2C Chr5:88213780:88215779 0.22205 0.21665 0.23685 
HOXA4 Chr7:27135870:27137876 0.7661 0.5757 0.8948 
ARHGAP4 Chr23:152843908:152845907 0.41815 0.4004 0.4464 
NCF2 Chr1:181825634:181827633 0.7065 0.4899 0.725 
NK overexpressed 
genes 
 NK-patient 1 NK-patient 2 NK-patient 3 
HOXA9 Chr7:27174794:27176793 0.30085 0.20595 0.19795 
HOXB2 Chr17:43976392:43978391 0.2698 0.3119 0.2602 
HOXA4 Chr7:27135870:27137876 0.35945 0.87205 0.7333 
PLXNC1 Chr12:93065631:93067630 0.21075 0.1668 0.2004 
NK underexpressed 
genes 
 NK-patient 1 NK-patient 2 NK-patient 3 
MPO Chr17:53712295:53714294 0.6347 0.83765 0.82945 
FGFR1 Chr8:38444509:38446508 0.2855 0.3869 0.3457 
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Table 4B DNA methylation of over- and underexpressed genes (Virtaneva et al. 2001) in 
trisomy 8 AML subgroup that was included in MeDIP-seq study  
Genes ID Promoter location Batman methylation scores 
  Patient 1 Patient 2 Patient 3 
Trisomy 8 
overexpressed 
genes 
 Trisomy 8-patient 1 Trisomy 8-patient 2 Trisomy 8-patient 3 
IGKV1D-8 Chr 2:  89896080: 89898079 0.2683 0.4485 0.5362 
TAF2 Chr 8: 120913255: 120915254 0.66775 0.5087 0.3461 
COPE Chr 19: 18890199: 18892198 0.1918 0.1868 0.2176 
IGHA1 Chr 14: 105245046: 105247045 0.49075 0.66435 0.4069 
NFIL3 Chr 9: 93224965: 93226964 0.07985 0.09075 0.11435 
CCT8 Chr 21: 29366989: 29368988 0.11265 0.14765 0.1582 
PSAP Chr 10: 73280132: 73282131 0.24215 0.16925 0.4575 
IGBP1 Chr 23: 69269044: 69271043 0.1912 0.2266 0.0922 
BTG1 Chr 12: 91062751: 91064750 0.07145 0.0707 0.0611 
DBI Chr 2: 119839975: 119841974 0.1754 0.3241 0.2013 
LYN Chr 8: 56953949: 56955948 0.31375 0.21285 0.2048 
PTK2 Chr 8: 142079514: 142081513 0.14975 0.1273 0.1273 
TCEB1 Chr 8: 75045959: 75047958 0.1714 0.18275 0.15245 
FXR1 Chr 3: 182112147: 182114146 0.23765 0.2642 0.2508 
Trisomy 8 under 
expressed genes 
 Trisomy 8-patient 1 Trisomy 8-patient 2 Trisomy 8-patient 3 
STAT1 Chr 2: 191586181: 191588180 0.39205 0.35755 0.2842 
ELA1 Chr 12: 50025730: 50027729 0.6701 0.78815 0.74805 
MPO Chr 17: 53712295: 53714294 0.6427 0.7478 0.6086 
SLC7A5 Chr 16: 86459615: 86461614 0.1012 0.06255 0.0547 
MCM5 Chr 22: 34125117: 34127116  0.38965 0.3915 0.3254 
RALGDS Chr 9: 135013542: 135015541 0.1313 0.13735 0.2413 
PRG2 Chr 11: 56913688: 56915687  0.63585 0.8634 0.794 
ARAF Chr 23: 47304523: 47306522  0.2604 0.21615 0.1918 
TPR Chr 1: 184610383: 184612382  0.1768 0.1503 0.0684 
IL1B Chr 2: 113309827: 113311826  0.4078 0.7727 0.7141 
MYC Chr 8: 128815863: 128817862 0.1053 0.0887 0.20465 
FUS Chr 16: 31097955: 31099954 0.10195 0.10305 0.07165 
APOC1 Chr 19: 50108420: 50110419 0.6994 0.4572 0.23565 
NBL1 Chr 1: 19841314: 19843313 0.4798 0.57355 0.548 
EPHB1 Chr 3: 135995945: 135997944 0.4255 0.1898 0.20795 
CLC Chr 19: 44920512: 44922511 0.7888 0.78925 0.6744 
MCM3 Chr 6: 52256541: 52258540  0.1322 0.2834 0.2697 
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Figure 5 Direct bisulphite sequencing validation of DMRs in MeDIP-seq DNA samples 
 (A) DPP6 gene, (B) CGI, (C & D) CGI shore and (E) SPHKAP gene. In all figures, the 
horizontal line represents the position of a CpG site and the vertical line represents the 
percentage of methylation at this particular CpG from 0-100%. Only > 95% bisulphite 
converted clones were analyzed using QUMA (Quantitative Method for Methylation 
Analysis). 
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Figure 5B CGI Chr20: 60319301-60319515  
t(8; 21)-1 
 
 
t(15; 17)-3 
 
 
t(8;21)-3 
 
 
t(15; 17)-2 
 
 
NK-1 
 
 
NBM-1 
 
 
NBM-2 
 
 
NBM-3 
 
 
 
 
 
 
Appendix 1 
224 
 
Figure 5C CGI shore (sequence a) Chr7: 8448450-8448728  
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Figure 5D CGI shore (sequence b) Chr7: 8448727-8448894  
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Figure 5E SPHKAP Chr2: 228754201-228754550  
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Figure 5F Correlation between MeDIP-seq and direct bisulphite sequencing 
For each MeDIP-seq sample in Figures 5A-E Appendix 1 (pages 222-226), the direct 
bisulphite sequencing percentage is correlated to the corresponding Batman score in all 
genomic regions investigated. There was a significant positive correlation between both 
methods (Pearson’s, R2 = 0.75, P < 0.0001).
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Figure 5G Pyrosequencing results for SPHKAP (sequence a) 
SPHKAP (sequence a) methylation was compared between AML patients of different 
cytogenetic subtypes, AML cell lines and NBMs (Table 3.9). Each symbol represents the 
average percentage of CpGs methylation in SPHKAP (sequence a) as calculated by 
pyrosequencing and the horizontal line is the mean of those methylation percentages. 
There was a significant methylation difference among samples (Kruskal-Wallis test, P 
<0.0001). 
 
 
 
Appendix 1 
229 
 
 
SPHKAP  (sequence b)
P
e
rc
e
n
ta
g
e
 o
f 
C
p
G
 m
e
th
y
la
ti
o
n
t(
15
;1
7)
 A
M
L
t(
8;
21
) A
M
L
in
v 
16
 A
M
L
V
ar
io
us
 A
M
Ls
A
M
L 
ce
ll 
lin
es
Tr
is
om
y 
8 
A
M
L
N
K
 A
M
L
N
B
M
0
20
40
60
80
100
 
 
Figure 5H Pyrosequencing results for SPHKAP (sequence b) 
SPHKAP (sequence b) methylation was compared between AML patients of different 
cytogenetic subtypes, AML cell lines and NBMs (Table 3.9). Each symbol represents the 
average percentage of CpGs methylation in SPHKAP (sequence b) as calculated by 
pyrosequencing and the horizontal line is the mean of those methylation percentages. 
There was a significant methylation difference among samples (Kruskal-Wallis test, P= 
0.0025). 
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Figure 5I Pyrosequencing results for DPP6 
DPP6 methylation was compared between AML patients of different cytogenetic 
subtypes, AML cell lines and NBMs (Table 3.9). Each symbol represents the average 
percentage of CpGs methylation in DPP6 as calculated by pyrosequencing and the 
horizontal line is the mean of those methylation percentages. There was a significant 
methylation difference among samples (Kruskal-Wallis test, P= 0.0002). 
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Figure 5J  Pyrosequencing results for ST6GAL2 
ST6GAL2 methylation was compared between AML patients of different cytogenetic 
subtypes, AML cell lines and NBMs (Table 3.9). Each symbol represents the average 
percentage of CpGs methylation in ST6GAL2 as calculated by pyrosequencing and the 
horizontal line is the mean of those methylation percentages. There was a significant 
methylation difference among samples (Kruskal-Wallis test, P <0.0001). 
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Figure 5K Pyrosequencing results for HHEX 
HHEX methylation was compared between AML patients of different cytogenetic 
subtypes, AML cell lines and NBMs (Table 3.9). Each symbol represents the average 
percentage of CpGs methylation in HHEX as calculated by pyrosequencing and the 
horizontal line is the mean of those methylation percentages. There was a significant 
methylation difference among samples (Kruskal-Wallis test, P <0.0001). 
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Figure 5L Pyrosequencing results for Alu 
Alu methylation was compared between AML patients of different cytogenetic subtypes, 
AML cell lines and NBMs (Table 3.9). Each symbol represents the average percentage 
of CpGs methylation in Alu as calculated by pyrosequencing and the horizontal line is 
the mean of those methylation percentages. There was a significant methylation 
difference among samples (Kruskal-Wallis test, P= 0.002. 
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Table 5A Common genes between the results of MeDIP-seq study and array-based DNA 
methylation study for t(15;17) AML (Figueroa et al. 2010b)  
 
Cytogenetic subtype Gene ID Absolute 
methylation 
difference 
(MeDIP-seq) 
 
P value 
(MeDIP-seq) 
(HELP) 
REFSEQ  
HELP status  
t(15;17) AML gene 
body, P < 0.05 
CCDC96 0.166367539 0.008595658 NM_153376 Hypermethylated 
EFNB3 0.11348914 0.002303019 NM_001406 Hypermethylated 
CTDP1 0.070320972 0.006361778 NM_048368 Hypomethylated 
PLD3 0.040474068 0.023572138 NM_012268 Hypomethylated 
C21orf55 0.122434283 0.005500719 NM_017833 Hypomethylated 
t(15;17) AML 
promoters, P < 0.05 
CCDC96 0.102184606 0.011459895 NM_153376 Hypermethylated  
CBLN4 0.203204604 0.00826159 NM_080617 Hypermethylated  
TCP11 0.137933767 0.027689113 NM_001093728 Hypomethylated 
CD3D 0.11644395 0.016107599 NM_000732 Hypomethylated 
t(15;17) AML CGIs, 
P < 0.05 TCP11 0.097680363 0.022919236 NM_018679 Hypomethylated 
Genes that have absolute methylation difference labelled red are hypermethylated in 
MeDIP-seq, genes that have absolute methylation difference labelled green are 
hypomethylated in MeDIP-seq. 
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Table 5B Common genes between the results of MeDIP-seq study and array-based DNA 
methylation study for t(8;21) AML (Figueroa et al. 2010b)  
Cytogenetic 
subgroup 
Gene ID Absolute 
methylation 
difference 
(MeDIP-seq) 
 
P value 
(MeDIP-seq) 
(HELP) REFSEQ  HELP status  
t(8;21) 
AML gene 
body, P < 
0.05 
YTHDF2 0.049138331 0.025445848 NM_016258 Hypermethylated 
ZNF501 0.073802318 0.032618972 NM_145044 Hypermethylated 
PCDHAC2 0.077956863 0.001810847 NM_018902 Hypermethylated 
PCDHB16 0.157136955 0.006028352 NM_020957 Hypermethylated 
PCDHB11 0.222558496 0.000521823 NM_018931 Hypermethylated 
PCDHB14 0.204600434 0.004087562 NM_018934 Hypermethylated 
PPARD 0.042234943 0.012778396 NM_006238 Hypomethylated 
C9orf79 0.120246549 0.019504062 NM_178828 Hypomethylated 
C12orf10 0.072701608 0.011939341 NM_021640 Hypomethylated 
t(8;21) 
AML 
promoters, 
P < 0.05  
CCDC96 0.102184606 0.011459895 NM_153376 Hypermethylated  
CBLN4 0.203204604 0.00826159 NM_080617 Hypermethylated  
TCP11 0.137933767 0.027689113 NM_001093728 Hypomethylated 
CD3D 0.11644395 0.016107599 NM_000732 Hypomethylated 
LHCGR 0.152270891 0.016855042 NM_000233 Hypermethylated 
ZNF501 0.173747967 0.033473437 NM_145044 Hypermethylated 
FAM19A4 0.217803741 0.003091864 NM_001005527 Hypermethylated 
GPR149 0.156230384 0.047399559 NM_001038705 Hypermethylated 
EREG 0.219778079 0.005244438 NM_001432 Hypermethylated 
PCDHAC2 0.173317067 0.049385319 NM_031861 Hypermethylated 
PCDHB16 0.201370413 0.01504728 NM_020957 Hypermethylated 
PCDHB11 0.221397798 0.015676353 NM_018931 Hypermethylated 
PCDHGB7 0.102454831 0.032863705 NM_032101 Hypermethylated 
ELAVL2 0.301884632 4.77E-05 NM_004432 Hypermethylated 
ZNF560 0.27700109 0.000177544 NM_152476 Hypermethylated 
HKR1 0.173093667 0.016492647 NM_181786 Hypermethylated 
NNAT 0.123240265 0.047400739 NM_005386 Hypermethylated 
DSCR6 0.132084428 0.042211139 NM_018962 Hypermethylated 
ARF6 0.074397933 0.023431079 NM_001663 Hypomethylated 
t(8;21) 
AML CGIs, 
P < 0.05  
LHCGR 0.435452379 0.021795084 NM_000233 Hypermethylated 
FAM19A4 0.13631079 0.014309141 NM_182522 Hypermethylated 
GPR149 0.397192766 0.019793536 NM_001038705 Hypermethylated 
CRHBP 0.368458302 0.019229988 NM_001882 Hypermethylated 
PCDHAC2 0.413549617 0.029743223 NM_018902 Hypermethylated 
PCDHB14 0.217743134 0.040831837 NM_018934 Hypermethylated 
ELAVL2 0.356943532 0.038633918 NM_004432 Hypermethylated 
ABLIM1 0.26685279 8.29E-05 NM_001003408 Hypermethylated 
ZNF560 0.426668856 0.005016187 NM_152476 Hypermethylated 
ZNF154 0.401566932 0.036694773 NM_001085384 Hypermethylated 
Genes that have absolute methylation difference labelled red are hypermethylated in 
MeDIP-seq, genes that have absolute methylation difference labelled green are 
hypomethylated in MeDIP-seq. 
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Figure 6 DNA methylation distributions of chromosomes 1, 6, 8, 11 in 3 diagnostic 
trisomy 8 AML compared with non-trisomic AMLs and NBMs. X-axis represents Batman 
methylation scores; Y-axis represents the frequencies of the methylation scores. Non-
trisomic AMLs (green line); NBMs (red line); trisomy 8 AML (blue line). Overall, 
chromosome 8 showed higher frequency of Batman scores > 0.8 in trisomy 8 AML than 
non-trisomic AMLs and NBMs. Chromosomes 1, 6, 11 showed higher frequency of 
Batman scores < 0.4 in trisomy 8 AML than non-trisomic AMLs and NBMs. 
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Figure 7 DNA methylation distributions of chromosomes 1, 6, 8, 11 in 3 relapse trisomy 
8 AML compared with non-trisomic AMLs and NBMs. X-axis represents Batman 
methylation scores; Y-axis represents the frequencies of the methylation scores. Non-
trisomic AMLs (green line); NBMs (red line); trisomy 8 AML (blue line). Overall, 
chromosome 8 showed higher frequency of Batman scores > 0.8 in trisomy 8 AML than 
non-trisomic AMLs and NBMs. Chromosomes 1, 6, 11 showed higher frequency of 
Batman scores < 0.4 in trisomy 8 AML than non-trisomic AMLs and NBMs. 
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Figure 8 DNA methylation distributions of chromosomes 1, 6, 8, 11 in 3 AML patients 
compared with NBMs and trisomy 8 AMLs. X-axis represents Batman methylation 
scores; Y-axis represents the frequencies of the methylation scores. Non-trisomic AML 
(green line); NBMs (red line); trisomy 8 AMLs (blue line). Overall, chromosome 8 
showed lower frequency of Batman scores > 0.8 in non-trisomic AML and NBMs than 
trisomy 8 AMLs. Chromosomes 1, 6, 11 showed lower frequency of Batman scores < 0.4 
in non-trisomic AML and NBMs than trisomy 8 AMLs. 
 Study No. 2 [t(15;17)] Study No. 5 [NK] Study No. 9 [t(8;21)] 
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 Study N0. 13 (NBM) Study No.14 (NBM) Study No.15 (NBM) 
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Figure 9 DNA methylation distributions of chromosomes 1, 6, 8, 11 in 3 NBM samples 
compared with non-trisomic AMLs and trisomy 8 AMLs. X-axis represents Batman 
methylation scores; Y-axis represents the frequencies of the methylation scores. Non-
trisomic AMLs (green line); NBM (red line); trisomy 8 AMLs (blue line).Overall,  
chromosome 8 showed lower frequency of Batman scores > 0.8 in NBM and non-
trisomic AMLs than trisomy 8 AMLs. Chromosomes 1, 6, 11 showed lower frequency of 
Batman scores < 0.4 in NBM and non-trisomic AMLs than trisomy 8 AMLs.  
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Figure 10 Hierarchical clustering analysis of diagnostic versus relapse trisomy 8 AML 
in 4 genomic features  
In each cluster analysis, each column represents AML patient and each row represents 
a DMR. Trisomy 8 AML D; diagnostic, trisomy 8 AML R; relapse. Colour represents 
methylation level (red = high methylation; green = low methylation).  Promoters (A), 
gene bodies (B), CGIs (C) and CGI shores (D). Clear separation between diagnostic 
and relapse trisomy 8 AML with few DMRs identified in the 4 genomic features.  
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Figure 11 Pair-wise comparison of the methylation profiles between diagnostic and 
relapse trisomy 8 AML in 4 genomic features 
The red and yellow colours indicate high and low similarity level respectively. Clear 
separation in the methylation profiles between diagnostic and relapse samples in 
promoters (A), gene bodies (B), CGIs (C) and CGI shores (D). 
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Figure 12 Hierarchical clustering analysis of diagnostic versus relapse trisomy 8 AML 
in repeat sequences  
In each cluster analysis, each column represents AML patient and each row represents 
a DMR. Trisomy 8 AML D; diagnostic, trisomy 8 AML R; relapse. Colour represents 
methylation level (red = high methylation; green = low methylation). Clear separation 
between diagnostic and relapse trisomy 8 AML with few DMRs detected in SINEs (A), 
LINEs (B) and LTRs (C). 
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                      Similarity 
Figure 12 Pair-wise comparison of the methylation profiles between diagnostic and 
relapse trisomy 8 AML in repeat sequences  
The red and yellow colours indicate high and low similarity level respectively. Clear 
separation of the methylation profiles between diagnostic and relapse samples was 
observed in SINEs (A), LINEs (B) and LTRs (C).
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 List of differentially methylated promoters in AML versus NBM  
 AMD; absolute methylation difference, red is hypermethylated DMR, green is 
hypomethylated DMR. 
ID AMD P.Value adj.P.Value 
KRTAP19-6 0.25518578 0.00016715 0.12989396 
AZU1 0.25705875 0.00900671 0.4080308 
SLC6A12 0.27548747 0.00061288 0.20270085 
DPP6 0.45601344 0.00073288 0.21094314 
NKX2-6 0.45452301 0.00100687 0.22581066 
PRLHR 0.45181914 8.05E-05 0.11299767 
SPHKAP 0.44987448 0.00027701 0.16398479 
GPR6 0.43340085 3.91E-05 0.09321829 
ELAVL2 0.42541917 3.30E-06 0.06297024 
DBX1 0.3981836 0.00078752 0.21094314 
DBC1 0.37952744 0.00079672 0.21094314 
NEF3 0.3726904 0.00012332 0.12632556 
KCNA4 0.37118134 0.00148693 0.25768479 
MTMR7 0.36684849 5.05E-05 0.09974153 
CASP7 0.363382 0.00218215 0.29316776 
ESRRG 0.36328294 0.00423115 0.34524317 
ZIC1 0.35628376 0.00138698 0.25180904 
PCDH8 0.3507965 0.0167231 0.47085454 
ADAMTS20 0.34690719 0.00440657 0.34855759 
FERD3L 0.34471255 0.00294585 0.30960593 
PCDHB1 0.34388633 5.23E-05 0.09974153 
GRM7 0.34264916 0.00285288 0.30900245 
DCC 0.34118076 0.00092099 0.2194598 
TRPC6 0.34073852 0.00013916 0.12632556 
PHYHIPL 0.33956548 0.01200638 0.43830871 
GSH1 0.33896305 0.00059788 0.20270085 
PABPC5 0.3362318 0.0002744 0.16398479 
TBX20 0.33232477 0.00686644 0.39010272 
CBLN4 0.33230275 0.00081995 0.21240683 
TMEM204 0.32922571 0.00017716 0.12989396 
UNC5D 0.32693553 0.00158506 0.26274847 
ZNF454 0.32688196 2.49E-05 0.09321829 
hsa-mir-124-2  0.3247822 0.00060929 0.20270085 
TERT 0.32209071 8.51E-06 0.08106907 
MYCL2 0.32182717 0.00013491 0.12632556 
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List of differentially methylated promoters in AML versus NBM  
 AMD; absolute methylation difference, red is hypermethylated DMR. 
ID AMD P.Value adj.P.Value 
ANKRD30B 0.31810065 0.00111299 0.23315343 
REC8 0.31748376 0.00132347 0.25044596 
MTNR1A 0.31690688 8.89E-05 0.11299767 
ADRA1A 0.31607323 0.0074865 0.3948074 
TACR3 0.3128527 0.00033722 0.16916979 
RAB36 0.31219005 0.00183025 0.27912062 
FUT9 0.31205972 0.00476765 0.34966423 
PCDHB6 0.30975585 0.00072009 0.21094314 
FOXI2 0.30861174 0.0156371 0.4681054 
PEG3 0.30849169 0.00062321 0.20270085 
HS3ST2 0.30482631 0.01937341 0.48594121 
RASGRF1 0.30429518 0.02117737 0.49632743 
GRIK2 0.30205727 0.00032793 0.16916979 
ABCC9 0.30167785 0.00165762 0.26779027 
PCDHGC5 0.30036742 0.0090386 0.4080308 
KCND2 0.29984112 0.00642648 0.37929217 
KCNJ3 0.2968213 0.00447908 0.3491654 
CARTPT 0.29593747 0.00016537 0.12989396 
ZFHX4 0.2956042 0.0057923 0.36021856 
CCBE1 0.29431554 0.00224701 0.29316776 
HTR1A 0.29311825 0.00140728 0.25308397 
TBX5 0.28738074 0.00226284 0.29316776 
CDH8 0.28737826 0.00349386 0.33301741 
HTRA4 0.28700315 0.0089399 0.4080308 
UGT8 0.28658932 0.01913349 0.48396697 
DOK6 0.28593594 0.01447169 0.46766412 
PCDHGA6 0.28522989 8.74E-05 0.11299767 
CKMT2 0.28497925 0.00062977 0.20270085 
ID4 0.2844317 0.00262542 0.30900245 
SLITRK3 0.28283453 0.0097397 0.41076978 
PDZRN3 0.28181632 0.01065718 0.42226885 
OLIG3 0.28140602 0.00281279 0.30900245 
KCNV1 0.28008829 0.01336877 0.45785189 
PCDH17 0.27980885 0.01884554 0.48396697 
CNTNAP5 0.27905588 0.00554606 0.3573199 
DRD4 0.27889856 0.00283627 0.30900245 
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List of differentially methylated promoters in AML versus NBM  
 AMD; absolute methylation difference, red is hypermethylated DMR. 
ID AMD P.Value adj.P.Value 
VAMP5 0.27795152 0.0240674 0.50417246 
FAM84A 0.27702976 0.00395014 0.34107744 
CDX4 0.27702585 0.01067635 0.42226885 
SLC5A7 0.27632528 8.03E-05 0.11299767 
LTF 0.27524999 0.00136853 0.25180904 
NOL4 0.27286101 0.02783268 0.50890045 
RTDR1 0.27232271 0.00526376 0.35363746 
ZNF154 0.27121444 0.00099938 0.22581066 
ENTPD3 0.26843041 0.00028472 0.16398479 
CDX1 0.26720014 0.00012948 0.12632556 
GABRG2 0.26652225 0.00013732 0.12632556 
RUSC1 0.26627656 0.00178309 0.27888764 
PCDHA6 0.26550261 0.00043984 0.1996344 
FEZF1 0.2653423 0.009192 0.4080308 
SOX14 0.26533083 0.01389646 0.46231808 
MTNR1B 0.26298538 0.004758 0.34966423 
GHSR 0.26127104 0.00390631 0.34107744 
LYPD1 0.26098885 0.02356187 0.50241598 
SLC6A3 0.25908187 0.01213526 0.43896468 
ZFP2 0.25874664 0.02660703 0.50890045 
WNT2 0.25863207 0.01417155 0.46673867 
VSX1 0.25841897 0.01162845 0.43722511 
IGHD3-22 0.25776362 0.00118142 0.24479781 
ASXL3 0.25557771 0.00241915 0.30141404 
SLIT2 0.25414099 0.01563595 0.4681054 
HTR2C 0.25404715 0.01907076 0.48396697 
TAC1 0.25387041 0.01368933 0.46207848 
UGT3A1 0.25342504 0.00033041 0.16916979 
KRT7 0.2533716 0.00088207 0.21627354 
CADPS 0.25298241 0.02143637 0.49632743 
MEI1 0.2518731 0.00143053 0.25486198 
CPT1C 0.25121528 0.01920161 0.48418022 
DSC3 0.25053152 0.01459269 0.46786713 
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List of differentially methylated gene bodies in AML versus NBM  
 AMD; absolute methylation difference, red is hypermethylated DMR, green is 
hypomethylated DMR. 
ID AMD P.Value adj.P.Value 
RPLP0P1 0.25593041 0.02840889 0.77288879 
OR2W5 0.25687406 0.00977825 0.67875964 
TRBV5-8 0.2592749 0.02975464 0.77381657 
OR51A3P 0.26015599 0.00197375 0.50899653 
hsa-mir-647 0.26767914 0.03334573 0.77502583 
TRGV1 0.27403184 0.0263417 0.77288879 
C11orf81. 0.2790551 0.01489811 0.72365005 
RTN4RL1 0.28161234 0.01769918 0.74362256 
TRGV5 0.28176093 0.00182683 0.50899653 
hsa-mir-373 0.28636449 0.04345759 0.79911517 
IGLJ3 0.28926322 0.00971343 0.67875964 
IGHV3-35 0.32789821 0.04090604 0.79911517 
hsa-mir-202 0.39082833 0.0143802 0.72294542 
hsa-mir-27a 0.49489854 0.00332849 0.57865536 
hsa-mir-23a 0.50708 0.0006575 0.36071508 
IGHD3-22 0.6179565 9.41E-06 0.09903879 
RXFP3 0.54234443 1.06E-05 0.09903879 
HTR1A 0.52384416 0.00028516 0.28413278 
IGHD5-12 0.48104354 0.00217097 0.50899653 
hsa-mir-124-2 0.47494369 0.00129854 0.48823183 
SLC18A3 0.44426458 0.00191133 0.50899653 
UCN 0.42389004 0.00798813 0.67353147 
SOX14 0.41568131 0.01163883 0.68282887 
IGHD6-19 0.41537631 0.02753564 0.77288879 
GSH1 0.3931666 0.00046749 0.33967026 
HTR1B 0.38598494 0.00211197 0.50899653 
MYCL2 0.37524243 0.00672701 0.64844858 
PRLHR 0.36005015 0.00031176 0.28413278 
ACTA1 0.35550133 0.00456825 0.62218161 
POU3F4 0.35527194 0.01985605 0.76385093 
hsa-mir-548o 0.3397486 0.00169757 0.50899653 
hsa-mir-128-2 0.33957395 0.00027368 0.28413278 
CLDN3 0.33861205 0.01706125 0.74362256 
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List of differentially hypomethylated CGIs in AML versus NBM  
 AMD; absolute methylation difference, green; hypomethylated DMR 
ID AMD P.Value adj.P.Value 
Location: promoter/ 
gene body/ intergenic 
chr16:29104038 0.46672714 0.00138561 0.11149277 intergenic 
chr16:30998890 0.47303554 0.01859198 0.31481581 gene body:ZNF646 
chr1:85946629 0.47347608 0.00019543 0.04278837 promoter:C1orf181 
chr19:898547 0.4802198 0.00015155 0.03969784 gene body:ARID3A 
chr7:156785358 0.48202108 0.01638066 0.30326759 intergenic 
chr2:240526885 0.48605898 0.02700673 0.35899656 intergenic 
chr17:58865385 0.48851456 0.0001609 0.0398182 gene body:CYB561 
chr19:2497620 0.49502888 5.39E-06 0.00535059 gene body:GNG7 
chr15:89163449 0.49779206 1.07E-06 0.00181351 intergenic 
chr17:75515660 0.49785463 0.00132717 0.10928624 intergenic 
chr9:138710258 0.50650911 0.00889994 0.25277714 intergenic 
chr15:66047555 0.50792459 0.00018233 0.04216107 intergenic 
chr1:1590844 0.51457186 0.00368381 0.18166694 gene body:CDK11B 
chr19:2674168 0.53012648 3.30E-05 0.01576432 intergenic 
chr8:1959316 0.53062959 2.25E-05 0.01229358 intergenic 
chr12:131645366 0.53571801 8.21E-07 0.00152786 gene body:FBRSL1 
chr4:3344531 0.53795201 0.00026589 0.05009062 gene body:RGS12 
chr2:174585811 0.53861674 2.88E-09 5.37E-05 intergenic 
chr7:5310091 0.53959428 3.49E-05 0.01585668 intergenic 
chr19:16327399 0.54550905 0.00213202 0.1358798 intergenic 
chr21:43688338 0.5537647 0.00016583 0.04007927 intergenic 
chr17:44651968 0.5541114 0.00015026 0.03969784 gene body:ABI3 
chr22:39144762 0.55545128 0.00673009 0.22614303 gene body:MKL1 
chr16:84539153 0.55568329 3.47E-07 0.000923 intergenic 
chr12:129983895 0.55583448 0.00034012 0.05702324 intergenic 
chr9:135556394 0.55672339 0.00046169 0.06460193 gene body:SARDH 
chr19:3141998 0.56003399 0.0019538 0.13047806 gene body:NCLN 
chr19:562291 0.56390766 0.00165952 0.11904726 gene body:HCN2 
chr22:41495891 0.56887356 5.15E-05 0.020374 intergenic 
chr14:104289411 0.57438949 0.0001337 0.03969784 intergenic 
chr22:18522807 0.60076483 1.46E-06 0.00212642 intergenic 
chr16:87694617 0.60293888 0.00031709 0.05530058 gene body:ACSF3 
chr19:1114466 0.61006579 1.99E-05 0.01229358 gene body:SBNO2 
chr20:60319362 0.62537016 0.00041176 0.06077395 gene body:LAMA5 
chr1:24734289 0.62555264 0.00403743 0.18435642 gene body:RCAN3 
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List of differentially hypomethylated CGIs in AML versus NBM  
 AMD; absolute methylation difference, green; hypomethylated DMR 
ID AMD P.Value adj.P.Value 
Location: promoter/ 
gene body/ intergenic 
chr6:150420531 0.32496038 0.03242265 0.37607842 intergenic 
chr17:77392542 0.32671474 0.0182684 0.31314135 intergenic 
chr1:27555864 0.32776527 0.02405401 0.34381342 gene body:MAP3K6 
chr19:52439203 0.32896959 0.00137987 0.11149277 intergenic 
chr16:87464556 0.33150599 0.02444711 0.34492857 intergenic 
chr13:109319980 0.33221242 0.02681703 0.35788147 intergenic 
chr22:28037479 0.3326269 0.00525504 0.20297693 gene body:GAS2L1 
chr1:233871941 0.33620078 0.00053719 0.06894613 gene body:GNG4 
chr16:275830 0.3373217 0.0176722 0.3108503 gene body:PDIA2 
chr19:377792 0.34120579 0.01210035 0.27662986 gene body:SHC2 
chr7:516976 0.34130485 0.00824108 0.24576414 gene body:PDGFA 
chr21:46119401 0.34236841 0.03178649 0.37444639 gene body:PCBP3 
chr21:14070275 0.34238666 0.02167702 0.33172977 promoter:TERF1P 
chr19:2839929 0.34260041 0.04806917 0.41939393 intergenic 
chr7:158443745 0.34410973 0.0128685 0.28089925 intergenic 
chr14:100978534 0.34586149 0.00491063 0.19953457 intergenic 
chr11:1859654 0.34655228 0.00390856 0.18435642 gene body:LSP1 
chr19:786272 0.34774618 0.04051375 0.40141394 intergenic 
chr22:44897118 0.34878629 0.00112426 0.10256132 intergenic 
chr19:44721966 0.34945623 0.00160753 0.11824549 promoter:EID2 
chr19:5773284 0.35108025 0.03349881 0.37822279 intergenic 
chr10:5922309 0.35141913 0.00861218 0.24897129 intergenic 
chr19:18132738 0.35195873 0.00661061 0.22490572 gene body:PIK3R2 
chr7:157994027 0.35590538 0.01517438 0.29978267 gene body:PTPRN2 
chr12:56451830 0.35913778 0.00143079 0.11167762 promoter:METTL1 
chr18:72243539 0.36040207 0.01498769 0.29978267 gene body:ZNF516 
chr10:102768594 0.36249791 0.0031382 0.16359094 gene body:PDZD7 
chr19:51079167 0.36402027 0.02668105 0.35788147 intergenic 
chr19:50797099 0.36443996 0.03844361 0.39459658 promoter:GPR4 
chr9:128473587 0.36763065 0.01144194 0.27206403 gene body:LMX1B 
chr22:48150999 0.36789394 0.03846309 0.39459658 intergenic 
chr7:2740970 0.36805295 0.02248087 0.33764396 gene body:GNA12 
chr6:170422814 0.36868118 0.00221328 0.13691709 intergenic 
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List of differentially hypermethylated CGIs in AML versus NBM  
 AMD; absolute methylation difference, red is hypermethylated DMR. 
ID AMD P.Value adj.P.Value 
Location: promoter/ 
gene body/ intergenic 
chr5:180474257 0.70207708 1.56E-07 0.00072696 intergenic 
chr8:25955252 0.66993556 4.53E-05 0.01873136 gene body:EBF2 
chr4:41443941 0.61954924 1.75E-06 0.0023252 gene body:PHOX2B 
chr8:116748872 0.61441911 1.19E-05 0.0085085 gene body:TRPS1 
chr1:13782193 0.60925248 0.00014661 0.03969784 promoter:PDPN 
chr20:22514821 0.59054628 5.75E-06 0.00535059 promoter:FOXA2 
chr2:171384798 0.585205 0.00033354 0.05702324 gene body:GAD1 
chr10:43138080 0.58508248 2.94E-07 0.00091084 intergenic 
chr7:8448499 0.57990282 0.00015101 0.03969784 gene body:NXPH1 
chr17:55571078 0.57210075 1.09E-05 0.00808107 intergenic 
chr4:174657922 0.56891266 2.86E-07 0.00091084 intergenic 
chr1:215377372 0.56739813 0.00085 0.08419013 promoter:ESRRG 
chrX:90576258 0.56737467 0.00039436 0.06065254 gene body:PABPC5 
chr4:196377 0.56016694 1.49E-06 0.00212642 intergenic 
chr4:288742 0.55830049 0.00022 0.04526357 intergenic 
chr16:10819660 0.55460408 3.44E-06 0.00426747 promoter:FAM18A 
chr5:140733838 0.55110579 0.0002804 0.05130083 promoter:PCDHGA6 
chr3:62330352 0.55066786 0.00054596 0.069591 intergenic 
chr21:45531119 0.54719563 5.60E-05 0.02124755 gene body:POFUT2 
chr16:34644670 0.54517017 2.88E-05 0.01411644 intergenic 
chr8:111057033 0.54185696 0.0013626 0.1112189 intergenic 
chr11:32417162 0.53337452 0.01775195 0.31095897 gene body:WT1AS 
chr5:1932689 0.53196686 0.00022115 0.04526357 gene body:IRX4 
chr8:65662302 0.52822354 0.00310765 0.16291066 intergenic 
chr13:49605586 0.52787162 2.75E-05 0.01381689 intergenic 
chr2:218960665 0.52645614 0.00307062 0.16291066 gene body:SLC11A1 
chr3:188870605 0.52303866 0.00294638 0.16039204 promoter:SST 
chr10:124568116 0.51558329 0.00167546 0.11904726 intergenic 
chr3:127490011 0.51487164 8.40E-05 0.02895283 intergenic 
chr19:63091757 0.51397752 0.00036694 0.05945361 gene body:ZNF814 
chr5:140242068 0.51390714 0.00152471 0.11395547 gene body:PCDHA6 
chr5:134413866 0.51286443 0.00055575 0.06999024 intergenic 
chr19:41427861 0.51200158 0.00026247 0.05009062 intergenic 
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List of differentially hypermethylated CGIs in AML versus NBM  
 AMD; absolute methylation difference, red is hypermethylated DMR. 
ID AMD P.Value adj.P.Value 
Location: promoter/ 
gene body/ intergenic 
chr6:29926064 0.48219052 0.00836564 0.24672675 intergenic 
chr13:83351665 0.48124427 0.01615713 0.30326759 gene body:SLITRK1 
chr2:88630550 0.47997477 0.00653723 0.22383115 intergenic 
chr11:32404837 0.47876783 0.00192911 0.12960568 gene body:WT1 
chr20:22507553 0.47688053 0.00159169 0.11754495 intergenic 
chr7:157689403 0.4764843 6.04E-06 0.00535059 gene body:PTPRN2 
chr19:19832577 0.47602029 0.00011464 0.03497491 intergenic 
chr10:50646353 0.47508967 0.00617501 0.21888958 intergenic 
chr5:140703732 0.47504536 0.00146971 0.11216135 promoter:PCDHGA3 
chr5:3659488 0.47348129 0.01475912 0.29725883 intergenic 
chr5:140187909 0.4724073 0.00245441 0.1459315 promoter:PCDHA6 
chrX:106402354 0.47124468 0.00697287 0.23008002 intergenic 
chr4:104860008 0.47052261 0.00964957 0.25771286 promoter:TACR3 
chr2:219904675 0.46495975 0.00832846 0.24629471 gene body:RESP18 
chrX:113724775 0.46411776 0.00145765 0.11209423 intergenic 
chr17:20628161 0.46366158 0.00063932 0.07280424 intergenic 
chr5:67619969 0.45885729 0.00656533 0.22418501 gene body:PIK3R1 
chr2:70984708 0.45821864 0.00022814 0.04530174 gene body:VAX2 
chr12:30245182 0.45805702 0.00561478 0.21080214 intergenic 
chr5:178300226 0.45730626 7.70E-08 0.00071647 promoter:ZNF454 
chr1:147422730 0.45708469 0.00229095 0.13978573 intergenic 
chr6:101010212 0.45585429 0.00115954 0.104443 gene body:SIM1 
chr15:87721797 0.45579173 2.11E-05 0.01229358 intergenic 
chr6:43720692 0.45459261 0.00018669 0.04216107 promoter:C6orf206 
chr19:813930 0.45423549 0.01971364 0.32083439 gene body:CFD 
chr11:20137776 0.45303898 0.00126529 0.10851151 promoter:DBX1 
chr7:128337645 0.45253066 0.01248051 0.27829439 promoter:CRIM2. 
chr19:49644256 0.45207447 0.00441747 0.19252726 promoter:ZNF229 
chr14:28324116 0.45183986 0.00062271 0.07280424 gene body:C14orf23 
chr5:92949243 0.45116992 0.00283646 0.15710297 gene body:NR2F1 
chr5:140782583 0.45022627 0.00506696 0.20148739 gene body:PCDHGA5 
chr1:119328305 0.45022366 0.00111447 0.10216868 gene body:TBX15 
chr3:56810690 0.44674101 9.77E-05 0.03190525 gene body:ARHGEF3 
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List of differentially hypomethylated CGI shores in AML versus NBM  
 AMD; absolute methylation difference, green; hypomethylated DMR  
A; upstream CGI shore, B; downstream CGI shore 
ID AMD P.Value adj.P.Value 
Location: promoter/ 
gene body/ intergenic  
chr20:60310894:B 0.25090455 0.03418872 0.59888625 gene body:ADRM1 
chr21:45700596:A 0.25137898 0.00018415 0.11295891 gene body:COL18A1 
chr2:242463729:A 0.25306557 0.00429384 0.35338129 gene body:C2orf85 
chr17:71292441:B 0.25510667 0.0007522 0.19015026 gene body:UNK 
chr4:3345629:A 0.25565931 0.00248047 0.28709641 gene body:RGS12 
chr20:61836693:B 0.25586524 0.00773521 0.41218534 intergenic 
chr1:110751415:A 0.25609464 0.0010072 0.21253474 gene body:HBXIP 
chr20:61904381:B 0.25712953 0.00027071 0.13472702 gene body:ZBTB46 
chr16:4671562:B 0.25800019 0.04116353 0.62494509 gene body:MGRN1 
chr19:51950649:B 0.26051572 0.0063768 0.39248191 intergenic 
chr12:100325178:A 0.26120913 5.52E-05 0.06250289 gene body:ARL1 
chr19:1311038:B 0.2622388 0.00732826 0.40628475 gene body:MUM1 
chr8:145465255:B 0.26326326 0.00989969 0.44063244 gene body:BOP1 
chr11:345947:A 0.26392538 9.06E-05 0.07755914 intergenic 
chr20:61554911:B 0.26491856 0.00470743 0.36097238 gene body:KCNQ2 
chr9:135556394:B 0.26541385 0.00124041 0.22450218 gene body:SARDH 
chr18:59136483:A 0.26628451 0.00682116 0.40027069 gene body:BCL2 
chr6:44463134:A 0.27115397 3.18E-06 0.02661579 intergenic 
chr17:35628966:B 0.27152674 0.00105305 0.21331417 gene body:WIPF2 
chr7:5308825:B 0.27279884 0.00243288 0.28709641 intergenic 
chr16:535848:B 0.27303606 0.00443466 0.35606975 gene body:SOLH 
chr11:2510679:B 0.27433423 0.00085981 0.19763666 gene body:KCNQ1 
chr1:1163778:A 0.27518925 0.01716057 0.50441637 intergenic 
chr17:76621179:A 0.27668554 0.0003338 0.1451847 gene body:FLJ90757 
chr1:226394131:A 0.28196686 4.29E-05 0.05525366 intergenic 
chr12:131646465:A 0.28256903 8.86E-05 0.07755914 gene body:FBRSL1 
chr6:1500261:A 0.28658607 0.00034167 0.14653896 intergenic 
chr7:2530136:B 0.28733421 0.01794645 0.50803674 gene body:LFNG 
chr7:158458887:B 0.28963599 0.00023898 0.1281286 intergenic 
chr17:1321966:A 0.29917157 0.00352553 0.3251718 gene body:MYO1C 
chr1:1590844:B 0.30187218 0.00106632 0.21405992 gene body:SLC35E2B 
chr7:2532398:A 0.30485955 0.00853662 0.41736863 gene body:LFNG 
chr13:113114947:A 0.30913466 0.00194493 0.26881262 intergenic 
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List of differentially hypermethylated CGI shores in AML versus NBM  
 AMD; absolute methylation difference, red is hypermethylated DMR. 
 A; upstream CGI shore, B; downstream CGI shore 
ID AMD P.Value adj.P.Value 
Location: promoter/ 
gene body/ intergenic 
chr4:174657922:B 0.48573834 8.53E-06 0.04091084 intergenic 
chr7:8449657:A 0.47887992 2.01E-05 0.05181698 gene body:NXPH1 
chr1:147414769:A 0.44552886 0.00029571 0.13657643 intergenic 
chr3:148598451:A 0.43928825 7.17E-05 0.0748142 gene body:ZIC4 
chr6:101002494:B 0.43806046 0.00069986 0.18760199 gene body:SIM1 
chr5:63290800:B 0.43663194 1.29E-06 0.02661579 intergenic 
chr11:32417162:A 0.43018539 0.00104223 0.21331417 gene body:WT1AS 
chr16:52882541:A 0.42878556 0.00018879 0.11393996 intergenic 
chr8:25956479:A 0.42404123 0.00028206 0.13657643 gene body:EBF2 
chr3:62331156:A 0.41397908 0.00056889 0.1727884 intergenic 
chr1:215378090:A 0.41359067 0.00043081 0.16468953 intergenic 
chr1:147412832:B 0.4132935 0.00054097 0.1727884 intergenic 
chr6:101001728:B 0.41304064 0.00460141 0.35962541 gene body:SIM1 
chr10:50491493:A 0.41097347 0.00038771 0.15855269 gene body:CHAT 
chr16:49747301:A 0.40588766 0.00235499 0.28604257 intergenic 
chr1:16425913:B 0.40184716 0.00011783 0.08880305 intergenic 
chr13:111808866:A 0.40146396 0.00112013 0.21786052 intergenic 
chr6:101003801:A 0.39979563 0.00697345 0.40073795 gene body:SIM1 
chr4:41442265:B 0.39850528 5.28E-05 0.06250289 gene body:PHOX2B 
chr9:23812412:B 0.39737654 4.78E-05 0.05999222 gene body:ELAVL2 
chr13:111755805:B 0.39706112 0.00056683 0.1727884 intergenic 
chr12:84198009:A 0.39570821 0.00028507 0.13657643 intergenic 
chr8:65661155:B 0.39513993 0.00063859 0.17919344 intergenic 
chr5:140757626:B 0.39096649 2.53E-06 0.02661579 gene body:PCDHGA3 
chr14:37746905:B 0.38663664 0.00143326 0.23642042 gene body:SSTR1 
chr7:157169647:A 0.38572427 0.00355965 0.32597694 gene body:PTPRN2 
chr4:13133160:B 0.3847363 7.62E-06 0.0401848 intergenic 
chr4:13135651:A 0.3847363 7.62E-06 0.0401848 intergenic 
chr3:62331810:A 0.38400901 0.00188593 0.26673083 intergenic 
chr1:215374367:B 0.38352415 0.0003606 0.15097743 intergenic 
chr18:65220913:A 0.37978082 0.00154312 0.2394286 intergenic 
chr1:896159:A 0.37926989 0.00590559 0.38462164 gene body:PLEKHN1 
chr13:27449514:B 0.3769629 0.00119127 0.22024159 gene body:PRHOXNB 
chr5:140243269:A 0.37541187 2.21E-05 0.05181698 gene body:PCDHA2 
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List of DMRs (P <0.001) between trisomy 8 AML diagnostic versus relapse in 
promoters, gene bodies, CGIs and CGI shores      AMD; absolute methylation 
difference, red is hypermethylated DMR in relapse, green is hypomethylated DMR in 
relapse. 
Genomic feature Location AMD P.Value adj.P.Val 
promoter IFNA2 0.322852392 0.000265534 0.999527866 
promoter SPANXN5 0.315409121 0.000319902 0.999527866 
promoter P2RY12 0.346811424 0.000328502 0.999527866 
promoter OR5D13 0.329580259 0.000671256 0.999527866 
promoter hsa-mir-513b 0.278592388 0.000838922 0.999527866 
promoter OR2AK2 0.311689582 0.000926206 0.999527866 
promoter KCNJ12 0.458422759 1.00E-05 0.175960891 
promoter MYL5 0.307338475 0.000655283 0.999527866 
gene body IGHV1-24 0.598042487 4.10E-05 0.311272799 
gene body C1orf195 0.304860416 8.30E-05 0.356633599 
gene body RGS2 0.278472917 0.000117406 0.356633599 
gene body PPP1R15B 0.280669558 0.000303063 0.767154673 
gene body C12orf60 0.407018129 0.000623857 0.992809513 
gene body SLITRK5 0.194388833 0.000948855 0.992809513 
gene body IGLV3-1 0.447781114 2.01E-05 0.305962617 
gene body ID3 0.283561339 0.000112485 0.356633599 
gene body GAST 0.392698254 0.000525292 0.992809513 
gene body KCNE2 0.299688577 0.000536274 0.992809513 
CGI; promoter:CNTNAP1 chr2:26579693 0.2739684 0.0006057 0.9869596 
CGI; intergenic chr17:77560143 0.3323045 0.0002335 0.9869596 
gene body:SLC11A1 chr18:55787649 0.423062 0.0001078 0.8143175 
CGI; intergenic chr2:218964193 0.434212 0.0002683 0.9869596 
CGI; gene body:ASPSCR1 chr1:156215344 0.4367145 0.000562 0.9869596 
CGI; gene body:OTOF chr17:38088317 0.484985 0.0004544 0.9869596 
CGI; intergenic chrX:8711285 0.4633522 0.0006178 0.9869596 
CGI; gene body:NKD2 chr5:1090964 0.53003 0.0006388 0.9869596 
CGI; intergenic chr1:1135431 0.5562785 5.17E-05 0.7812268 
CGI; intergenic chr1:2377529 0.5944278 0.0008037 0.9869596 
CGI shore; intergenic chr3:130516227:A 0.386525414 0.000682893 0.999758558 
CGI shore; gene body:TMEM14C chr6:10831008:B 0.374763653 0.000259384 0.999758558 
CGI shore; gene body: SLC25A13 chr7:95788715:A 0.373762652 0.000560037 0.999758558 
CGI shore; gene body: GAB2 chr11:77805613:A 0.372177733 0.000564853 0.999758558 
CGI shore; gene body: SIM1 chr6:101015931:A 0.363252141 0.000709308 0.999758558 
CGI shore; intergenic chr11:129802611:B 0.360916472 0.000391364 0.999758558 
CGI shore; intergenic chr7:152222391:A 0.360610611 0.000397109 0.999758558 
CGI shore; intergenic chr2:55362737:A 0.35463241 0.000766182 0.999758558 
CGI shore; gene body: CDK19 chr6:111242208:A 0.350628406 0.000797832 0.999758558 
CGI shore; intergenic chr6:97478902:A 0.349126905 0.0007199 0.999758558 
CGI shore; gene body: IRX6 chr16:53920238:A 0.34745857 0.000874676 0.999758558 
CGI shore; gene body: PER3 chr1:7809785:B 0.329218107 0.000927811 0.999758558 
CGI shore; intergenic chr6:168968082:B 0.361917473 0.000960674 0.999758558 
CGI shore; intergenic chr12:131218976:A 0.437493049 0.000488241 0.999758558 
CGI shore; intergenic chr5:1438978:B 0.535479924 4.30E-06 0.087283078 
CGI shore; gene body: EEF1A2 chr20:61592302:B 0.539317095 1.93E-05 0.243041742 
CGI shore; intergenic chr7:302618:B 0.555388722 5.20E-06 0.087283078 
CGI shore; gene body: GSDMD chr8:144706451:B 0.787259482 2.27E-08 0.001140559 
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